

# Index to Volume 54

The index to Volume 54 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP Statements and Guidelines, are indexed under "American Society of Health-System Pharmacists" as well as being

covered by IPA in many cases. The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the following: ASHP Foundation Reports, Book Reviews, Editorials, Frontline Pharmacist, How To, Letters, Managed Care Forum, Management Consultation, News, Questions and Answers, Self-study Materials, and Software Reviews. The page numbers of articles that appear in ASHP Affiliates are listed under that heading by the names of the societies. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January 1	1-108
January 15	109-226
February 1	227-334
February 15	335-478
March 1	479-602
March 15	603-730
April 1	731-854
April 15	855-1004
May 1	1005-1132
May 15	1133-1220
June 1	1221-1368
June 15	1369-1466
July 1	1467-1564

Issue	Pages
July 15	1565-1670
August 1	1671-1778
August 15	1779-1914
September 1	1915-2018
September 15	2019-2140
October 1	2141-2258
October 15	2259-2418
November 1	2419-2536
November 15	2537-2640
November 15 Supplement	S1-S32
December 1	2641-2776
December 15	2777-2862
December 15 Supplement	S1-S24

## Subject Index

### A

#### Absorption

furosemide; prokinetic agents, 2609  
minoxidil; prokinetic agents, 2609

**Acarbose**; interactions; warfarin, 1551

#### Accreditation

degrees; pharmacy, 2439  
hospitals; JCAHO standards, 743  
long-term-care facilities; JCAHO standards, 743  
managed care systems; quality assurance, 1528  
pharmacists; NABP resolutions, 1932  
residencies; managed care systems, 2099, 2055

**Acetaminophen**; concomitant therapy, 85

**Acetylcysteine sodium**; incompatibilities; artificial tears, 549

#### Adriasis

metformin; interactions, 587  
roentgenographic agents; interactions, 587

**Acne vulgaris**; tazarotene; FDA approvals, 2037

#### Acquired immunodeficiency syndrome

antivirals; protocols, 1681  
delavirdine mesylate; FDA approvals, 1233  
drugs; AIDS buyers' clubs, 2122  
nelfinavir mesylate; FDA approvals, 1233  
patient care; continuity, 1407  
prophylaxis; pharmacists' role, 2800  
ritonavir; pediatric labeling, 1233  
somatropin; wasting syndrome, 2618

**Additives**; injections; amphotericin B incompatibilities, 683; antineoplastic agents incompatibilities, 915; bumetanide incompatibilities, 422; ceftriaxone-metronidazole incompatibilities, 424; ciprofloxacin incompatibilities, 1193; cisatracurium incompatibilities, 1735; compounding, 258, 904; dexamethasone-ondansetron incompatibilities, 1065; doxorubicin incompatibilities, 2708; filgrastim incompatibilities, 185; granisetron incompatibilities, 56; incompatibilities, 64, 181; insulin-ranitidine incompatibilities, 1304; iron dex-

tran, 570; ketamine-meperidine incompatibilities, 205; meropenem incompatibilities, 412; midazolam incompatibilities, 913; propofol incompatibilities, 1287; remifentanyl incompatibilities, 2192; thiopental incompatibilities, 2588; warfarin incompatibilities, 2599

#### Administration

accreditation; ASHP standards, 2099  
ambulatory care; pharmacists' interventions, 2719  
American Council on Pharmaceutical Education; degree accreditation, 2439

American Society of Health-System Pharmacists; H. Manasse, 1477

clinical studies; evidence-based practice centers, 2668

decision-making; clinical pharmacists, 1307  
Department of Veterans Affairs; pharmaceutical services, 761

drug information centers; databases, 1763; telecommunication networks, 1930

education, pharmaceutical; residencies, 1521  
Food and Drug Administration; new-drug approvals, 494

health care; computers, 269; technology, 274

health maintenance organizations; computerized databases, 1510; disease management, 32; formularies, 1941; home health care, 1968; indigent patient consultation, 2449; psychopharmacy clinic, 2717; U.S., 19

hospital pharmacy; ambulatory care, 1584; clerkships, 1727; clinical interventions, 1722; clinical studies, 1742; clinical training programs, 1794; code of conduct, 142; contract services, 37, 43, 48; controlled substances, 630, 1392; cost control, 1196; drug administration routes, 200; drug expenditures, 2302; drug information databases, 2392; emergency rooms, 1702; formularies, 95; insulin protocols, 1046; interventions, 392; i.v. compounding, 904; i.v. syringe checking, 1611; i.v. to oral conversion, 524; manual vs. bar codes, 1623; mathematical models, 2491; medication errors, 171; outsourcing, 41, 45; personnel competence, 1412; pharmacists' interventions, 2811, 1591; pharmacists' liability, 1152; regional consolidation, 1076; survey, 653; trends, 639

hospitals; ethics committees, 2007; ownership,

2238; patient-focused care, 2174; university affiliated, 1711

integrated health care; statistics, 2786; U.S., 19, 238

leadership; ASHP, 1889; pharmacy, 1701

managed care systems; backlash, 1049; disease management, 2217; integrated health care, 1752; patient education, 1497; pharmacists' education, 2055; quality assurance, 1528

mental retardation facilities; anticonvulsant substitution, 1716

organizations; professional competence, 2433

pharmaceutical services; hospitals, 1262; immunization programs, 490; patient satisfaction, 2721

pharmacists; resignation, 1946

pharmacists; hospital; ethics, 687

pharmacy; drug cost projections, 153; staff performance, 2680; technicians' certification, 2562

pharmacy, institutional; clinical information systems, 1501, 1505, 1515; future, 2503; mail order, 520; training, 674

policies and procedures; *AJHP*, 30; *APhA*, 1025; ASHP, 2181; e-mail, 886; gene-therapy handling, 1604; hospital pharmacy, 1110, 2516; latex allergies, 1071; Medicare, 830; needle sticks, 258

United States Air Force; pharmaceutical services, 783

United States Army; pharmaceutical services, 773

United States Navy; pharmaceutical services, 778

United States Public Health Service; pharmaceutical services, 766

**Administrators**  
American Society of Health-System Pharmacists; H. Manasse, 1477

hospital pharmacy; self-renewal residencies, 2116

managed care systems; disease management, 1277

Oddis, J.; ASHP, 1815; endowment, 1804

salaries; managed care systems, 1049

**Admixtures**, see **Additives**

**Adolescents**  
drug abuse; survey, 365

vaccines; protocols, 494

**Adrenergic agents**, see **Sympathomimetic agents**

**Adsorption**; bumetanide; polyvinyl chloride, 422

**Adverse reactions**, see **Drugs, adverse reactions**

## Annual Index

### Advertising

employment; pharmacist positions, 1260  
health care; Internet, 757  
prescription drugs; direct to consumer, 2664; FDA guidelines, 2181; references, 2596

**Advertising Index**, 108, 226, 334, 478, 602, 730, 854, 1004, 1132, 1220, 1368, 1466, 1564, 1670, 1778, 1914, 2018, 2140, 2258, 2418, 2536, 2640, 2776, 2832

### Aerosols

see also **Inhalers**

albuterol; status asthmaticus, 199  
inhalers; metered dose, 1021  
ipratropium bromide; status asthmaticus, 199

### Age

patients; adult immunization, 379; diabetes mellitus, 1062; famciclovir, 1180  
pharmacists; hours, 558  
students; drug abuse, 365  
women; health care, 2288

**Agency for Health Care Policy and Research**; United States Public Health Service; pharmaceutical services, 766

**Agency for Toxic Substances and Disease Registry**; United States Public Health Service; pharmaceutical services, 766

**AIDS**, see **Acquired immunodeficiency syndrome**

**AIDS Facts**, 1646, 2122, 2232, 2618

**AJHP**, see **American Journal of Health-System Pharmacy**

**AJHP Continuing Education**, 90, 197, 1444, 2004, 2125, 2236, 2512, 2741, 2821

**Akathisia**; antipsychotic agents; toxicity, 2461

**Albendazole**; echinococcosis; monitoring, 319

### Allergies

status asthmaticus; oxapropin reactions, 199  
toxicity; emergency room visits, 295

**Albuterol sulfate**; sustained-action; excretion, 2403

### Alcohols, ethyl

abuse; adolescents, 365  
diluents; docetaxel incompatibilities, 566  
interactions; nonprescription drugs, 1762  
patient information; hospital pharmacists, 564

**Alcohols, polyvinyl**; incompatibilities; acetylcysteine, 549

**Aldesleukin**; toxicity; palliative care, 1191

**Alkalinizing agents**; sodium bicarbonate; heart arrest, 85; incompatibilities, 1193

**Alkaloids**; ephedrine; FDA regulations, 1578

### Allergies

cross-sensitivity; anticonvulsants, 2616  
documentation; medical records, 1627  
drugs; emergency room visits, 295  
latex; guidelines, 1688; overview, 1071; pharmacy policies, 2516; pharmacy standards, 2517  
penicillin; patient histories, 2457  
sulfamethoxazole, combination, trimethoprim; adverse reactions, 1545

### Alteplase

cardiovascular disorders; protocols, 1447  
cerebrovascular disorders; protocols, 2213  
mechanism of action; thrombolytics, Nov 15 suppl 517  
myocardial infarction; comparisons, Nov 15 suppl 527; methamphetamine toxicity, 586

### Alternative medicine

acquired immunodeficiency syndrome; buyers' clubs, 2122  
American Pharmaceutical Association; policies, 1025  
control, quality; toxicity, 1707

**Aluminum hydroxide**; hyperphosphatemia; sodium phosphate toxicity, 2488

**Alzheimer's disease**; donepezil hydrochloride; review, 2805

**Amantadine**; Parkinson's disease; antipsychotic toxicity, 2461

### Ambulatory care

clinical pharmacists; hospital pharmacy, 1280; primary care, 2079  
databases; managed care systems, 1973  
hospital pharmacy; Medicare reimbursement, 2433; services, 1584; survey, 653  
hypertension; pharmacists' role, 564  
managed care systems; disease management, 2217; pharmacists, 1497  
neoplasms; pharmacists' protocols, 680  
patient education; ASHP guidelines, 431  
pharmaceutical care; cost-benefit analysis, 554  
pharmaceutical services; Department of Veterans Affairs, 761; psychopharmacy clinic, 2717; rational therapy, 2719; United States Army, 773

pharmacists, institutional; prisons, 674

**American Association of Colleges of Pharmacy**; professional competence; JCPP working groups, 2433

**American College of Cardiology**; protocols; myocardial infarction, Nov 15 suppl 53

**American Council on Pharmaceutical Education**; accreditation; pharmacy schools, 2439

**American Heart Association**; protocols; myocardial infarction, Nov 15 suppl 53

**American Journal of Health-System Pharmacy** acknowledgment of reviewers, November 1, 1996, to October 31, 1997, 2819

advertising; employment, 1260  
instructions for submitting computer disks, 84  
policies and procedures; industry ties, 30  
procedure for submissions to, 82  
sections, 84

**American Pharmaceutical Association** guidelines; immunization, 2553

meetings; Remington Honor Medal, 1012  
policies and procedures; 1997 annual meeting, 1025

**American Society of Health-System Pharmacists**

administration; mentoring programs, 1701  
administrators; H. Manasse, 1477  
Annual Meeting; call for papers, 1640; program, 922  
annual report, 1315

attitudes; pharmacotherapy examinations, 1015  
Board of Directors; actions, September 20, 1996, meeting, 75; actions, November 16-17, 1996, meeting, 580; actions, April 23-24, 1997, meeting, 1639; actions, June 1, 1997, meeting, 2114  
Council on Administrative Affairs; report on, 803  
Council on Educational Affairs; report on, 808  
Council on Legal and Public Affairs; report on, 812  
Council on Organizational Affairs; report on, 815  
Council on Professional Affairs; report on, 819  
Executive Vice President; report of, 1873  
Executive Vice President-Designate; report of, 1877  
focus group on pharmacy and managed care, 2500  
guidelines; clinical care plans, 314; patient consultation, 431; recruitment, 1260  
Harvey A. K. Whitney Lecture Award 1997, 1827  
history; C. Lyons, 1095  
Home Care '97 meeting; call for papers, 193; program, 1536  
House of Delegates; 48th annual session, members of, 1850; proceedings, 1849  
information; WWW, 1273  
managed care systems; pharmaceutical education, 2055  
Manasse, H.; professional issues, 1877  
membership; satisfaction, 1037  
Midyear Clinical Meeting; call for papers, 76; call for student posters, 578; program, 2307  
National Residency Preceptors Conference; structuring residencies to meet the challenge of changes in contemporary pharmacy practice, 2110  
Oddis, J.; history, 1804, 1815  
officers, directors, councils, committees, and headquarters staff; directory of, 1879  
oncology pharmacy work force survey, 434  
pharmaceutical services; survey, 653  
Pharmacy Student Forum, report, 829  
policies and procedures; direct-to-consumer advertising, 2181  
policy recommendations—invitation to comment, 801  
Practitioner Recognition Program—1997 fellows, 1080  
President and Chair of the Board; report of, 1862  
President-elect and Vice Chair of the Board; report of, 1865  
professional competence; JCPP working groups, 2433  
protocols; ACE inhibitors, 299; aspirin, 1984; niacin, 2815; *S. pneumoniae* resistance, 575; tuberculosis, 428  
residencies; job satisfaction, 1521  
role; evidence-based practice centers, 2668; Healthy People 2000, 2169; quality control reports, 1240; twenty-first century, 1865  
roster of residents completing ASHP-accredited programs in calendar year 1997, 1200  
Section of Clinical Specialists, report, 828  
Section of Home Care Practitioners, report, 826  
standards; latex allergies, 2517; residencies, 2099  
strategic planning; reports, 1889  
Student Leadership Award; recipients, 2115  
Treasurer; report of, 1868

**Amifostine**; review, 787

**Amikacin sulfate**; incompatibilities; filgrastim, 185

**Amino acids**; dietary supplements; labeling, 2561

### Aminoglycosides

amikacin sulfate; incompatibilities, 185  
gentamicin; interactions, 2704; pharmacokinetics, 541, 2201  
gentamicin sulfate; incompatibilities, 185  
tobramycin; pharmacokinetics, 541, 2201  
tobramycin sulfate; incompatibilities, 185, 1068

**Amlodipine**; absorption; prokinetic agents, 2609

**Amoxicillin**; otitis media; DUE, 2736

**Amphetamines**; abuse; adolescents, 365

### Amphotericin B

approvals; FDA, 2426  
incompatibilities; griseofulvin, 56; remifentanyl, 2192; soybean oil, 683

**Amisacrine**; incompatibilities; griseofulvin, 56

### Analgesics and antipyretics

allergies; ICU, 1841  
allergies; sulfamethoxazole-trimethoprim, 1545  
bromfenac sodium; FDA approvals, 2151  
concomitant therapy, 85  
fentanyl; transdermal patches, 87  
fentanyl citrate; injections, 87  
morphine sulfate; incompatibilities, 61  
pain; pharmacists' role, 2451  
remifentanyl hydrochloride; incompatibilities, 2192  
tramadol; review, 643  
tramadol hydrochloride; DUE, 696  
use; consumers, 2664

### Anesthetics

ketamine hydrochloride; incompatibilities, 205  
propofol; fat emulsions, 2515; incompatibilities, 1287; parenteral nutrition, 694; pharmacoeconomics, 1953  
thiopental sodium; incompatibilities, 64

### Anesthetics, local

administration; needle-stick policies, 258  
bupivacaine hydrochloride; incompatibilities, 61  
lidocaine, combination, prilocaine; comparisons, 388  
tetracaine; comparisons, 388

**Angina pectoris**; mibefradil dihydrochloride; FDA approvals, 2033

**Angiotensin-converting-enzyme inhibitors** contraindications; renal artery obstruction, 1552  
myocardial infarction; protocols, Nov 15 suppl 59  
review, 2689

ventricular dysfunction; pharmacists' interventions, 264; protocols, 299

### Anorexics

dexfenfluramine hydrochloride; product withdrawal, 2269; review, 2059  
fenfluramine hydrochloride; product withdrawal, 2269  
toxicity; heart diseases, 1785

**Anthelmintics**; albendazole; echinococcosis, 319

**Antiarrhythmic drugs**, see **Cardiac drugs**

### Antibiotics

aztreonam; pharmacokinetics, 537  
emergency kits; disasters, 1110  
imipenem, combination, cilastatin sodium; incompatibilities, 185  
mupirocin calcium; staphylococcal infections, 2185  
vancomycin; *S. aureus* resistance, 2457

**Antibodies**; tests, laboratory; HIV infections, 2232

### Anticoagulants

ardeparin sodium; FDA approvals, 1575  
coronary disease; stents, 437  
education, pharmaceutical; ASHP traineeship, 2169  
enoxaparin; comparisons, 1185  
enoxaparin sodium; home health care, 1968  
heparin; comparisons, 1185; myocardial infarction, Nov 15 suppl 59  
heparin sodium; myocardial infarction, 586  
research; history, 1992  
warfarin sodium; interactions, 320, 692, 1551; incompatibilities, 2599

### Anticonvulsants

carbamazepine; cross-sensitivity, 2616  
compliance; prisons, 2585  
divalproex sodium; substitution, 1716  
phenobarbital; cross-sensitivity, 2616  
phenytoin; emergency room visits, 295  
phenytoin sodium; cross-sensitivity, 2616  
tiagabine hydrochloride; FDA approvals, 2544  
valproic acid; substitution, 1716

**Antidepressants**

depression; compliance, 2668  
 methylphenidate; geriatrics, 2510  
 serotonin-reuptake inhibitors; geriatrics, 2510  
 tricyclic; geriatrics, 2510; pain, 2451

**Antidiabetic agents**

acarbose; interactions, 1551  
 glyburide; dosage, 1062  
 metformin; interactions, 587  
 metformin hydrochloride; review, 893  
 troglitazone; FDA approvals, 623

**Antidiarrheal agents**; prescribing; pharmacists, 680**Antiemetics**

costs; Medicare policies, 830  
 granisetron; comparisons, 2478  
 granisetron hydrochloride; comparisons, 1172; incompatibilities, 56; liquid compounding, 1404  
 incompatibilities; Y-site injections, 181  
 ondansetron; comparisons, 2478; palliative care, 1191  
 ondansetron hydrochloride; comparisons, 1172; incompatibilities, 915, 1065  
 prescribing; pharmacists, 680  
 reimbursement; antineoplastic toxicity, 2433

**Antifungals**

amphotericin B; FDA approvals, 2426; incompatibilities, 683; remifentanyl incompatibilities, 2192  
 fluconazole; incompatibilities, 185

**Antihistamines**

allergies; latex, 2516; sulfamethoxazole-trimethoprim, 1545  
 azelastine hydrochloride; FDA approvals, 234  
 fexofenadine hydrochloride; approvals, 342  
 terfenadine; product withdrawal, 342

**Anti-infective agents**

adverse reactions; comparisons, 1176  
 amphotericin B; granisetron incompatibilities, 56  
 drug use; evaluation, 1837  
 incompatibilities; cisatracurium, 1735; doxorubicin, 2708; parenteral nutrition, 1295; propofol, 1287; Y-site injections, 181  
 meropenem; incompatibilities, 412  
 metronidazole hydrochloride; incompatibilities, 424  
 resistance; *Enterococcus*, *Staphylococcus* species, 1420  
 thalidomide; marketing, 2270  
 toxicity; emergency room visits, 295  
 trimethoprim, combination, sulfamethoxazole; allergies, 1545; otitis media, 2736

**Anti-inflammatory agents**

asthma; protocols, 862  
 oxaprozin; adverse reactions, 199

**Antilipemic agents**

cerivastatin sodium; FDA approvals, 1793  
 niacin; pharmacists' role, 2803; ASHP protocols, 2815

**Antimalarial agents**; pyrimethamine; incompatibilities, 2714**Antineoplastic agents**

amsacrine; granisetron incompatibilities, 56  
 compounding; errors, 904; personnel competence, 1412  
 dacarbazine; incompatibilities, 915  
 docetaxel; comparisons, Dec 15 suppl S11; incompatibilities, 566; overview, Dec 15 suppl S2, S7, S19; pharmacokinetics, Dec 15 suppl S16  
 dosage; innovative therapy, 572  
 doxorubicin hydrochloride; incompatibilities, 915, 2708  
 drug administration; needle-stick policies, 258  
 fluorouracil; incompatibilities, 1845  
 gemcitabine; review, 162  
 incompatibilities; doxorubicin, 2708; parenteral nutrition, 1295; propofol, 1287; Y-site injections, 181  
 interferon alfa-2a; renal cell carcinoma, 190  
 paclitaxel; comparisons, Dec 15 suppl S11; incompatibilities, 566; labeling, 2128  
 thiotepa; incompatibilities, 2588  
 toxicity; amifostine therapy, 787; antiemetic comparisons, 2478; antiemetic reimbursement, 2433; anemetics, 830; pharmacists' protocols, 680  
 tretinoin; renal cell carcinoma, 190  
 vincristine sulfate; incompatibilities, 915; toxicity, 1755

**Antiparkinson agents**

amantadine; antipsychotic toxicity, 2461  
 ropinirole hydrochloride; FDA approvals, 2655

**Antiparkinson drugs**; pramipexole dihydrochloride; FDA approvals, 1922**Antipsychotic agents**

chlorpromazine hydrochloride; remifentanyl incompatibilities, 2192

quetiapine fumarate; FDA approvals, 2547  
 toxicity; basal ganglia diseases, 2461

**Antiseptics**; emergency kits; disasters, 1110**Antituberculars**

patient information; pharmacists' interventions, 375  
 tuberculosis; ASHP protocols, 428

**Antivirals**

cidofovir; incompatibilities, 2204; toxicity, 12  
 delavirdine mesylate; FDA approvals, 1233  
 famciclovir; postherpetic neuralgia, 1180  
 HIV infections; protocols, 1681, 2652  
 interferon alfacon-1; FDA approvals, 2656  
 nelfinavir mesylate; FDA approvals, 1233  
 protease inhibitors; toxicity, 1575  
 ritonavir; labeling, 126; pediatric labeling, 1233  
 zidovudine; HIV infections, 1018

**Anxiolytics, sedatives and hypnotics**

administration; needle-stick policies, 258  
 algorithms; ICU, 1841  
 incompatibilities; emulsions, 1287; parenteral nutrition, 1295  
 midazolam hydrochloride; incompatibilities, 913  
 prescribing; pharmacists, 680

**Apparatus, see Equipment****Ardeparin sodium**; approvals; FDA, 1575**Arizona**; cannabis; laws, 126**Arterial occlusive diseases**

surgery; comparisons, 1963  
 thrombolytic agents; clinical studies, 1992  
 urokinase; comparisons, 1963; DUE criteria, 2000; regional infusion, 1988

**Artificial tears**; alcohols, polyvinyl; acetylcysteine incompatibilities, 549**Asclepias**; vasopressin; toxicity, 2230**Aspic areas**

cleanrooms; gene-therapy handling, 1604  
 hospital pharmacy; personnel competence, 1412

**ASHP, see American Society of Health-System Pharmacists****ASHP Affiliates**, 20, 244, 514, 879, 1030, 1244, 1490, 1692, 2157, 2292, 2446, 2670

Alabama Society, 254, 884, 1937, 1940, 2678

Arizona Society, 1938

Arkansas Association, 515, 884, 2448

California Society, 244, 515, 1697, 2300

Chapter Briefs, 24, 254, 515, 884, 1036, 1248, 2300, 2678

Chapter conference features Whitney Award recipients, 1692

Chapter conference to feature Whitney Award recipients, 879

Colorado Society, 514, 515, 881, 1036, 1494

Connecticut Society, 247, 881, 1036, 1693, 2447

Delaware Society, 1496

Educational Meetings, 26, 247, 519, 881, 1036, 1253, 1494, 1693, 1940, 2300, 2447, 2674

Florida Society, 254, 884, 2296

Fourteen state societies send trainers to clinical skills workshops, 879

Georgia Society, 22, 1253, 2300, 2674

Hawaii Society, 884

Idaho Society, 2676

Illinois Council, 24, 26, 1696, 2292, 2300, 2301, 2447, 2678

Indiana Society, 1035, 1494, 2292

Iowa Society, 1695

Kansas Society, 24, 1253, 2678

Kentucky Society, 2446

Louisiana Society, 26, 1493, 2674

Maine Society, 881, 1036, 1494

Maryland Society, 247, 515, 519, 1036, 1494, 2300

Massachusetts Society, 515, 519, 881, 1254, 1940

Michigan Society, 22

Minnesota Society, 884, 1494

Mississippi Society, 884, 1696

Missouri Society, 519, 1697, 2300, 2678

Nebraska Society, 1254

Nevada Society, 247, 254, 884, 1698, 2674

New Hampshire Society, 254

New Jersey Society, 247, 1494, 1495, 2300

New Mexico Society, 26, 1036, 2676

New York State Council, 514, 1490

1996 state society survey results reported, 2298

North Carolina Society, 24, 881, 884, 1036, 2674

North Dakota Society, 2678

The Odds quilt: a joint project of the ASHP affiliated state chapters, 2157

Ohio Society, 1693, 2300

Oklahoma Society, 26, 1696

Oregon Society, 26, 884, 1036, 1937, 2447

Pennsylvania Society, 20, 1030, 1940, 2300

Presidential officers from 45 states attend retreats, 20

Rhode Island Society, 26, 519, 884, 1494, 2300

South Carolina Society, 247, 1258, 2674

South Dakota Society, 1494

Tennessee Society, 1493, 2300

Texas Society, 247, 254, 881, 884, 1036, 1244, 2678

Upcoming Meetings, 29, 253, 519, 882, 1032, 1254, 1496, 1698, 1938, 2295, 2676

Utah Society, 1494, 2670

Vermont Society, 1248

Virginia Society, 880, 884, 1253, 2673

Washington Metropolitan Society, 26, 29, 1248, 1253, 1693, 1940, 2447

Washington State Society, 24

West Virginia Society, 1248

Wisconsin Society, 24, 1694, 2674

Wyoming Society, 1940

**ASHP Foundation Reports**, 1451, 2624

Fall session trains 16 pharmacists for anticoagulation service, 2626

Five receive New Pharmacy Practice Researchers Grants, 2625

Foundation awards fellowships in geriatrics, immunology-immunotherapy, 1451

Literature award winners to be honored at Midyear, 2624

Other Foundation activities, 1452, 2626

Pharmacists complete training for dialysis service, 2625

Research Grants, funded by Merck, awarded, 2624

Sixteen complete spring anticoagulation traineeships, 1451

**ASHP Research and Education Foundation**; grants; J. Oddis endowment, 1804**Aspirin**; myocardial infarction; methamphetamine toxicity, 586; prophylaxis, 1949, 1984; protocols, Nov 15 suppl S9**Asthma**

anti-inflammatory agents; protocols, 862

disease management; physicians' prescribing, 2197

oxaprozin; adverse reactions, 199

patient information; consultation, 2449

**Athletes**; drug abuse; Olympic Games, 1053

**Attention deficit disorder with hyperactivity**; diagnosis; pediatrics, 2685**Authorship**; publications; pharmaceutical industry employees, 30**Automation**

clinical pharmacy; training, 674

compounding; errors, 904; parenteral nutrition, 678

computers; dosage checking, 545

costs; pharmacy outsourcing, 48

Department of Veterans Affairs; pharmaceutical services, 761

dispensing; hospital pharmacy, 45; mail order, 520;

United States Navy, 778

drug distribution systems; controlled substances, 630

**Autonomic drugs**; nicotine; FDA approvals, 1478

**Availability, drugs, see Drugs, availability****Awards**

American Pharmaceutical Association; Remington

Honor Medal, 1012

pharmacists; J. Hunter, 2050

**Azelastine hydrochloride**; approvals; FDA, 234

**AZT, see Zidovudine**

**Aztreonam**; critical illness; pharmacokinetics, 537

**B****Bacterial infections**

levofloxacin; review, 2569

trovafloxacin mesylate; review, 2569

**Balanced Budget Act of 1997**; Medicare; reimbursement, 2433**Barbiturates**; abuse; adolescents, 365**Basal ganglia diseases**; antipsychotic agents; toxicity, 2461**BCG vaccines**; immunization; adults, 379**Benchmarking**; patient care; outcomes standards, 743**Benzodiazepines**; basal ganglia diseases; antipsychotic toxicity, 2461**Beta lactamase inhibitors**; tazobactam sodium, combination, piperacillin sodium; interactions, 2704**Bid contracting, see Purchasing****Billing**; pharmacy, institutional; mail order, 520**Bioavailability, see Drugs, availability****Biologicals**; product development; FDA regulations, 877

**Blood levels**

aminoglycosides; patients' weight, 2201; pharmacokinetic calculations, 541  
antibodies; HIV home tests, 2232  
aztreonam; critical illness, 537  
N-butyl-p-aminobenzoic acid; tetracaine metabolites, 388  
dextrose; insulin protocols, 1046; monitoring, 1058; self-monitoring, 1062  
fentanyl; transdermal patches, 85  
gentamicin; piperacillin-tazobactam interactions, 2704  
tetracaine; and metabolites, 388

**Blood substitutes;** emergency kits; disasters, 1110  
**Board of Pharmaceutical Specialties;** examinations; 1996 pass rate, 1015

**Bodine Aluminum;** cases; Henderson, 572

**Book Reviews,** 106, 223, 333, 471, 597, 724, 852, 1000, 1130, 1218, 1366, 1462, 1562, 1668, 1909, 2016, 2138, 2254, 2415, 2534, 2774, 2831  
*An Anthropologist on Mars: Seven Paradoxical Tales,* 852

*Biostatistics: The Bare Essentials,* 223

*Breaking Free: A Prescription for Personal and Organizational Change,* 2774

*Bringing the Hospital Home: Ethical and Social Implications of High-Tech Home Care,* 852

*The Business of Managed Care: An Annual Review of Contracting and Health Services,* 224

*Changing Health Care: Creating Tomorrow's Winning Health Enterprise Today,* 2016

*Clinical Research in Pharmaceutical Development,* 1218

*Comprehensive Pharmacy Review, Third Edition,* 2017

*The Cytotoxic Handbook, Third Edition,* 2138

*Drug Information: A Guide for Pharmacists,* 106

*Drug Use in Assisted Suicide and Euthanasia,* 1462

*Essential Psychopharmacology: Neuroscientific Basis and Practical Applications,* 471

*Ethical Issues in Pharmacy,* 2254

*EveryWoman's Guide to Prescription and Nonprescription Drugs,* 2415

*Guidelines for Administration of Intravenous Medications to Pediatric Patients, Fifth Edition,* 1000

*Handbook of Clinical Drug Data, Eighth Edition,* 1562

*The Healthcare Customer Service Revolution: The Growing Impact of Managed Care on Patient Satisfaction,* 2416

*Integrated Pharmacology,* 2534

*An Introduction to Survey Research, Polling, and Data Analysis, Third Edition,* 1130

*Literature review: Alternative therapies,* 2635

*Mama Can't Remember Anymore: Care Management of Aging Parents and Loved Ones,* 1366

*Managed Care Made Simple,* 2256

*Managing in a Time of Great Change,* 1130

*Market-Driven Health Care: Who Wins, Who Loses in the Transformation of America's Largest Service Industry,* 1219

*Marketing Health Care into the Twenty-First Century: The Changing Dynamic,* 472

*Mentoring Strategic Change in Health Care: An Action Guide,* 1001

*Mosby's Medical Surfer: A Guide to Exploring the Internet and Discovering the Top Health Care Resources,* 1464

*Outcome Measures for Health Education and Other Health Care Interventions,* 1002

*Pain Management Secrets,* 2831

*Patient Education: A Practical Approach, Second Edition,* 472

*Pharmacotherapy: A Pathophysiologic Approach, Third Edition,* 1668

*Pharmaceutical: Minimizing Medications to Maximize Results,* 333

*Points of Light: A Guide for Assisting Chemically Dependent Health Professional Students,* 1908

*Remaking Health Care in America: Building Organized Delivery Systems,* 1367

*The Right Thing: Ten Years of Ethics Columns from the Healthcare Forum Journal,* 2775

*The Role of Pharmacoeconomics in Outcomes Management,* 2139

*Romance, Poetry, and Surgical Sleep: Literature Influences Medicine,* 724

*The Strategic Middle Manager: How to Create and Sustain Competitive Advantage,* 597

*Studying a Study and Testing a Test: How to Read the Health Science Literature, Third Edition,* 1913

**Books Received,** 333, 476, 601, 729, 1002, 1131, 1219, 1563, 1669, 1776, 1913, 2139, 2417, 2639

**Boston Dispensary;** pharmacy, institutional; history, 1097

**Bradycardia;** calcium chloride; sodium phosphate toxicity, 2488

**Breast neoplasms**

antineoplastic agents; innovative therapy, 572

docetaxel; overview, Dec 15 suppl S19; pharmacoeconomics, Dec 15 suppl S11

paclitaxel; pharmacoeconomics, Dec 15 suppl S11

**Bromfenac sodium;** approvals; FDA, 2151

**Budgets**

hospitals; university affiliated, 1711

pharmacy; drug cost projections, 153

**Bumetanide;** incompatibilities; concentration, 422

**Bupivacaine hydrochloride;** incompatibilities; morphine, 61

**Bupropion hydrochloride;** approvals; FDA, 1478

**N-butyl-p-aminobenzoic acid;** metabolites; tetracaine, 388

**C**

**Caffeine citrated;** incompatibilities; polypropylene syringes, 1106

**Calcium;** dosage; dietary reference intakes, 2438

**Calcium antagonists**

costs; pharmacists' interventions, 2079

mibefradil dihydrochloride; FDA approvals, 2033

**Calcium chloride;** bradycardia; sodium phosphate toxicity, 2488

**Calcium regulators;** tiludronate disodium; FDA approvals, 1145

**Calculations**

dosage; alteplase, 1447; compounding, 1449; computer checking, 545; kidney failure, 2505

pharmacokinetics; aminoglycosides, 541

**California**

cannabis; laws, 126

errors, medication; geriatrics, 2282

**Caloric agents;** dextrose; flow rates, 1277; hyperphosphatemia, 2488

**Calories;** propofol; fat emulsions, 2515; vehicles, 694

**Cancer, see Antineoplastic agents**

**Cancer drugs, see Antineoplastic agents**

**Cannabis**

abuse; adolescents, 365

laws; prescribing, 126

pain; pharmacist consultation, 2451

**Capitation**

health maintenance organizations; patient consultation, 2449

integrated health care; pharmaceutical services, 2207

**Capsules**

omeprazole; liquid compounding, 1833

phenoxybenzamine hydrochloride; compounding, 2073

tacrolimus; suspension compounding, 178

ursodiol; suspension compounding, 1401

**Captopril;** incompatibilities; oral liquids, 2483

**Carbamazepine;** adverse reactions; cross-sensitivity, 2616

**Carcinoma**

interferon alfa-2a; renal cell, 190

retinoin; renal cell, 190

**Cardiac drugs**

epoprostenol; congestive heart failure, 2613

incompatibilities; parenteral nutrition, 1295; propofol, 1287

isobarbital dinitrate; sustained-action, 2403

lidocaine; heart arrest, 85

nifedipine; myocardial infarction, 586

nitroglycerin; incompatibilities, 1417

propafenone hydrochloride; incompatibilities, 1293

**Cardiovascular agents;** incompatibilities; doxorubicin, 2708

**Cardiovascular disorders;** alteplase; protocols, 1447

**Cardiovascular drugs;** toxicity; emergency room visits, 295

**Career Opportunities,** 96, 206, 322, 450, 589, 702, 832, 988, 1112, 1210, 1336, 1455, 1553, 1658, 1765, 1902, 2009, 2130, 2240, 2406, 2518, 2628, 2749, 2825

**Careers;** pharmacists; managed care systems, 2055; mentoring programs, 1701; U.S. Public Health Service, 1236

**Caregivers;** drug administration; vasopressin, 2230

**Cefepime hydrochloride;** toxicity; neutropenia, 2621

**Cefoperazone sodium;** incompatibilities; cisatra-

curium, 1735; remifentanyl, 2192

**Cefotaxime sodium;** dosage schedules; cost comparison, 1614

**Ceftazidime;** incompatibilities; filgrastim, 185

**Ceftriaxone sodium**

dosage schedules; cost comparison, 1614

incompatibilities; metronidazole, 424

**Cells;** therapy; FDA regulations, 877

**Centers for Disease Control and Prevention**

immunization; pharmacists' education, 490

United States Public Health Service; pharmaceutical services, 766

**Central nervous system drugs**

bupropion hydrochloride; FDA approvals, 1478

sumatriptan succinate; stability, 1619

**Central nervous system stimulants**

attention deficit disorder with hyperactivity; diagnosis, 2685

caffeine citrated; incompatibilities, 1106

**Cephalosporins**

cefepime hydrochloride; toxicity, 2621

cefoperazone sodium; incompatibilities, 1735;

remifentanyl incompatibilities, 2192

cefotaxime sodium; cost comparison, 1614

ceftazidime; incompatibilities, 185

ceftriaxone sodium; cost comparison, 1614; incompatibilities, 424

**Cerebral ischemia;** thrombolytic agents; cerebrovascular disorders, 2213

**Cerebrovascular disorders**

alteplase; protocols, 2213

anticoagulants; ASHP traineeship, 2169

**Cervastatin sodium;** approvals; FDA, 1793

**Certification**

clinical pharmacy; prisons, 674

examinations; pharmacotherapy, 1015

pharmacists; NABP resolutions, 1932; recruitment, 1260; U.S. Public Health Service, 1236

pharmacists, hospital; life support, 1702

technicians; benefits, 2562; continuing education, 1486

**Charity;** drugs; FIP guidelines, 2800

**Chelating agents;** edetate disodium; incompatibilities, 549, 2483

**Cherry syrup;** vehicles; granisetron liquids, 1404

**Chlorobutanol;** incompatibilities; acetylcysteine, 549

**Chlorofluorocarbons;** propellants; FDA regulations, 1021

**Chlorpromazine hydrochloride;** incompatibilities; remifentanyl, 2192

**Cholelitholytic agents;** ursodiol; stability, 1401

**Cholera vaccines;** adults; research, 379

**Cidofovir**

incompatibilities; containers, 2204

toxicity; kidney failure, 12

**Cilastatin sodium;** combination, imipenem; incompatibilities, 185

**Ciprofloxacin lactate;** incompatibilities; sodium bicarbonate, 1193

**Cisapride**

gastroparesis; drug absorption, 2609

interactions; warfarin, 320

**Cisatracurium besylate;** incompatibilities; anti-infective agents, 1735

**Citric acid;** incompatibilities; phenoxybenzamine, 2073

**Classification;** drugs; prescription to nonprescription, 1207

**Classified advertising, see Career Opportunities**

**Clearance, see Excretion**

**Clinical pharmacists**

decision-making; models, 1307

hospitals; staff development, 48

interventions; antihypertensive programs, 2079;

documentation, 1623; ICU, 2811

primary care; role, 1280

role; drug use, 2207

services; mail order, 613

staff development; clinical training programs, 1794

**Clinical Pharmacology;** databases; comparisons, 2592

**Clinical pharmacy**

computers; intervention documentation, 1727

decision-making; models, 1307

history; twentieth century, 1805

hospitals; interventions, 392; practice trends, 639;

staff development, 48; survey, 653

intensive care units; pharmacists' interventions, 2811

managed care systems; information systems, 1501;

pharmacists, 1497

- pharmacists; hospital; interventions, 1596; outcomes, 1591  
 primary care; team, 1280  
 protocols; ASHP guidelines, 314  
 quality assurance; hospitals, 1722  
 residencies; self-renewal programs, 2116  
 services; hospital rounds, 670; integrated health care, 2207; mail order, 613; prisons, 674  
 United States Public Health Service; services, 766
- Clinical Reference Library;** databases; comparisons, 2592
- Clinical studies**  
 administration; evidence-based practice centers, 2668  
 amifostine; review, 787  
 analgesics and antipyretics; physician prescribing, 2451  
 aspirin; myocardial infarction, 1949  
 breast neoplasms; innovative therapy, 572  
 costs; hospitals, 1742  
 databases; ambulatory care, 1973  
 decision-making; formularies, Nov 15 suppl S5  
 docetaxel; neoplasms, Dec 15 suppl S19; overview, Dec 15 suppl S7; pharmacokinetics, Dec 15 suppl S16  
 epoprostenol; congestive heart failure, 2613  
 HIV infections; pregnancy, 1018  
 medicinal plants; efficacy, 2656  
 methylphenidate; depression, 2510  
 mupirocin calcium; infection control programs, 2185  
 pharmacists; depression monitoring, 2668  
 sulfamethoxazole, combination, trimethoprim; re-institution, 1545  
 theophylline; roentgenographic toxicity, 587  
 thrombolytic agents; cerebrovascular disorders, 2213; myocardial infarction, Nov 15 suppl S27; outcome markers, Nov 15 suppl S23; thrombosis, 1992  
 urokinase; overview, 1988
- Closures;** vials; latex, 2516
- Cocaine;** abuse; adolescents, 365
- Codes**  
 bar; hospital pharmacy, 45; pharmacists' interventions, 1623  
 ethics; conduct, 142
- Color;** warfarin sodium; incompatibilities, 2599
- Columbia/HCA Healthcare;** mergers; Value Health, 513
- Combined therapy**  
 albuterol and ipratropium bromide; status asthmaticus, 199  
 antineoplastic agents and docetaxel; breast neoplasms, Dec 15 suppl S19; overview, Dec 15 suppl S2  
 antivirals; HIV infections, 1681, 2652  
 docetaxel and antineoplastic agents; breast neoplasms, Dec 15 suppl S19; overview, Dec 15 suppl S2  
 fenfluramine and phentermine; obesity, 1785  
 globulin immune and zidovudine; pregnancy, 1018  
 human immunodeficiency virus immune globulin and zidovudine; pregnancy, 1018  
 interferon alfa-2a and tretinoin; renal cell carcinoma, 190  
 ipratropium bromide and albuterol; status asthmaticus, 199  
 phentermine and fenfluramine; obesity, 1785  
 tretinoin and interferon alfa-2a; renal cell carcinoma, 190  
 zidovudine and human immunodeficiency virus immune globulin; pregnancy, 1018
- Commentaries,** 85, 437, 584, 1307, 1434, 1742, 1988, 2213, 2503, 2609, 2733
- Committees**  
 health care; quality assurance, 2238  
 hospitals; ethics, 2007; pharmacists' interventions, 392
- Communication**  
 American Society of Health-System Pharmacists; WWW, 1273  
 consumers; pharmacists, 2664  
 health professions; HMOs, 1510  
 hospital pharmacy; drug administration routes, 200  
 personnel, pharmacy; code of conduct, 142; e-mail, 886  
 pharmacists; patient consultation, 2084  
 pharmacists; hospital; attitudes, 584; emergency rooms, 1702; terminal patients, 753  
 pharmacists; institutional; patient consultation, 1497
- students; community service, 354; public relations, 1236
- Community service;** minorities; pharmacy students, 354
- Compliance;** patients; analgesics, 2451; anticonvulsants, 2585; antidepressants, 2668; antituberculars, 375, 428; antivirals, 1681; pharmacists' interventions, 2719; pharmacists' role, 2503
- Compounding**  
 acetylcysteine sodium; ophthalmic solutions, 549  
 alteplase; hospital pharmacists, 2213  
 captopril; oral liquids, 2483  
 docetaxel; injections, Dec 15 suppl S7  
 granisetron hydrochloride; oral liquids, 1404  
 hospital pharmacy; needle sticks, 258; personnel competence, 1412  
 injections; errors, 904; latex allergies, 2516, 2517  
 omeprazole; oral liquids, 1833  
 parenteral nutrition; automation, 678; incompatibilities, 1295  
 pentoxifylline; suspensions, 1301  
 pharmacists; drug hydrates, 1449  
 phenoxylbenzamine hydrochloride; incompatibilities, 2073  
 pyrimethamine; suspensions, 2714  
 sterile products; technicians, 1702  
 sumatriptan succinate; suspensions, 1619  
 tacrolimus; suspensions, 178  
 ursodiol; suspensions, 1401
- Computers**  
 bar codes; pharmacists' interventions, 1623  
 communication; e-mail, 886  
 costs; pharmacy outsourcing, 48  
 databases; ambulatory care, 1973; comparisons, 2592; drug information centers, 1763; HMOs, 1510  
 data collection; e-mail, 1334  
 Department of Veterans Affairs; pharmaceutical services, 761  
 drug distribution systems; controlled substances, 630  
 drug information centers; networks, 1930  
 equipment; clinical information systems, 1505  
 health care; information systems, 269  
 health maintenance organizations; clinical information systems, 1515  
 hospital pharmacy; clinical interventions, 1722; practice trends, 639; service outsourcing, 45; survey, 653  
 hospitals; pharmacists' interventions, 392  
 information; health care, 274; pharmacists' attitudes, 584  
 Internet; drug information, 1732; health care information, 757; pharmacy information, 34  
 managed care systems; clinical information systems, 1505  
 models; nomenclature similarities, 1161; pharmacy management, 2491  
 patient-focused care; pharmacists' role, 263  
 pharmaceutical services; mail order, 613  
 pharmacy; United States Navy, 778  
 programs; ambulatory care, 2719; aminoglycoside pharmacokinetics, 541; clinical information systems, 1501; dosage checking, 545; HMO formularies, 1941; infection monitoring, 1897; intervention documentation, 1727; medical logic modules, 281
- Concentration**  
 amphotericin B; incompatibilities, 683  
 antineoplastic agents; incompatibilities, 915  
 bumetanide; incompatibilities, 422  
 bupivacaine hydrochloride; incompatibilities, 61  
 ceftriaxone sodium; incompatibilities, 424  
 cidofovir; incompatibilities, 2204  
 ciprofloxacin lactate; incompatibilities, 1193  
 cisatracurium besylate; incompatibilities, 1735  
 dexamethasone sodium phosphate; incompatibilities, 1065  
 dextrose; flow rates, 1277  
 docetaxel; incompatibilities, 566  
 dopamine hydrochloride; incompatibilities, 1417  
 drugs, nonprescription; self-medication, 2664  
 edetate disodium; acetylcysteine incompatibilities, 549  
 epinephrine hydrochloride; incompatibilities, 1417  
 filgrastim; incompatibilities, 185  
 fluorouracil; incompatibilities, 1845  
 granisetron hydrochloride; stability, 1404  
 meropenem; incompatibilities, 412  
 metronidazole hydrochloride; incompatibilities, 424  
 midazolam hydrochloride; incompatibilities, 913  
 morphine sulfate; incompatibilities, 61  
 nafcillin sodium; incompatibilities, 1068
- nitroglycerin; incompatibilities, 1417  
 norepinephrine bitartrate; incompatibilities, 1417  
 ondansetron hydrochloride; incompatibilities, 1065  
 paclitaxel; incompatibilities, 566  
 penicillin G potassium; incompatibilities, 1068  
 phenoxylbenzamine hydrochloride; incompatibilities, 2073  
 propafenone hydrochloride; incompatibilities, 1293  
 ranitidine hydrochloride; incompatibilities, 1304  
 remifentanyl hydrochloride; incompatibilities, 2192  
 sodium bicarbonate; incompatibilities, 1193  
 sumatriptan succinate; suspension compounding, 1619  
 thiopeta; incompatibilities, 2588  
 tobramycin sulfate; incompatibilities, 1068  
 TrophAmine; incompatibilities, 570
- Consumers**  
 attitudes; community pharmacy services, 531  
 geriatrics; coalitions, 2282  
 patient information; survey, 1381  
 prescription drugs; advertising, 2181
- Containers**  
 ethylene; copolymers, 2204  
 glass; dextrose-nitroglycerin incompatibilities, 1417; meropenem incompatibilities, 412; midazolam incompatibilities, 913; pyrimethamine suspensions, 2714; tacrolimus suspensions, 178  
 incompatibilities; pentoxifylline suspensions, 1301; propafenone injections, 1293  
 plastics; fluorouracil incompatibilities, 1845; pyrimethamine suspensions, 2714; tacrolimus suspensions, 178  
 polyethylene; acetylcysteine incompatibilities, 549  
 polyisoprene; incompatibilities, 915  
 polyvinyl chloride; bumetanide, 422; ceftriaxone-metronidazole, 424; dextrose-drug incompatibilities, 1417; docetaxel injections, Dec 15 suppl S7; incompatibilities, 61, 566, 915, 1065, 1068, 2204; insulin-ranitidine incompatibilities, 1304; meropenem incompatibilities, 412  
 propylene; copolymers, 2204
- Contamination**  
 microbiological; bulk packages, 2006; sumatriptan suspensions, 1619  
 needles; hospital policies, 258
- Contraceptives postcoital;** new-drug applications; FDA actions, 874
- Contracts**  
 Department of Veterans Affairs; pharmacy benefit management, 761  
 health maintenance organizations; community pharmacy, 32  
 managed care systems; industry discounts, 1041
- Contract services**  
 drug distribution systems; hospital pharmacy, 37, 41, 48  
 health maintenance organizations; hospital rounds, 670  
 hospital pharmacy; costs, 43; drug distribution systems, 52; wholesalers, 45  
 integrated health care; statistics, 2786  
 pharmacists; APHA policies, 1025  
 pharmacy benefit management companies; integrated health care, 2207  
 ValueRx; mergers, 513
- Contraindications**  
 angiotensin-converting-enzyme inhibitors; renal artery obstruction, 1552  
 cidofovir; toxicity, 12  
 oxaprozin; asthma, 199  
 ritonavir; liver diseases, 126
- Control**  
 costs; drugs, 2302; hospitals, 1196  
 cross infection; prevention programs, 2185
- Controlled substances**  
 distribution systems; computers, 630  
 documentation; surgery, 1392
- Control, quality**  
 dietary supplements; manufacturing, 1707  
 history; ASHP, 1240  
 water; USP standards, 1633
- Copolymers**  
 ethylene and propylene; containers, 2204  
 propylene and ethylene; containers, 2204
- Coronary disease;** thrombolytic agents; stents, 437
- Correction notices,** 442, 587, 1110, 1335, 1552, 2517  
 Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration (Jan 15, 1997, Report), 587

## Annual Index

- Compatibility of selected critical care drugs during simulated Y-site administration (May 1, 1996, Note), 1110
- Metformin hydrochloride: an antihyperglycemic agent (Apr 15, 1997, Clinical Review), 1335
- New trends in the drug therapy of localized and disseminated *Mycobacterium avium* complex infection (Nov 1, 1996, Therapy Update), 442
- Observational study of accuracy in compounding i.v. admixtures at five hospitals (Apr 15, 1997, Report), 1110
- Pharmacists on a primary care team at a Veterans Affairs medical center (Jun 1, 1997, Report), 2517
- Quicker dosage adjustment for transdermal fentanyl (Jan 1, 1997, Therapy Consultation), 1552
- Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days (Jun 15, 1996, Note), 1110
- Cost-benefit**, see **Economics**; **cost-benefit analysis**
- Cost-effectiveness**, see **Economics**; **cost-benefit analysis**
- Casts**
- analgesics and antipyretics; pain, 2451
  - angiotensin-converting-enzyme inhibitors; review, 2689
  - antibiotics; otitis media, 2736
  - anti-infective agents; DUE, 1837
  - asthma; physicians' prescribing, 2197
  - calcium antagonists; pharmacists' interventions, 2079
  - cefotaxime sodium; comparisons, 1614
  - ceftriaxone sodium; comparisons, 1614
  - dalteparin sodium; home health care, 1995
  - databases; drug information, 2592; drug information centers, 1763
  - data collection; Internet, 1334
  - discounts; infant formulas, 687
  - divalproex sodium; prescribing, 1716
  - docetaxel; quality of life, Dec 15 suppl S11
  - drugs; AIDS buyers' clubs, 2122; ambulatory care, 2719; i.v. to oral conversion, 524; 1997 projections, 153; reports, 2302
  - enoxaparin; comparisons, 1185
  - enoxaparin sodium; home health care, 1995
  - famciclovir; postherpetic neuralgia, 1180
  - health care; Boston Dispensary, 1097; direct-to-consumer advertising, 2181; informatics, 274; managed care systems, 1049; models, 554
  - health maintenance organizations; computerized databases, 1510
  - heparin; comparisons, 1185
  - home health care; AIDS, 1407
  - hospital pharmacy; contract services, 43, 45; outsourcing, 48; pharmacists' interventions, 2811, 1591
  - hospitals; control, 1196; patient-focused care, 1262; pharmacists' interventions, 392; university affiliated, 1711
  - interventions; manual vs. bar codes, 1623
  - managed care systems; ambulatory care databases, 1973; disease management, 2217; formularies, 1041
  - paclitaxel; quality of life, Dec 15 suppl S11
  - palliative care; aldesleukin toxicity, 1191
  - pharmaceutical services; hospital rounds, 670; integrated health care, 2207; psychopharmacy clinic, 2717
  - pharmacy; integrated health care, 238
  - pharmacy, institutional; clinical information systems, 1515
  - prescription drugs; HMO formularies, 1941; low-income patients, 1702
  - primary care; clinical pharmacists, 1280
  - propofol; review, 1953
  - research, 1742
  - roentgenographic agents; protocol analysis, 1395
  - surgery; arterial occlusive diseases, 1963
  - tests, laboratory; HIV infections, 1646, 2232
  - urokinase; arterial occlusive diseases, 1963; regional infusion, 1988
  - valproic acid; prescribing, 1716
- Crack**, see **Cocaine**
- Creams**
- lidocaine, combination, pilocaine; phlebotomy pain, 388
  - tetracaine; phlebotomy pain, 388
  - triamcinolone acetonide; dermatitis, 1333
- Creoline**; clearance; drug dosage, 2505
- Critical illness**
- arteonam; pharmacokinetics, 537
  - injections; incompatibilities, 64
- Critical pathways**; patient care; clinical care plans, 314
- Cross infection**; staphylococcal infections; prevention programs, 2185
- Crystallization**; warfarin sodium; incompatibilities, 2599
- Current Literature**, 103, 219, 329, 462, 596, 718, 849, 998, 1128, 1217, 1360, 1461, 1561, 1667, 1772, 1908, 2015, 2136, 2250, 2414, 2528, 2635, 2772, 2830
- Curriculum**; education, pharmaceutical; memory disorders, 92
- Cyclosporine**; incompatibilities; Y-site injections, 181
- Cytoprotectants**
- amifostine; review, 787
- Cytotoxic agents**, see **Antineoplastic agents**
- D**
- Dacarbazine**; incompatibilities; containers, 915
- Dalteparin sodium**; thrombophlebitis; overview, 1995
- Databases**
- computers; drug information centers, 1763
  - drug information; comparisons, 2592
  - drug information centers; networks, 1930
  - health care; pharmacoeconomics, 2601
  - health maintenance organizations; administration, 1510
  - hospital pharmacy; drug expenditures, 2302
  - information; health care, 274
  - managed care systems; ambulatory care, 1973
  - pharmaceutical services; clinical information systems, 1505
- Data collection**
- American Society of Health-System Pharmacists; membership, 1037
  - consumers; community pharmacy services, 531; patient information, 1381; self-medication, 2664
  - costs; ambulatory care databases, 1973
  - drug abuse; adolescents, 365
  - drugs; adverse reactions; home health care, 1176
  - hospital pharmacy; i.v. to oral conversion policies, 200; latex policies, 2516; survey, 653
  - hospitals; pharmacists' interventions, 392
  - infections; medical devices, 1897
  - integrated health care; survey, 2786
  - Internet; surveys, 1334
  - managed care systems; National Committee for Quality Assurance, 2551
  - pharmacists; Wisconsin, 558
  - pharmacists, institutional; AIDS pharmaceutical care, 1407
- Death**
- drugs; North Carolina, 2434
  - fentanyl; toxicity, 85
  - patients; pharmacists' relations, 753
  - sodium phosphate dibasic; hyperphosphatemia, 2488
- Decision-making**
- clinical pharmacists; models, 1307
  - computers; medical logic modules, 281
  - formularies; authorization programs, 1941; models, Nov 15 suppl S5
  - hospital pharmacy; computers, 639; computer models, 2491
  - models; cost-benefit analysis, 1180
  - pharmacists; staff performance, 2680
- Degrees**
- Bachelor of Science; ACPE phaseout, 2439
  - Doctor of Pharmacy; accreditation standards, 2439; clerkships, 1727; pharmacists' careers, 1236; residents, 1521
- DEHP**, see **Diethylhexyl phthalate**
- Dehydrated alcohol**, see **Alcohols**, **ethyl**
- Delavirdine mesylate**; approvals; FDA, 1233
- Dementia**; donepezil hydrochloride; review, 2805
- Demographics**; pharmacists; specialty examinations, 1015
- Department of Health and Human Services**
- patient information; regulations, 352
  - protocols; antivirals, 1681
  - public health; Healthy People 2000, 2169
- Department of Veterans Affairs**; pharmaceutical services; administration, 761
- Dependence**; drugs; students, 365
- Depression**; methylphenidate; geriatrics, 2510
- Dermatitis**; losartan potassium; adverse reactions, 1333
- Desensitization**; sulfamethoxazole, combination, trimethoprim; allergies, 1545
- Devices**
- home tests; blood dextrose, 1058
  - infusion pumps; elastomeric, 915; home health care, 2230; portable, 1277; reservoir incompatibilities, 1068; reservoirs, 1845
  - inhalers; metered dose, 1021
  - medical; infection monitoring, 1897
  - stents; coronary disease, 437
- Dexamethasone sodium phosphate**; incompatibilities; ondansetron, 1065
- Dexfenfluramine**; toxicity; heart diseases, 1785
- Dexfenfluramine hydrochloride**
- product withdrawal; toxicity, 2269
  - review, 2059
- Dextruse**
- administration rate; portable infusion pumps, 1277
  - blood levels; insulin protocols, 1046; self-monitoring, 1062
  - diluents; amphotericin B incompatibilities, 683; antineoplastic incompatibilities, 566; ceftriaxone-metronidazole, 424; ciprofloxacin incompatibilities, 1193; cisatracurium incompatibilities, 1735; dexamethasone-ondansetron incompatibilities, 1065; doxorubicin, 2708; drug stability, 915; granisetron incompatibilities, 56; incompatibilities, 64, 1295, 1417; injections, 1845; propofol emulsions, 1287; remifentanyl incompatibilities, 2192
  - home tests; blood levels, 1058
  - hyperphosphatemia; sodium phosphate toxicity, 2488
  - incompatibilities; bumetanide, 422; midazolam, 913; propafenone, 1293
- Diabetes mellitus**
- acarbose; interactions, 1551
  - ciapride; gastroparesis, 2609
  - dextrose; self-monitoring, 1062
  - erythromycin lactobionate; gastroparesis, 2609
  - insulin; protocols, 1046
  - metformin hydrochloride; non-insulin dependent, 893
  - patient education; Medicare reimbursement, 2433
  - patient information; consultation, 2449
  - triglitazone; FDA approvals, 623
- Diacetylmorphine**
- abuse; adolescents, 365
  - pain; pharmacist consultation, 2451
- Diagnosis**
- attention deficit disorder with hyperactivity; pediatric, 2685
  - depression; geriatrics, 2510
  - thrombophlebitis; diagnosis, 66
- Dialysis**; pharmaceutical services; i.v. syringe checking, 1611
- Diarrhea**; therapy; pharmacists' protocols, 680
- Dietary Supplement Health and Education Act of 1994**; labeling; FDA regulations, 2561
- Dietary supplements**
- control, quality; laws, 1707
  - ephedrine; FDA regulations, 1578
  - ginger; interactions, 692
  - labeling; FDA regulations, 2561
  - sodium phosphate dibasic; errors, 2488
- Diethylhexyl phthalate**; leaching; antineoplastic agents, 566; docetaxel injections, Dec 15 suppl S7
- Diluents**
- alcohols, ethyl; docetaxel incompatibilities, 566
  - dextrose; amphotericin B incompatibilities, 683; antineoplastic agents incompatibilities, 915; antineoplastic incompatibilities, 566; bumetanide, 422; ceftriaxone-metronidazole, 424; ciprofloxacin incompatibilities, 1193; dexamethasone-ondansetron incompatibilities, 1065; doxorubicin incompatibilities, 2708; fluorouracil injections, 1845; granisetron incompatibilities, 56; incompatibilities, 1295, 1417; midazolam incompatibilities, 913; propafenone incompatibilities, 1293; propofol emulsions, 1287; remifentanyl incompatibilities, 2192
  - sodium chloride; antibiotic-polyvinyl chloride incompatibilities, 1068; antineoplastic agents incompatibilities, 915; antineoplastic incompatibilities, 566; bumetanide, 422; ceftriaxone-metronidazole, 424; ciprofloxacin injections, 2204; ciprofloxacin incompatibilities, 1193; dexamethasone-ondansetron incompatibilities, 1065; doxorubicin incompatibilities, 2708; granisetron incompatibilities, 56; incompatibilities, 1295; insulin-ranitidine incompatibilities, 1304; meperidine, 205; meropenem, 412; midazolam incompatibilities, 913; propafenone incompatibilities, 1293; propofol emulsions, 1287; remifentanyl incompatibilities, 2192; thiopeta incompatibilities, 2588
  - water for injection; antibiotic-polyvinyl chloride

- incompatibilities, 1068; meropenem, 412; warfarin incompatibilities, 2599
- Diphtheria and tetanus toxoids; immunization;** adults, 379
- Diphtheria and tetanus toxoids and pertussis vaccines;** combination, *Haemophilus b* oligosaccharide vaccines; concomitant therapy, 2488
- Disaster planning;** hospital pharmacy; emergency services, 1110
- Disasters;** pharmaceutical services; hospitals, 1110
- Disease management**
- asthma, DUR, 2197
- managed care systems; administration, 2217
- myocardial infarction; protocols, Nov 15 suppl S9
- pain; NABP resolutions, 1932; pharmacists' role, 2451
- pharmaceutical services; clinical care plans, 314
- pharmacists, institutional; patient education, 1497
- pharmacy, community; services, 32
- thrombolytic agents; myocardial infarction, Nov 15 suppl S3
- Diseases;** economics; ambulatory care databases, 1973
- Dispensing**
- automation; mail order, 520; United States Navy, 778
- gene therapy; handling, 1604
- hospital pharmacy; automation, 45; methodology, 171
- unit dose; i.v. syringe checking, 1611
- Dissolution;** drugs; USP standards, 1633
- Diuretics**
- bumetanide; stability, 422
- furosemide; absorption, 2609; incompatibilities, 64
- Divalproex sodium;** substitution; mental retardation facilities, 1716
- Docetaxel**
- incompatibilities; polyvinyl chloride, 566
- mechanism of action; overview, Dec 15 suppl S2
- neoplasms; overview, Dec 15 suppl S19
- overview, Dec 15 suppl S7
- pharmacoeconomics; comparisons, Dec 15 suppl S11
- pharmacokinetics; clinical studies, Dec 15 suppl S16
- Documentation**
- allergies; medical records, 1627
- computers; clinical interventions, 1727
- controlled substances; computers, 630; surgery, 1392
- health maintenance organizations; formularies, 1941
- hospital pharmacy; pharmacists' rounds, 670
- interventions; hospital pharmacists, 1596; manual vs. bar codes, 1623
- outcomes; i.v. to oral conversion, 524; JCAHO standards, 743
- personnel; latex allergies, 1071
- pharmaceutical services; clinical care plans, 314; clinical information systems, 1505
- pharmacists; rational therapy, 527
- pharmacists, community; disease management, 32
- pharmacists, hospital; clinical interventions, 1722; interventions, 392
- pharmacists, institutional; interventions, 2503
- pharmacy, institutional; patient consultation, 1515
- Donepezil hydrochloride;** Alzheimer's disease; review, 2805
- Dopamine hydrochloride;** incompatibilities; dextrose, 1417
- Dosage**
- alteplase; forms, 1447
- amifostine; review, 787
- amphotericin B; liposomes, 2426
- analgesics and antipyretics; pain, 2451
- angiotensin-converting-enzyme inhibitors; review, 2689
- antineoplastic agents; innovative therapy, 572
- antipsychotic agents; basal ganglia diseases, 2461
- antivirals; HIV infections, 2652
- ardeparin sodium, 1575
- aspirin; myocardial infarction, 1949; myocardial infarction prophylaxis, 1984
- azelastrine hydrochloride, 234
- bromfenac sodium; overview, 2151
- bupropion hydrochloride; smoking cessation, 1478
- cerivastatin sodium; overview, 1793
- cisapride; gastroparesis, 2609
- delavirdine mesylate; FDA approvals, 1233
- dexfenfluramine hydrochloride; review, 2059
- docetaxel; overview, Dec 15 suppl S7, S19; pharmacokinetics, Dec 15 suppl S16
- donepezil hydrochloride; review, 2805
- drug; computer checking, 545; kidney failure, 2505
- enoxaparin sodium; thrombophlebitis, 1968
- errors, medication; compounding errors, 1449
- fentanyl; i.v. to transdermal, 87
- furosemide; gastroparesis, 2609
- gemcitabine; review, 162
- glyburide; diabetes mellitus, 1062
- insulin; sliding scales, 1046
- interferon alfacon-1; overview, 2656
- losartan potassium; adverse reactions, 1333
- metformin hydrochloride; review, 893
- mibefradil dihydrochloride; overview, 2033
- minerals; dietary reference intakes, 2438
- mupirocin calcium; review, 2185
- mycophenolate mofetil; review, 285
- nelfinavir mesylate; FDA approvals, 1233
- nicotine; inhalers, 1478
- nitrogen; enteral nutrition, 2239
- overdose; emergency room visits, 295; fentanyl, 85; sodium phosphate, 2488
- patches transdermal; reduced, 1759
- piperacillin sodium, combination, tazobactam sodium; interactions, 2704
- pramipexole dihydrochloride; overview, 1922
- propofol; fat emulsions, 2515
- proteins; enteral nutrition, 2239
- quetiapine fumarate; overview, 2547
- reteplase; myocardial infarction, 12
- ropinirole hydrochloride; Parkinson's disease, 2655
- sermorelin acetate; overview, 2547
- sulfamethoxazole, combination, trimethoprim; desensitization, 1545
- tazarotene; overview, 2037
- tiagabine hydrochloride; overview, 2544
- tiludronate disodium; overview, 1145
- tramadol; review, 643
- tramadol hydrochloride; DUE, 696
- troglitazone, 623
- urokinase; DUE criteria, 2000, 2002
- vasopressin; home infusion, 2230
- vincristine sulfate; toxicity, 1755
- vitamins; dietary reference intakes, 2438
- Dosage forms**
- aspirin; myocardial infarction, 1949
- fentanyl; transdermal patches, 85
- sustained-action medications; patient information, 2403
- Dosage schedules**
- analgesics and antipyretics; pain, 2451
- angiotensin-converting-enzyme inhibitors; initiation, 2689
- antimetotics; Medicare reimbursement, 2433
- anti-infective agents; DUE, 1837
- antituberculars; ASHP protocols, 428
- antivirals; HIV infections, 2652
- cefotaxime sodium; cost comparison, 1614
- ceftriaxone sodium; cost comparison, 1614
- drugs; long term, 2084
- epoprostenol; congestive heart failure, 2613
- fentanyl citrate; injections, 87
- hypotensive agents; long term, 2079
- insulin; sliding scales, 1046
- interferon alfa-2a; renal cell carcinoma, 190
- interferons; hepatitis C, 1140
- parenteral nutrition; long term, 1789
- piperacillin sodium, combination, tazobactam sodium; interactions, 2704
- propofol; fat emulsions, 2515; long term, 694
- sulfamethoxazole, combination, trimethoprim; desensitization, 1545
- tretinoin; renal cell carcinoma, 190
- vaccines; adolescents, 494
- Doxorubicin hydrochloride;** incompatibilities; containers, 915; i.v. injections, 2708
- Drug abuse**
- adolescents; survey, 365
- athletes; Olympic Games, 1053
- fentanyl; transdermal patches, 85
- interactions; nonprescription drugs, 1762
- methamphetamine; toxicity, 586
- patient information; hospital pharmacists, 564
- Drug administration**
- amifostine; review, 787
- cefotaxime sodium; cost comparisons, 1614
- cidofovir; toxicity, 12
- controlled substances; automation, 630
- fentanyl; transdermal patches, 87
- injections; needle-stick policies, 258
- self-medication; consumer survey, 2664; dextrose levels, 1058; enoxaparin, 1968
- vaccines; pharmacists, 490
- vasopressin; home infusion, 2230
- Drug administration rate**
- infusion pumps; portable, 1277
- granisetron hydrochloride; toxicity, 1172
- transdermal; fentanyl, 87
- Drug administration routes**
- in utero; HIV infection prophylaxis, 1018
- intra-arterial; urokinase, 1988
- intranasal; azelastine, 234; methamphetamine, 586; mupirocin, 2185
- intravenous; antineoplastic agents, 830; conversion to oral, 200, 524; fentanyl, 87; granisetron vs. ondansetron, 1172; urokinase, 1988
- oral; antiemetics, 830; conversion from i.v., 200, 524; furosemide, 2609; hypotensive agents, 2609
- transdermal; dosage, 1759; fentanyl toxicity, 85
- Drug administration sites;** urokinase; regional infusions, 2000; thrombosis, 1988
- Drug administration systems;** ceftriaxone sodium; cost comparisons, 1614
- Drug comparisons**
- alteplase and reteplase; myocardial infarction, Nov 15 suppl S27
- anti-infective agents, nafcillin and oxacillin; adverse reactions, 1176
- cefotaxime sodium and ceftriaxone sodium; dosage schedules, 1614
- ceftriaxone sodium and cefotaxime sodium; dosage schedules, 1614
- divalproex sodium and valproic acid; epilepsy, 1716
- docetaxel and paclitaxel; pharmacoeconomics, Dec 15 suppl S11
- enoxaparin and heparin; pharmacoeconomics, 1185
- granisetron and ondansetron; antineoplastic toxicity, 2478
- granisetron hydrochloride and ondansetron hydrochloride; toxicity, 1172
- heparin and enoxaparin; pharmacoeconomics, 1185
- lidocaine, combination, prilocaine and tetracaine; phlebotomy pain, 388
- nafcillin, anti-infective agents and oxacillin; adverse reactions, 1176
- ondansetron and granisetron; antineoplastic toxicity, 2478
- ondansetron hydrochloride and granisetron hydrochloride; toxicity, 1172
- oxacillin, anti-infective agents and nafcillin; adverse reactions, 1176
- paclitaxel and docetaxel; pharmacoeconomics, Dec 15 suppl S11
- reteplase and alteplase; myocardial infarction, Nov 15 suppl S27
- serums; pregnancy, 1018
- surgery and urokinase; arterial occlusive diseases, 1963
- tetracaine and lidocaine, combination, prilocaine; phlebotomy pain, 388
- urokinase and surgery; arterial occlusive diseases, 1963
- valproic acid and divalproex sodium; epilepsy, 1716
- Drugdex;** databases; comparisons, 2592
- Drug distribution;** pharmacy, institutional; mail order, 520
- Drug distribution systems**
- administration; pharmacists' opportunities, 1049
- controlled substances; computers, 630
- errors, medication; methodology, 171
- home health care; AIDS, 1407
- hospital pharmacy; contract services, 37, 41, 43, 52; gene-therapy handling, 1604; outsourcing models, 48; survey, 653; wholesalers, 45
- hospitals; patient-focused care, 1262
- unit dose; i.v. syringe checking, 1611
- Drug histories, see Patient information; drug histories**
- Drug information**
- computers; academic centers, 1763; patient-focused care, 1501; programs, 281
- databases; comparisons, 2592
- education, pharmaceutical; museum exhibits, 1236
- industry, pharmaceutical; AHP policies, 30
- Internet; pharmacy news groups, 1732
- medicinal plants; sources, 2656
- newspapers; drug abuse, 1762
- patient information; private sector, 352
- pharmacists, hospital; patient-focused care, 1262
- pharmacists, institutional; hospital rounds, 670
- technology; pharmacists' role, 2503
- telecommunications; networks, 1930
- writing; guidelines, 1572

**Drug information centers**

databases; administration, 1763  
information; errors, 1732  
telecommunications; networks, 1930

**Drug Information Fulltext**; databases; comparisons, 2592

**Drug Information Network**; administration; telecommunications, 1930

**Drug interactions**

acarbose and warfarin; blood coagulation, 1551  
angiotensin-converting-enzyme inhibitors; review, 2689

cidofovir; toxicity, 12  
cisapride and warfarin sodium; hypoprothrombinemias, 320

computers; pharmacists' interventions, 2719  
donepezil hydrochloride; review, 2805  
food; pharmacists' interventions, 405

gentamicin and piperacillin sodium, combination, tazobactam sodium; pharmacokinetics, 2704  
ginseng and warfarin sodium; international normalized ratio, 692

hospitals; admissions, 295  
metformin and roentgenographic agents; lactic acidosis, 587

metformin hydrochloride; review, 893  
monitoring; computers, 1515  
parenteral nutrition and propofol; hypertriglyceridemia, 2515

patient information; pharmacists, 2664  
piperacillin sodium, combination, tazobactam sodium and gentamicin; pharmacokinetics, 2704

prescriptions; patient information, 2664  
propofol and parenteral nutrition; hypertriglyceridemia, 2515

pseudoephedrine hydrochloride, combination, terfenadine; product withdrawal, 342  
ritonavir; toxicity, 126

roentgenographic agents and metformin; lactic acidosis, 587  
terfenadine; product withdrawal, 342

warfarin sodium and acarbose; blood coagulation, 1551  
warfarin sodium and cisapride; hypoprothrombinemias, 320

warfarin sodium and ginseng; international normalized ratio, 692

**Drug product selection**, see **Substitution; generic**

**Drug Reaction Alerts**, 103, 329, 596, 849, 1128, 1360, 1561, 1772, 2015, 2250, 2528, 2772

**Drugs**

approvals; amphotericin B, 2426; antivirals, 1233; ardeparin, 1575; azelastine, 234; bromfenac, 2151; bupropion, nicotine, 1478; cerivastatin, 1793; FDA, 1996, 494; fexofenadine, 342; interferon alfacon-1, 2656; mibefradil, 2033; pramipexole, 1922; quetiapine, 2547; reteplase, 12; ropinirole, 2655; sermorelin, 2547; tazarotene, 2037; tiagabine, 2544; tiludronate, 1145; troglitazone, 623; USPHS pharmacists, 766

emergency; disasters, 1110  
generic; estrogens, conjugated, 1376; narrow therapeutic index, 1630; patient information, 2664

illicit; AIDS buyers' clubs, 2122; students' abuse, 365  
new; FDA approvals, 494

recall; product withdrawal, 2269  
recalls; levothyroxine, 2151

reconstitution; meropenem, 412  
selection; ACE inhibitors, 2689; analgesics, 2451; antidepressants, 2510; antivirals, 1681, 2652; aspirin, 1949; clinical care plans, 314; i.v. to oral conversion, 524; *S. pneumoniae* resistance, 527

unapproved; AIDS buyers' clubs, 2122

**Drugs, adverse reactions**  
see also **Toxicity**

acarbose; interactions, 1551  
anticonvulsants; cross-sensitivity, 2616  
anti-infective agents; comparisons, 1176

hospitals; admissions, 295  
late; allergies, 1071, 1688, 2517; pharmacy policies, 2516

losartan potassium; dermatitis, 1333  
nafcillin; comparisons, 1176

oxacillin; comparisons, 1176  
oxaprozin; status asthmaticus, 199

pharmacists, hospital; patient-focused care, 1262  
reports; dietary supplements, 1707; therapeutic interchange, 1149

roentgenographic agents; protocols, 1395  
sulfamethoxazole, combination, trimethoprim; allergies, 1545

warfarin sodium; interactions, 1551

**Drugs, availability**; United States Pharmacopeia; standards, 1633

**Drugs, body distribution**  
aminoglycosides; patients' weight, 2201; pharmacokinetic calculations, 541  
aztreonam; critical illness, 537

**Drugs, clinical effectiveness**; myocardial infarction; thrombolytic agents, Nov 15 suppl S23

**Drugs, investigational**  
clinical studies; pharmaceutical services, 1742  
gene therapy; handling, 1604

new-drug applications; FDA regulations, 874;  
levothyroxine, 2151

**Drugs, nonprescription**  
classification; prescription to nonprescription, 1207

consumers; self-medication, 2664  
interactions; drug abuse, 1762  
pseudoephedrine hydrochloride, combination, terfenadine; product withdrawal, 342

terfenadine; product withdrawal, 342  
toxicity; emergency room visits, 295

**Drug use**  
analgesics and antipyretics; consumers, 2664  
divalproex sodium; costs, 1716

evaluation; antibiotics, 2736; anti-infective agents, 1837; clinical information systems, 1515; mail-order prescriptions, 613; tramadol, 696; urokinase criteria, 2000, 2002

gastrointestinal drugs; consumers, 2664  
pharmaceutical services; integrated health care, 2207

pharmacists, hospital; interventions, 1596  
pneumococcal vaccines; pharmacists' role, 527  
review; asthma prescribing, 2197

valproic acid; costs, 1716  
women; FDA programs, 2288

**DUE Criteria**, 696, 2000  
tramadol hydrochloride, 696  
urokinase, 2000, 2002

**Dyspnea**; vasopressin; toxicity, 2230

**Dystonia**; antipsychotic agents; toxicity, 2461

**E**

**Echinococcosis**; albendazole; monitoring, 319

**Economics**  
computers; health care, 263  
contract services; hospital pharmacy, 37, 41

cost-benefit analysis; calcium antagonists, 2079;  
cefotaxime vs. ceftriaxone, 1614; docetaxel vs. paclitaxel, Dec 15 suppl S11; drug information databases, 2592; enoxaparin vs. heparin, 1185; famciclovir, 1180; formularies, 95; hospital pharmacy, 1196; institutional pharmacists, 2503, 2668; i.v. to oral conversion, 524; otitis media, 2736; pharmaceutical care, 554; pharmacists' interventions, 2811, 1591; roentgenographic agents protocols, 1395; thrombolytic agents, Nov 15 suppl S23

diseases; ambulatory care databases, 1973  
financial management; pharmacy benefits, 2207  
health care; technology, 269

pharmacists; hours, 558  
pharmacy; drug cost projections, 153

**Edetate disodium**; incompatibilities; acetylcysteine, 549; captopril, 2483

**Editorials**, 37, 263, 375, 527, 639, 757, 1049, 1273, 1501, 1707, 1804, 1949, 2055, 2181, 2457, 2685, 2803

Adverse reactions to alternative medicine, 1707  
ASHP's Web site, 1273

An aspirin a day: advice that makes sense, 1949  
Chasing the curve of innovation: trends from the 1996 survey, 639

Combating tuberculosis, 375  
Controlling pneumococcal resistance to penicillin, 527

Direct-to-consumer prescription drug advertising, 2181  
The Joseph A. Oddis Endowment, 1804

Making software work for pharmacy, 1501  
Managed care backlash, 1049

Outsourcing drug distribution, 37  
Patient-centered computing, 263

Promoting rational thought about ADHD, 2685  
Promoting use of angiotensin-converting-enzyme inhibitors, 264

Safe use of niacin, 2803  
Slowing the emergence of multidrug-resistant pathogens, 2457

Training pharmacists for careers in managed care, 2055  
Trouble on the Internet, 757

**Education**  
athletes; drug abuse, 1053  
health professions; enteral nutrition, 2239; Medicare reimbursement, 2433

nurses; i.v. to oral conversion, 524  
personnel; latex allergies, 1071

physicians; ACE inhibitors, 264; antibiotic resistance, 2457; i.v. to oral conversion, 524; Medicare reimbursement, 2433; pharmacy students, 1727

universities; hospitals, 1711

**Education, pharmaceutical**  
anticoagulants; ASHP traineeship, 2169  
clerkships; clinical interventions, 1727; community service, 354

clinical pharmacy; prisons, 674  
continuing; pharmacists' competence, 2433; technician certification, 1486; United States Navy, 778

degrees; accreditation, 2439  
drug information; museum exhibits, 1236

pharmacists; hyperactivity, 2685; immunization programs, 490; job description, 1260; new roles, 1477; United States Air Force, 783; United States Army, 773; United States Navy, 778

pharmacists, hospital; administration, 1076; clinical interventions, 1722; disasters, 1110; training programs, 1794

rational therapy; antibiotics, 575  
residencies; Department of Veterans Affairs, 761; drug information, 1930; job satisfaction, 1521; managed care systems, 2055, 2099; memory disorders, 92; self-renewal programs, 2116; survey, 653

standards; NABP resolutions, 1932  
technicians; certification, 2562; United States Air Force, 783; United States Army, 773; United States Navy, 778

**Educators**; pharmacists; Internet, 34  
**Elements**; trace; parenteral nutrition, 570

**Elimination**, see **Metabolism**

**Embolism**; warfarin sodium; interactions, 1551

**Emergencies**; alteplase; protocols, 1447

**Emergency kits**; hospital pharmacy; disasters, 1110

**Emergency services**  
hospital pharmacy; disasters, 1110

pharmacists, hospital; patient-focused care, 1262

**Employment**  
pharmacists; professional competence, 1260; resignation, 1946

technicians; certification, 2562

**Emulsions**; propofol; incompatibilities, 1287

**England**; pharmacists, hospital; interventions, 1596

**Enoxaparin**; pharmacoeconomics; comparisons, 1185

**Enoxaparin sodium**; thrombophlebitis; home health care, 1968; overview, 1995

**Enterococcus species**; resistance; anti-infective agents, 1420

**Enzyme inhibitors**; cilastatin sodium, combination, imipenem; incompatibilities, 185

**Ephedrine**; dietary supplements; FDA regulations, 1578

**Epidemiology**; pneumococcal infections; *S. pneumoniae* infections, 575

**Epilepsy**  
divalproex sodium; substitution, 1716  
valproic acid; substitution, 1716

**Epinephrine**; heart arrest; therapy, 85

**Epinephrine hydrochloride**; incompatibilities; dextrose, 1417

**Epoprostenol**; heart failure; congestive, 2613

**Equipment**  
computers; health care, 269  
hospital costs; pharmacy outsourcing, 48

hospital pharmacy; ambulatory care, 1584  
**Equivalency**; fentanyl; i.v., transdermal, 87

**Equivalency, generic**  
drugs; narrow therapeutic index, 1630  
levothyroxine sodium; FDA regulations, 2151  
prescription drugs; patient information, 2664

**Errors**  
codes; ambulatory care databases, 1973  
compounding; automation, 678  
documentation; manual vs. bar codes, 1623  
drug information; Internet, 1732

**Errors, medication**  
dosage; compounding, 1449; computer checking, 545  
geriatrics; coalitions, 2282  
hospital pharmacy; methodology, 171

- injections; i.v. compounding, 904; i.v. syringe checking, 1611; storage, 2006  
 insulin; sliding scales, 1046  
 nomenclature; computer models, 1161  
 pharmacists; role, 1477  
 ritonavir; nomenclature, 126  
 sodium phosphate dibasic; dosage, 2488  
 television; PBS programs, 1486  
 USP quality control; USP, 1240
- Erythema nodosum**; thalidomide; FDA regulations, 2270
- Erythromycin lactobionate**; gastroparesis; furosemide absorption, 2609
- Estrogens**; estrogens, conjugated; FDA regulations, 1376
- Estrogens, conjugated**; generic; FDA regulations, 1376
- Ethanol**, see **Alcohols, ethyl**
- Ethics**  
*American Journal of Health-System Pharmacy*; authorship policies, 30  
 committees; hospitals, 2007  
 personnel; pharmacy; code of conduct, 142  
 pharmacists; managed care systems, 1041; pharmaceutical care, 2733  
 pharmacists, hospital; infant formula kits, 687  
 quackery; Internet, 757  
 suicides; physician-assisted, 1025
- Ethylene**; copolymers; propylene, 2204
- Ethylene hydrochloride**; sustained-action; excretion, 2403
- Examinations**  
 certification; pharmacotherapy, 1015  
 clinical pharmacy; training, 674  
 pharmacists; professional competence, 2433
- Excipients**  
 drugs; USP standards, 1633  
 sodium deoxycholate; amphotericin B, 2426
- Excretion**  
 aminoglycosides; patients' weight, 2201; pharmacokinetic calculations, 541  
 creatinine; drug dosage, 2505  
 docetaxel; dosage, Dec 15 suppl S16  
 tablets; stools, 2403
- Extravasation**; roentgenographic agents; protocols, 1395
- F**
- Facts and Comparisons**; databases; comparisons, 2592
- Famciclovir**; neuralgia; postherpetic, 1180
- Fat emulsion**  
 propofol; calories, 2515; parenteral nutrition, 694  
 soybean oil; incompatibilities, 683
- Fees**; technicians; recertification, 1486
- Fenfluramine**; toxicity; heart diseases, 1785
- Fenfluramine hydrochloride**; product withdrawal; toxicity, 2269
- Fentanyl**  
 abuse; transdermal patches, 85  
 transdermal patches; i.v. to transdermal, 87
- Fentanyl citrate**; injections; i.v. to transdermal, 87
- Fexofenadine hydrochloride**; metabolites; terfenadine, 342
- Filgrastim**; incompatibilities; anti-infective agents, 185
- Flow**; rates; portable infusion pumps, 1277
- Fluconazole**; incompatibilities; filgrastim, 185
- Fluorides**; dosage; dietary reference intakes, 2438
- Fluorouracil**; incompatibilities; containers, 1845
- Food**; interactions; pharmacists' interventions, 405
- Food and Drug Administration (U.S.)**  
 approvals; amphotericin B liposomes, 2426; antiviral marketing, 1233; ardeparin, 1575; azelastine, 234; bromfenac, 2151; cerivastatin, 1793; interferon alfacon-1 marketing, 2656; mibefradil, 2033; new drugs, 494; pramipexole, 1922; quetiapine, 2547; reteplase marketing, 12; ropinirole marketing, 2655; sermorelin, 2547; smoking cessation therapy, 1478; tazarotene, 2037; tiagabine, 2544; tiludronate, 1145; troglitazone, 623  
 attitudes; narrow therapeutic index, 1630  
 dexfenfluramine hydrochloride and fenfluramine hydrochloride; product withdrawal, 2269  
 drugs, adverse reactions; therapeutic interchange, 1149  
 FDA Medical Products Reporting Form and Instructions, 101, 1559  
 guidelines; direct-to-consumer advertising, 2181; gene-therapy handling, 1604  
 health care; women, 2288
- interferon alfa-2b; dosage schedules, 1140  
 MedGuide; patient information, 352  
 new-drug applications; oral contraceptives, 874  
 paclitaxel; labeling, 2128  
 product withdrawal; terfenadine, 342  
 protease inhibitors; hyperglycemia toxicity, 1575  
 regulations; AIDS buyers' clubs, 2122; anorexics labeling, 1785; chlorofluorocarbons, 1021; dietary supplement labeling, 2561; dietary supplements, 1707; ephedrine, 1578; estrogens, conjugated, 1376; gene therapy, 877; Internet, 757; levothyroxine, 2151; tobacco, 2050  
 role; quality control reports, 1240  
 thalidomide; marketing regulations, 2270  
 United States Public Health Service; pharmaceutical services, 766  
 vitamins; imports, 1789  
 withdrawal, 2269
- Forms**  
 alteplase; dosage, 1447  
 data collection; device-related infections, 1897  
 hospital pharmacy; personnel competence, 1412
- Formularies**  
 calcium antagonists; costs, 2079  
 decision-making; models, Nov 15 suppl S5  
 drugs, adverse reactions; therapeutic interchange, 1149  
 health maintenance organizations; authorization programs, 1941  
 history; Boston Dispensary, 1097  
 hospital pharmacy; ACE inhibitors, 2689; administration, 1076; amifostine, 787; cost-benefit analysis, 95; survey, 653  
 integrated health care; U.S., 238  
 pharmacy, institutional; clinical information systems, 1515  
 restricted; managed care systems, 1041
- Formulations**  
 amphotericin B; FDA approvals, 2426  
 captopril; oral liquids, 2483  
 docetaxel; overview, Dec 15 suppl S7  
 enteral nutrition; labeling, 2239  
 medicinal plants; efficacy, 2656  
 parenteral nutrition; automated compounding, 678; incompatibilities, 1295  
 propofol; fat emulsions, 2515  
 ursodiol; suspensions, 1401
- Foundation for Accountability**; reports; managed care systems, 1528
- France**; laws; hospital pharmacists, 1110
- Freezing**; propafenone hydrochloride; incompatibilities, 1293
- Frontline Pharmacist**, 34, 258, 524, 753, 1046, 1262, 1702, 1946, 2174, 2451, 2680  
 Decentralizing an i.v.-to-oral conversion program, 524  
 Guiding patients to better pain relief, 2451  
 Leaving a job on an up note, 1946  
 Pharmacists in patient-focused care, 1262  
 Preparing for the last visit with a dying patient, 753  
 Prioritizing pharmacy services in the emergency department, 1702  
 Recapping needles in the pharmacy, 258  
 Recognizing a nurse as team leader, 2174  
 Standardizing regimens for sliding-scale insulin, 1046  
 Surfing the Net for pharmacy sites, 34  
 Work styles, 2680
- Furosemide**  
 absorption; prokinetic agents, 2609  
 incompatibilities; i.v. additives, 64
- G**
- Gastrointestinal drugs**  
 cisapride; gastroparesis, 2609; interactions, 320  
 erythromycin lactobionate; gastroparesis, 2609  
 histamine H<sub>2</sub> antagonists; latex allergies, 2516  
 incompatibilities; propofol, 1287  
 omeprazole; stability, 1833  
 prescribing; anticonvulsant toxicity, 1716  
 ranitidine hydrochloride; incompatibilities, 1304  
 use; consumers, 2654
- Gastrointestinal hemorrhage**; vasopressin; home infusion, 2230
- Gastroparesis**  
 cisapride; drug absorption, 2609  
 erythromycin lactobionate; furosemide absorption, 2609
- Gencitabine**; review, 162
- Generic substitution**, see **Substitution; generic**
- Gene therapy**  
 handling; hospital pharmacy, 1604  
 regulations; FDA, 877
- Genitamicin**  
 interactions; piperacillin-tazobactam, 2704  
 pharmacokinetics; Bayesian calculations, 541; patients' weight, 2201
- Genitamicin sulfate**; incompatibilities; filgrastim, 185
- Geography**; pharmacists, hospital; France, 1110
- Geriatrics**  
 antidepressants; selection, 2510  
 errors, medication; coalitions, 2282  
 immunization; APhA guidelines, 2553  
 prescriptions; mail order, 613
- Gilead Sciences**; cidofovir; toxicity warnings, 12
- Ginseng**; interactions; warfarin, 692
- Glass**  
 containers; dextrose-nitroglycerin incompatibilities, 1417; midazolam incompatibilities, 913  
 incompatibilities; meropenem, 412; pentoxifylline suspensions, 1301; pyrimethamine suspensions, 2714; tacrolimus suspensions, 178
- Globulin immune**; HIV infections; pregnancy, 1018
- Gloves**; latex; allergies prophylaxis, 1688
- Glucose**, see **Dextrose**
- Glyburide**; diabetes mellitus; dosage, 1062
- Glycerin**; vehicles; ursodiol suspensions, 1401
- Good Manufacturing Practices**; industry, pharmaceutical; dietary supplements, 1707
- Granisetron**; nausea; comparisons, 2478
- Granisetron hydrochloride**  
 incompatibilities; i.v. additives, 56  
 stability; compounding, 1404  
 toxicity; comparisons, 1172
- Grants**; ASHP Research and Education Foundation; J. Oddis endowment, 1804
- Group purchasing**, see **Purchasing**
- Growth disorders**; sermorelin acetate; FDA approvals, 2547
- Guidelines**  
 see also **Protocols**  
 American Pharmaceutical Association; immunization, 2553  
 American Society of Health-System Pharmacists; clinical care plans, 314; patient consultation, 431; recruitment, 1260; S. pneumoniae resistance, 575  
 Food and Drug Administration; direct-to-consumer advertising, 2181; gene-therapy handling, 1604  
 health care; Internet information, 757  
 health maintenance organizations; pharmaceutical services, 32  
 hospital pharmacy; contract services, 43  
 International Pharmaceutical Federation; drug donations, 2800  
 National Institute for Occupational Safety and Health; latex allergies, 1688  
 patient information; writing, 1572
- H**
- Haemophilus b oligosaccharide vaccines**; combination, diphtheria and tetanus toxoids and pertussis vaccines; concomitant therapy, 2488
- Half-life**  
 aminoglycosides; patients' weight, 2201  
 gentamicin; piperacillin-tazobactam interactions, 2704
- Hallucinogens**; abuse; adolescents, 365
- Harvey A. K. Whitney Lecture Award**; pharmacy; professional practice, 1827
- Head and neck neoplasms**; docetaxel; overview, Dec 15 suppl S19
- Health-benefit programs**  
 contracts; disease management, 32  
 managed care systems; quality assurance, 2551  
 Medicaid; asthma DUR, 2197  
 Medicare; capitation, 2449; reimbursement policies, 830; reimbursement regulations, 2433  
 membership; U.S., 19  
 third party; AIDS home care, 1407; clinical studies, 1742; innovative therapy, 572  
 United States Air Force; managed care, 783  
 United States Army; managed care, 773  
 United States Navy; managed care, 778
- Health care**  
 computers; pharmacists' role, 263  
 costs; direct-to-consumer advertising, 2181; managed care systems, 1049  
 databases; pharmacoeconomics, 2601

- education; universities, 1711  
geriatrics; medication errors, 2282  
history; Boston Dispensary, 1097  
home; adverse drug reactions, 1176; AIDS pharmaceutical care, 1407; computers, 269; data collection, 2044; enoxaparin, 1968; low-molecular-weight heparins, 1995; memory disorders, 92; patient consultation, 431; reimbursement, 2433; vasopressin, 2230  
Hungary; politics, 1207  
information; Internet, 34, 757  
patient education; pharmacists, 1497  
pharmaceutical care; outcomes, 1434  
pharmacists; role, 1477  
pharmacists, institutional; future, 2503  
quality assurance; hospitals, 2238  
technology; information, 274  
women; FDA programs, 2288; psychopharmacy clinic, 2717
- Health maintenance organizations**  
administration; computerized databases, 1510; indigent patient consultation, 2449  
costs; antibiotics, 2736; purchasing, 153  
disease management; pharmaceutical services, 32  
formularies; authorization programs, 1941  
home health care; enoxaparin monitoring, 1968  
membership; U.S., 19  
ownership; hospitals, 2044  
pharmaceutical services; clinical information systems, 1515; psychopharmacy clinic, 2717  
pharmacy, institutional; hospital rounds, 670  
prescriptions; mail order, 520
- Health Plan Employer Data and Information Set**; quality assurance; managed care systems, 1528
- Health professions**  
communication; HMOs, 1510  
contract services; pharmacists, 1025  
documentation; allergies, 1627  
drugs, adverse reactions; therapeutic interchange, 1149  
education; enteral nutrition, 2239; Medicare reimbursement, 2433; universities, 1711  
guidelines; Internet information, 757  
monitoring; niacin toxicity, 2803, 2815  
quality assurance; health care, 2238
- Health Resources and Services Administration**; United States Public Health Service; pharmaceutical services, 766
- Hearing disorders**; amifostine; prophylaxis, 787
- Heart arrest**; fentanyl; toxicity, 85
- Heart diseases**; anorexics; toxicity, 1785
- Heart failure**; epoprostenol; congestive, 2613
- Hematologic diseases**  
amifostine; prophylaxis, 787  
aminoglycosides; pharmacokinetic calculations, 541
- Hematopoietic agents**; filgrastim; incompatibilities, 185
- Hemorrhologic agents**; pentoxifylline; stability, 1301
- Hemostatics**; vasopressin; home infusion, 2230
- Henderson v. Boline Aluminum**; health benefit programs; innovative therapy, 572
- Henry J. Kaiser Family Foundation**; protocols; antivirals, 1681
- Heparin**  
myocardial infarction; protocols, Nov 15 suppl 59  
pharmacoeconomics; comparisons, 1185
- Heparins**; low molecular weight; overview, 1995
- Heparin sodium**; myocardial infarction; methamphetamine toxicity, 586
- Hepatitis A vaccines**; immunization; adults, 379
- Hepatitis C**  
interferon alfacon-1; FDA approvals, 2656  
interferons; protocols, 1140
- Hepler, C.**; pharmacy; future, 1012
- Heroin**, see **Diacetylmorphine**
- Herpes vaccines**; adults; research, 379
- Herpes zoster**; famciclovir; cost-benefit analysis, 1180
- Hip prosthesis**  
enoxaparin; surgery, 1185  
heparin; surgery, 1185
- History**  
anticoagulants; research, 1992  
certification; technicians, 2562  
control, quality; ASHP, 1240  
drugs; museum exhibits, 1236  
hospital pharmacy; contract services, 41  
Lyons, C.; hospital pharmacy, 1095  
Manasse, H.; pharmacy practice, 1477  
Odds, J.; ASHP, 1804; pharmacy, 1815  
pharmacy; professional practice, 1827; twentieth century, 1805; twenty-first century, 1865  
pharmacy, institutional; Boston Dispensary, 1097; future, 2503  
thrombolytic agents; research, 1992  
United States Public Health Service; pharmaceutical services, 766
- HIV**, see **Human immunodeficiency virus**
- HIV-IG**, see **Human immunodeficiency virus immune globulin**
- HMOs**, see **Health maintenance organizations**
- Home Care Exchange**, 2230
- Home health care**, see **Health care; home**
- Home tests**  
dextrose; blood levels, 1058; self-monitoring, 1062  
HIV infections; reliability, 2232
- Hormones**  
sermorelin acetate; FDA approvals, 2547  
somatropin; AIDS wasting syndrome, 2618
- Hospital pharmacy**, see **Pharmacy, institutional, hospital**
- Hospitals**  
administration; drug administration routes, 200; pharmacy consolidation, 1076; university affiliated, 1711  
admissions; drug toxicity, 295  
clinical studies; costs, 1742  
contract services; HMOs, 670  
costs; control, 1196; patient-focused care, 1262  
emergency rooms; pharmaceutical services, 1702  
intensive care units; algorithms, 1841; drug incompatibilities, 64; pharmacists' interventions, 2811  
length of stay; arterial occlusive diseases, 1963; enoxaparin vs. heparin, 1185; integrated health care, 238; pharmacists' interventions, 392, 1591; propofol, 1953  
operating rooms; controlled-substances documentation, 1392  
ownership; HMOs, 2044; quality assurance, 2238  
patient care; outcomes standards, 743  
pharmaceutical services; immunization programs, 490; outsourcing, 37, 41  
physicians; allergy documentation, 1627  
policies and procedures; latex allergies, 1071; needle sticks, 258  
protocols; roentgenographic agents, 1395  
quality assurance; pharmacists' interventions, 1722  
reimbursement; laws, 2433  
team; patient-focused care, 2174
- Hours**  
after-hours service; formularies, 1941  
part time; ICU pharmacists, 2811  
pharmacists; economics, 558  
pharmacists, hospital; patient-focused care, 1262  
24-hour service; hospital pharmacy, 1110
- Human immunodeficiency virus**; tests, laboratory; ribonucleic acid levels, 1646
- Human immunodeficiency virus immune globulin**; HIV infections; pregnancy, 1018
- Human immunodeficiency virus infections**  
aldesleukin; palliative care, 1191  
antivirals; protocols, 1681, 2652  
drugs; AIDS buyers' clubs, 2122  
globulin immune; pregnancy, 1018  
human immunodeficiency virus immune globulin; pregnancy, 1018  
patient care; continuity, 1407  
protease inhibitors; hyperglycemia toxicity, 1575  
sulfamethoxazole, combination, trimethoprim; allergies, 1545  
tests, laboratory; ribonucleic acid levels, 1646; non-blood-based, 2232  
zidovudine; pregnancy, 1018
- Hungary**; drugs, nonprescription; prescription to nonprescription, 1207
- Hunter, J.**; awards; tobacco regulations, 2050
- Hydrates**; drugs; compounding errors, 1449
- Hydrogen ion concentration**; thiotepa; incompatibilities, 2588
- Hyperalimentation**, see **Nutrition; parenteral**
- Hypercholesterolemia**; cerivastatin sodium; FDA approvals, 1793
- Hyperglycemia**; protease inhibitors; toxicity, 1575
- Hyperphosphatemia**; sodium phosphate dibasic; errors, 2488
- Hypertension**  
ambulatory care; pharmacists' role, 564  
clinical pharmacists; primary care, 2079  
mibefradil dihydrochloride; FDA approvals, 2033
- Hypertriglyceridemia**; propofol; fat emulsions, 2515
- Hypoalbuminemia**; aminoglycosides; pharmacokinetics, 2201
- Hypoprothrombinemias**  
cisapride; interactions, 320  
warfarin sodium; interactions, 320
- Hypotensive agents**  
amlodipine; absorption, 2609  
captopril; incompatibilities, 2483  
costs; pharmacists' interventions, 2079  
hypertension; information, 564  
losartan potassium; adverse reactions, 1333  
minoxidil; absorption, 2609
- Introgenic diseases**, see **Drugs, adverse reactions**
- Imipenem**; combination, clastatin sodium; incompatibilities, 185
- Immunization**  
diseases; adolescents, 494; adults, 379; pharmaceutical services, 490  
guidelines; APHA, 2553  
pneumococcal infections; ASHP position statement, 575; pharmacists' role, 527
- Immunosuppressive agents**  
cyclosporine; incompatibilities, 181  
incompatibilities; Y-site injections, 181  
mycophenolate mofetil; review, 285  
tacrolimus; suspensions, 178
- Immunotherapy**  
aldesleukin; toxicity, 1191  
interferon alfa-2b; hepatitis C, 1140
- Imports**  
drugs; AIDS buyers' clubs, 2122  
Food and Drug Administration; multivitamins, 1789
- Incompatibilities**  
acetylcysteine sodium; ophthalmic solutions, 549  
alcohols, polyvinyl and acetylcysteine sodium; ophthalmic solutions, 549  
amphotericin B; i.v. additives, 56  
amphotericin B and rifemintanil hydrochloride; Y-site simulation, 2192  
amphotericin B and soybean oil, 683  
amascrine; i.v. additives, 56  
antimetotics; bone marrow transplantation, 181  
anti-infective agents; bone marrow transplantation, 181  
anti-infective agents and filgrastim; i.v. additives, 185  
antineoplastic agents; bone marrow transplantation, 181  
bumetanide, dextrose and polyvinyl chloride, 422  
bupivacaine hydrochloride and morphine sulfate; stability, 61  
caffeine citrated and polypropylene; injections, 1106  
captopril and vehicles; stability, 2483  
ceftiozone sodium and rifemintanil hydrochloride; Y-site simulation, 2192  
ceftriaxone sodium and metronidazole hydrochloride, 424  
chlorpromazine hydrochloride and rifemintanil hydrochloride; Y-site simulation, 2192  
cidofovir and containers; stability, 2204  
ciprofloxacin lactate and sodium bicarbonate; Y-site injections, 1193  
cisatracurium besylate; i.v. additives, 1735  
containers and meropenem; stability, 412  
containers and pentoxifylline; suspensions, 1301  
cyclosporine; bone marrow transplantation, 181  
dacarbazine and containers; temperature, 915  
dexamethasone sodium phosphate and ondansetron hydrochloride; injections, 1065  
dextrose and nitroglycerin or sympathomimetic agents; stability, 1417  
dextrose, bumetanide and polyvinyl chloride, 422  
dilutents and midazolam hydrochloride; stability, 913  
dilutents and propafenone hydrochloride; injections, 1293  
doxetaxel and polyvinyl chloride; plasticizer leaching, 566  
doxorubicin hydrochloride; liposomes, 2708  
doxorubicin hydrochloride and containers; temperature, 915  
edetate disodium and acetylcysteine sodium; ophthalmic solutions, 549  
excipients and acetylcysteine sodium; ophthalmic solutions, 549  
filgrastim and anti-infective agents; i.v. additives, 185  
fluorouracil and plastics; precipitation, 1845  
furosemide; i.v. additives, 64  
granisetron hydrochloride; i.v. additives, 56; liquid compounding, 1404

- immunosuppressive agents; bone marrow transplantation, 181  
 insulin human and ranitidine hydrochloride; i.v., Y-site injections, 1304  
 iron dextran and TrophAmine; parenteral nutrition, 570  
 ketamine hydrochloride and meperidine hydrochloride, 205  
 meperidine hydrochloride and ketamine hydrochloride, 205  
 meropenem and containers; stability, 412  
 metronidazole hydrochloride and ceftriaxone sodium, 424  
 midazolam hydrochloride and diluents or polypropylene; stability, 913  
 morphine sulfate and bupivacaine hydrochloride; stability, 61  
 nitroglycerin and dextrose; stability, 1417  
 omeprazole; stability, 1833  
 ondansetron hydrochloride and containers; temperature, 915  
 ondansetron hydrochloride and dexamethasone sodium phosphate; injections, 1065  
 opiates; bone marrow transplantation, 181  
 paclitaxel and polyvinyl chloride; plasticizer leaching, 566  
 parenteral nutrition; bone marrow transplantation, 181; Y-site injections, 1295  
 penicillins and polyvinyl chloride; injections, 1068  
 pentoxifylline and containers; suspensions, 1301  
 phenoxylbenzamine hydrochloride and vehicles; oral liquids, 2073  
 plastics and fluorouracil; precipitation, 1845  
 plastics and propafenone hydrochloride; injections, 1293  
 polyisoprene and antineoplastic agents; temperature, 915  
 polypropylene and caffeine citrated; injections, 1106  
 polypropylene and midazolam hydrochloride; stability, 913  
 polyvinyl chloride and antineoplastic agents; temperature, 915  
 polyvinyl chloride and cidofovir; stability, 2204  
 polyvinyl chloride and docetaxel or paclitaxel; plasticizer leaching, 566  
 polyvinyl chloride and penicillins; injections, 1068  
 polyvinyl chloride and tobramycin sulfate; injections, 1068  
 polyvinyl chloride, bumetanide and dextrose, 422  
 propafenone hydrochloride and diluents or plastics; injections, 1293  
 propofol; Y-site injections, 1287  
 pyrimethamine; suspensions, 2714  
 ranitidine hydrochloride and insulin human; i.v., Y-site injections, 1304  
 remifentanyl hydrochloride; stability, 2192  
 sodium bicarbonate and ciprofloxacin lactate; Y-site injections, 1193  
 sodium chloride and thiotepa; i.v. additives, 2588  
 soybean oil and amphotericin B, 683  
 sumatriptan succinate; suspension compounding, 1619  
 sympathomimetic agents and dextrose; stability, 1417  
 tacrolimus; stability, 178  
 thiopental sodium; i.v. additives, 64  
 thiotepa and sodium chloride; i.v. additives, 2588  
 tobramycin sulfate and polyvinyl chloride; injections, 1068  
 TrophAmine and iron dextran; parenteral nutrition, 570  
 ursodiol; suspension compounding, 1401  
 vehicles and captopril; stability, 2483  
 vehicles and phenoxylbenzamine hydrochloride; oral liquids, 2073  
 vincristine sulfate and containers; temperature, 915  
 warfarin sodium; i.v. additives, 2599
- Indian Health Service;** United States Public Health Service; pharmaceutical services, 766
- Industry;** tobacco; investigations, 2050
- Industry, pharmaceutical**  
 advertising; prescription drugs, 2596  
 clinical studies; reimbursement, 1742  
 contraceptives, oral; postcoital indications, 874  
 contracts; managed care systems, 1041  
 control, quality; USP reports, 1240  
 dietary supplements; labeling, 2561  
 disease management; managed care systems, 2217  
 drug information; writing, 1572  
 drugs; cost projections, 153  
 patient information; survey, 1381  
 personnel; AHP policies, 30  
 regulations; dietary supplements, 1707
- Infections**  
 arterial occlusive diseases; surgery vs. urokinase, 1963  
 computers; programs, 1897
- Information**  
 American Society of Health-System Pharmacists; WWW, 1273  
 computers; patient-focused care, 1501; pharmacists' attitudes, 584  
 databases; managed care systems, 1973  
 health care; Internet, 757; technology, 269, 274  
 labeling; dietary supplements, 2561  
 pharmacy; Internet, 34
- Infusion devices, see Devices; infusion pumps**
- Inhalers**  
 see also **Aerosols**  
 metered dose; chlorofluorocarbons, 1021  
 nicotine; smoking cessation, 1478
- Injections**  
 amphotericin B; incompatibilities, 683; liposomes, 2426  
 antineoplastic agents; incompatibilities, 915  
 bumetanide; stability, 422  
 bupivacaine hydrochloride; incompatibilities, 61  
 caffeine citrated; incompatibilities, 1106  
 ceftriaxone sodium; incompatibilities, 424  
 cidofovir; incompatibilities, 2204  
 ciprofloxacin lactate; incompatibilities, 1193  
 cisatracurium besylate; incompatibilities, 1735  
 compounding; latex allergies, 2516, 2517  
 dexamethasone sodium phosphate; incompatibilities, 1065  
 dextrose; incompatibilities, 1417  
 docetaxel; compounding, Dec 15 suppl S7; incompatibilities, 566  
 doxorubicin hydrochloride; incompatibilities, 2708  
 epiprostenol; congestive heart, 2613  
 filgrastim; incompatibilities, 185  
 fluorouracil; incompatibilities, 1845  
 gentamicin; piperacillin-tazobactam interactions, 2704  
 granisetron hydrochloride; comparisons, 1172; incompatibilities, 56  
 incompatibilities; Y-site injections, 181  
 insulin human; incompatibilities, 1304  
 intra-arterial; urokinase, 1988  
 intravenous; adverse drug reactions, 1176; compounding, 904; conversion to oral, 524; error checking, 1611; fentanyl, 87; incompatibilities, 64, 1295; needle-stick policies, 258; portable infusion pumps, 1277; technician compounding, 1702; time studies, 1614; urokinase, 1988; vasopressin, 2230; warfarin incompatibilities, 2599  
 iron dextran; incompatibilities, 570  
 ketamine hydrochloride; incompatibilities, 205  
 meperidine hydrochloride; incompatibilities, 205  
 meropenem; incompatibilities, 412  
 metronidazole hydrochloride; incompatibilities, 424  
 midazolam hydrochloride; incompatibilities, 913  
 morphine sulfate; incompatibilities, 61  
 nitroglycerin; incompatibilities, 1417  
 ondansetron hydrochloride; comparisons, 1172; incompatibilities, 1065  
 paclitaxel; incompatibilities, 566; labeling, 2128  
 parenteral nutrition; automated compounding, 678  
 penicillins; incompatibilities, 1068  
 propafenone hydrochloride; incompatibilities, 1293  
 propofol; fat emulsions, 2515; incompatibilities, 1287; parenteral nutrition, 694  
 ranitidine hydrochloride; incompatibilities, 1304  
 remifentanyl hydrochloride; incompatibilities, 2192  
 sodium bicarbonate; incompatibilities, 1193  
 storage; preservatives, 2006  
 sympathomimetic agents; incompatibilities, 1417  
 thiotepa; incompatibilities, 2588  
 tobramycin sulfate; incompatibilities, 1068  
 toxicity; pain, 388  
 TrophAmine; incompatibilities, 570  
 United States Pharmacopeia; standards, 1633  
 vitamins; shortage, 1789
- Insulin**  
 protocols; hospital pharmacy, 1046  
 toxicity; emergency room visits, 295
- Insulin human;** incompatibilities; ranitidine, 1304
- Insulins**  
 insulin; emergency room visits, 295; protocols, 1046  
 insulin human; incompatibilities, 1304
- Integrated health care**  
 administration; cost control, 1196; pharmacy benefits, 2207  
 costs; purchasing, 153  
 managed care systems; laws, 1752; U.S., 238  
 membership; U.S., 19  
 pharmaceutical services; outsourcing, 41  
 pharmacists, institutional; opportunities, 1049  
 statistics; survey, 2786  
 technology; information systems, 269
- Integrated health systems;** patient education; ASHP guidelines, 431
- Interferon alfa-2a**  
 carcinoma; renal cell, 190  
 dosage schedules; hepatitis C, 1140
- Interferon alfacon-1;** approvals; FDA, 2656
- Interferons;** protocols; hepatitis C, 1140
- International normalized ratio;** ginseng; warfarin interactions, 692
- International Olympic Committee;** regulations; drug abuse, 1053
- International Pharmaceutical Federation;** history; C. Lyons, 1095  
 meetings, 2800
- Internet**  
 data collection; surveys, 1334  
 drug information; errors, 1732  
 Drug Information Network, 1930  
 information; health care, 757  
 pharmacy; information, 34
- Interventions**  
 clinical pharmacists; antihypertensive programs, 2079; documentation, 1623; ICU, 2811  
 pharmacists; ACE inhibitors, 264; asthma DUR, 2197; tuberculosis, 375  
 pharmacists, hospital; ambulatory care, 2719; costs, 392; documentation, 1596; dosage checking, 545; drug-food interactions, 405; hypertension clinics, 564; i.v. to oral conversion, 524; outcomes, 1591; peer review, 1722; physicians' acceptance, 397  
 pharmacists, institutional; documentation, 2503; hospital rounds, 670; psychopharmacy clinic, 2717  
 students; clinical documentation, 1727
- Inventory**  
 controlled substances; computers, 630; surgery, 1392  
 hospital pharmacy; methodology, 171; wholesalers, 45  
 pharmacy, institutional; mail order, 520
- Investigational drugs, see Drugs, investigational**
- Ipratropium bromide;** status asthmaticus; oxaprozin reactions, 199
- Iron;** precipitation; parenteral nutrition, 570
- Iron dextran;** incompatibilities; parenteral nutrition, 570
- Iron preparations;** iron dextran; incompatibilities, 570
- Isosorbide dinitrate;** sustained-action; excretion, 2403
- IVIG, see Globulin immune**
- J**
- Job description;** pharmacists; advertising, 1260; hours, 558
- Job performance**  
 personnel, pharmacy; professional competence, 1412  
 pharmacists; work styles, 2680
- Job satisfaction**  
 clinical pharmacists; primary care, 1280  
 residents; ASHP-accredited programs, 1521  
 technicians; certification, 2562
- Joint Commission of Pharmacy Practitioners;** professional competence; working groups, 2433
- Joint Commission on Accreditation of Health-care Organizations**  
 accreditation; managed care systems, 1528  
 regulations; controlled-substances documentation, 1392  
 standards; patient care outcomes, 743; personnel competence, 1412
- Journal References,** 219, 462, 718, 998, 1217, 1461, 1667, 1908, 2136, 2414, 2638, 2830
- Journals;** American Journal of Health-System Pharmacy; authorship policies, 30

# K

**Kaiser Permanente**; pharmaceutical services; computerized databases, 1510  
**Keratolytic agents**; tazarotene; FDA approvals, 2037  
**Ketamine hydrochloride**; incompatibilities; mep-  
 eridine, 205  
**Kidney diseases**; amifostine; prophylaxis, 787  
**Kidney failure**  
 cidofovir; toxicity, 12  
 dosage; computer checking, 545  
 drugs; dosage, 2505  
 roentgenographic agents; toxicity, 587  
**Knee prosthesis**; ardeparin sodium; FDA approvals,  
 1575

# L

## Labeling

anorexics; toxicity warnings, 1785  
 cidofovir; toxicity, 12  
 contraceptives, oral; postcoital indications, 874  
 delavirdine mesylate; FDA approvals, 1233  
 dietary supplements; FDA regulations, 2561  
 drugs; food interactions, 405; molecular weight,  
 1449  
 drugs, nonprescription; patient information, 2664  
 enteral nutrition; nitrogen, proteins, 2239  
 ephedrine; FDA regulations, 1578  
 injections; storage, 2006  
 nelfinavir mesylate; FDA approvals, 1233  
 paclitaxel; revisions, 2128  
 ritonavir; FDA approvals, 1233; toxicity, 126  
**Languages**; computers; Arden Syntax, 281  
**Latex**; allergies; guidelines, 1688; hospital policies,  
 2516; overview, 1071; pharmacy standards, 2517  
**Law Notes**, 1630  
**Laws**  
 Balanced Budget Act of 1997; Medicare reimburse-  
 ment, 2433  
 cases; *Henderson v. Boline Aluminum*, 572  
 cannabis; prescribing, 126  
 clinical studies; administration, 1742  
 dietary supplements; quality control, 1707  
 hospital pharmacy; service outsourcing, 45  
 managed care systems; integrated health care, 1752  
 pharmacists; hospital; France, 1110  
 suits; drug deaths, 2434  
**Leaching**; diethylhexyl phthalate; docetaxel injec-  
 tions, Dec 15 suppl 57; polyvinyl chloride contain-  
 ers, 566  
**Legislation**  
 drugs; cost projections, 153  
 managed care systems; health care, 1049  
**Leishmaniasis**; amphotericin B; visceral, 2426  
**Leptosy**; thalidomide; lepromatous, 2270  
**Letters**, 92, 199, 319, 441, 586, 699, 830, 986, 1106,  
 1207, 1333, 1447, 1551, 1652, 1762, 1893, 2006,  
 2127, 2238, 2403, 2515, 2621, 2744, 2822  
 Additional contraindication to use of angiotensin-  
 converting-enzyme inhibitors, 1552  
 Advice on treatment of drug-resistant tuberculosis,  
 700  
 Advice on treatment of *Mycobacterium avium* com-  
 plex infection, 1208  
 Albendazole monitoring, 319  
 Bioethics committee activities, 2007  
 Bulk packages of injectable products, 2006  
 A case in point, 2404  
 Change from zolpidem to clonazepam won't solve  
 the patient's problem, 588  
 Comparing cefmetazole compatibility data from  
 different sources, 831  
 Compatibility of ketamine hydrochloride and mep-  
 eridine hydrochloride, 205  
 Computer program for tracking incidence of intra-  
 vascular-device-related infections in patients re-  
 ceiving parenteral nutrition, 1897  
 E-mail for conducting surveys, 1334  
 Estimating aminoglycoside dosage requirements in  
 patients with low serum creatinine concentra-  
 tions, 986  
 Facilitating emergency use of alteplase for stroke,  
 1447  
 Fact versus opinion in the judgment on fospheny-  
 toin articles, 1652  
 Haunting medicines, 2403  
 Hypoprotection induced by warfarin sodium  
 and cisapride, 320

Implementation of a computerized drug informa-  
 tion database, 1763  
 Important issues to consider in pursuing prescrib-  
 ing authority for pharmacists, 987  
 Important points to note when preparing nutri-  
 tional admixtures for latex-sensitive patients,  
 2128  
 Inconsistencies in labeling of enteral nutrition  
 products, 2239  
 Medicare reimbursement for oral antiemetics in  
 management of chemotherapy-induced emesis,  
 830  
 Medication errors and drug hydrates, 1449  
 Memory disorders consultation service, 92  
 Metformin, contrast media, and theophylline, 2007  
 Miracle is not the same as luck, 1208  
 More on mechanisms of bacterial resistance, 2744  
 Multidisciplinary handbook on pediatric nutrition-  
 al support, 1335  
 Myocardial infarction after intranasal metham-  
 phetamine, 586  
 New address for publisher, 1110  
 Nonprescription drugs in Hungary, 1207  
 Office-practiced pharmacy, 2824  
 Once-daily aminoglycoside therapy, 2824  
 Order form for restricting vancomycin prescribing,  
 1893  
 Our professional responsibility after hospitals  
 change ownership, 2238  
 Pharmacist as newspaper columnist, 1762  
 Pharmacist's role in rescue efforts after plane crash  
 in Indian Ocean, 1110  
 Pharmacists should be recognized as providers of  
 nonprescription drug information, 2127  
 Position statement from infectious diseases society,  
 2822  
 Possible losartan-induced rash, 1333  
 Precipitation of amphotericin B from i.v. fat emul-  
 sion, 1449  
 Probable interaction of warfarin and acarbose, 1551  
 Procedures for preparing injectable medications for  
 latex-sensitive patients, 2516  
 Propofol infusion and nutritional support, 2515  
 Reactions to fosphenytoin editorial and review arti-  
 cle, 441  
 Reports of labeling problems do get action, 2128  
 Severe asthmatic reaction to contraindicated anti-  
 inflammatory drug, 199  
 Smoothing the path for i.v.-to-oral conversion, 200  
 Stability of caffeine citrate injection in polypropy-  
 lene syringes at room temperature, 1106  
 Standardized antiemetic regimens, 2404  
 Theophylline option for attenuating contrast me-  
 dia-induced nephrotoxicity in patients on met-  
 formin, 587  
 Two cases of possible cefepime-induced neutrope-  
 nia, 2621  
 Useful Internet sites, 1450  
 User-friendly weight-based heparin protocol for  
 initial infusion, 699  
 Where is the evidence for formulary effectiveness?  
 95  
**Levofloxacin**; bacterial infections; review, 2569  
**Levothyroxine sodium**; marketing; FDA regula-  
 tions, 2151  
**Liability**; pharmacists; hospital; overview, 1152  
**Licensure**; pharmacists; NABP resolutions, 1932  
**Lidocaine**  
 combination, prilocaine; comparisons, 388  
 heart arrest; therapy, 85  
**Liposomes**  
 amphotericin B; FDA approvals, 2426  
 doxorubicin hydrochloride; incompatibilities,  
 2708  
**Liquids**  
 captopril; incompatibilities, 2483  
 granisetron hydrochloride; compounding, 1404  
 omeprazole; compounding, 1833  
 phenoxybenzamine hydrochloride; compounding,  
 2073  
**Literature**  
 drugs; molecular weight, 1449  
 formularies; overview, 95  
**Liver diseases**  
 docetaxel; dosage, Dec 15 suppl 516  
 ritonavir; contraindications, 126  
**Long-term-care facilities**  
 patient care; outcomes standards, 743  
 patient education; ASHP guidelines, 431;  
**Losartan potassium**; adverse reactions; dermatitis,  
 1333  
**LSD**, see **Lysergide**  
**Lung neoplasms**; docetaxel; overview, Dec 15 sup-  
 pl 519

**Lyme disease vaccines**; adults; research, 379  
**Lyons, C.**; pharmacists; hospital; history, 1095  
**Lyophilization**; thiotepa; incompatibilities, 2588  
**Lysergide**; abuse; adolescents, 365

# M

**Magnesium**; dosage; dietary reference intakes, 2438  
**Magnetic resonance imaging**; thrombophlebitis;  
 diagnosis, 66  
**Malaria vaccines**; adults; research, 379  
**Malpractice**; pharmacists; hospital; liability, 1152  
**Managed care**, see **Health maintenance organ-  
 izations**  
**Managed Care Forum**, 32, 520, 1041, 1497, 1941,  
 2449  
 Computer-assisted help desk for handling drug  
 benefits, 1941  
 Ethical issues for pharmacists in managed care,  
 1041  
 Improving drug use in a capitated program for the  
 poor, 2449  
 Involving network pharmacies in disease manage-  
 ment programs, 32  
 The pharmacist as a health education coordinator,  
 1497  
 Planning the basics of a mail-service pharmacy, 520  
**Managed care systems**  
 administration; backlash, 1049  
 ambulatory care; databases, 1973; psychopharmacy  
 clinic, 2717  
 disease management; administration, 2217  
 education, pharmaceutical; residencies, 2055  
 formularies; cost-benefit analysis, 95; ethics, 1041  
 integrated health care; U.S., 238  
 laws; administration, 1752  
 patient education; ASHP guidelines, 431; pharma-  
 cists, 1497  
 pharmaceutical services; clinical information sys-  
 tems, 1501, 1505, 1515; computerized databases,  
 1510; economics, 2207; immunization programs,  
 490; outsourcing, 41  
 pharmacists; institutional; Internet, 34; role, 2503  
 quality assurance; accreditation, 1528; National  
 Committee for Quality Assurance, 2551  
 residencies; ASHP standards, 2099  
 United States Air Force; pharmaceutical services,  
 783  
 United States Army; pharmaceutical services, 773  
 United States Navy; pharmaceutical services, 778  
**Management**, see **Administration**  
**Management Case Studies**, 1076, 1196, 2736,  
 2811  
**Management Consultation**, 142, 630, 886, 1152,  
 1392, 1584, 1794, 2302, 2562  
 Benefits of a board-certified technician, 2562  
 Changing department culture through a code of  
 conduct, 142  
 Computerized system for controlled-substances  
 distribution, 630  
 Inhouse clinical training program for staff pharma-  
 cists, 1794  
 Involving anesthesiology in drug control, 1392  
 Liability for expanded responsibilities, 1152  
 Planning for an ambulatory care service, 1584  
 The power and perils of e-mail, 886  
 Tracking and reporting drug expenditures, 2302  
**Manasse, H.**; American Society of Health-System  
 Pharmacists; administrators, 1477; professional is-  
 sues, 1877  
**Manpower**  
 hospital pharmacy; service outsourcing, 45  
 layoffs; hospital pharmacy, 43; institutional phar-  
 macists, 2503; pharmacists, 773, 778, 783  
 pharmacists; survey, 558  
**Manufacturers**  
 dietary supplements; quality control, 1707  
 nutrition; pediatrics, 687  
**Manufacturing**  
 control, quality; USPAP reports, 1240  
 ephedrine; dietary supplements, 1578  
 vitamins; shortage, 1789  
**Marijuana**, see **Cannabis**  
**Marketing**  
 amphotericin B; FDA approvals, 2426  
 ardeparin sodium; FDA approvals, 1575  
 azelastine hydrochloride; FDA approvals, 234  
 bromfenac sodium; FDA approvals, 2151  
 bupropion hydrochloride; FDA approvals, 1478  
 cerivastatin sodium; FDA approvals, 1793  
 delavirdine mesylate; FDA approvals, 1233  
 ephedrine; FDA regulations, 1578

- interferon alfacon-1; FDA approvals, 2656  
 levothyroxine sodium; FDA regulations, 2151  
 mibefradil dihydrochloride; FDA approvals, 2033  
 nelfinavir mesylate; FDA approvals, 1233  
 nicotine; FDA approvals, 1478  
 nutrition; pediatrics, 687  
 pharmaceutical services; disease management, 32  
 pramipexole dihydrochloride; FDA approvals, 1922  
 quetiapine fumarate; FDA approvals, 2547  
 research; membership satisfaction, 1037  
 reteplase; FDA approvals, 12  
 ropinirole hydrochloride; FDA approvals, 2655  
 sermorelin acetate; FDA approvals, 2547  
 tazarotene; FDA approvals, 2037  
 thalidomide; FDA regulations, 2270  
 tiagabine hydrochloride; FDA approvals, 2544  
 tiludronate disodium; FDA approvals, 1145  
 troglitazone; FDA approvals, 623
- Mathematics;** models; pharmacy management, 2491
- Mean;** pharmacists; hours, 558
- Mechanism of action**  
 acarbose; interactions, 1551  
 amifostine; review, 787  
 angiotensin-converting-enzyme inhibitors; review, 2689  
 anti-infective agents; resistance, 1420  
 aspirin; myocardial infarction prophylaxis, 1984  
 cisapride; interactions, 320  
 docetaxel; overview, Dec 15 suppl S2  
 drugs; museum exhibits, 1236  
 gastrointestinal drugs; GI absorption, 2609  
 latex; allergies, 1071  
 levofloxacin; review, 2569  
 mycophenolate mofetil; review, 285  
 sulfamethoxazole, combination, trimethoprim; adverse reactions, 1545  
 thrombolytic agents; molecular pharmacology, Nov 15 suppl S17  
 trovafloxacin mesylate; review, 2569  
 warfarin sodium; interactions, 320, 1551
- MedGuide;** drug information; FDA, 352
- Medication errors;** see **Errors, medication**
- Medication orders**  
 alteplase; forms, 1447  
 emergency rooms; technician entry, 1702  
 pharmacists, hospital; patient-focused care, 1262
- MedWatch;** drugs, adverse reactions; therapeutic interchange, 1149
- Meetings**  
 American Pharmaceutical Association; 1997 annual, 1025; Remington Honor Medal, 1012  
 International Pharmaceutical Federation, 2800  
 National Association of Boards of Pharmacy; 1997 resolutions, 1932
- Membership**  
 American Society of Health-System Pharmacists; professional issues, 1877; satisfaction, 1037  
 health maintenance organizations; U.S., 19  
 integrated health care; U.S., 19
- Membranes;** patches transdermal; dosage, 1759
- Memory disorders;** education, pharmaceutical curriculum, 92
- Men;** pharmacists; residency satisfaction, 1521
- Mental retardation facilities;** administration; anticonvulsant prescribing, 1716
- Meperidine hydrochloride;** incompatibilities; ketamine, 205
- Merck-Medco Rx Services;** clinical pharmacy; services, 613
- Mergers**  
 Columbia/HCA Healthcare; Value Health, 513  
 Value Health; Columbia/HCA Healthcare, 513
- Meropenem;** incompatibilities; i.v. injections, 412
- Metabolism**  
 angiotensin-converting-enzyme inhibitors; review, 2689  
 dexfenfluramine hydrochloride; review, 2059
- Metformin;** interactions; roentgenographic agents, 587
- Metformin hydrochloride;** review, 893
- Methamphetamine;** toxicity; myocardial infarction, 586
- Methicillin;** resistance; *S. aureus*, 2185
- Methodology**  
 aminoglycosides; pharmacokinetic calculations, 541  
 anticoagulants; pharmacoeconomic models, 1185  
 clinical studies; ambulatory care databases, 1973  
 data collection; Internet, 1334  
 decision-making; models, Nov 15 suppl S5  
 dosage; calculations, 2505  
 drug distribution systems; failure mode and effects analysis, 171
- errors, medication; prediction models, 1161  
 interventions; documentation validity, 1596; physicians' acceptance, 397  
 models; decision-making, 2491  
 outcomes; pharmaceutical care, 1434  
 pharmaceutical services; patient satisfaction, 2721
- Methylcellulose;** incompatibilities; captopril, 2483; pyrimethamine, 2714
- Methylphenidate;** depression; geriatrics, 2510
- Metoclopramide;** concomitant therapy, 320
- Metoprolol;** akathisia; antipsychotic toxicity, 2461
- Metoprolol succinate;** concomitant therapy, 1333
- Metronidazole hydrochloride;** incompatibilities; ceftriaxone, 424
- Mibefradil dihydrochloride;** approvals; FDA, 2033
- Midazolam hydrochloride;** incompatibilities; i.v. additives and syringes, 913
- Military;** pharmaceutical services; United States Air Force, 783; United States Army, 773; United States Navy, 778
- Minerals**  
 dosage; dietary reference intakes, 2438  
 labeling; FDA regulations, 2561
- Minoxidil;** absorption; prokinetic agents, 2609
- Models**  
 communication; patient consultation, 2084  
 decision-making; clinical pharmacists, 1307; formularies, Nov 15 suppl S5; pharmacy management, 2491  
 drug distribution systems; hospital pharmacy, 48  
 economics; ambulatory care databases, 1973; pharmaceutical care, 554  
 errors, medication; nomenclature similarities, 1161  
 famciclovir; cost-benefit analysis, 1180  
 pharmacists, hospital; interventions, 397  
 pharmacoeconomics; enoxaparin vs. heparin, 1185
- Molecular weight;** drugs; compounding errors, 1449
- Morphine sulfate;** incompatibilities; bupivacaine, 61
- Mortality**  
 arterial occlusive diseases; surgery vs. urokinase, 1963  
 breast neoplasms; docetaxel vs. paclitaxel, Dec 15 suppl S11  
 diseases; pharmaceutical care, 554  
 myocardial infarction; thrombolytic agents, Nov 15 suppl S23, S27
- Mucolytic agents;** acetylcysteine sodium; incompatibilities, 549
- Mupirocin calcium;** staphylococcal infections; review, 2185
- Mycobacterium tuberculosis;** resistance; antituberculars, 428
- Mycophenolate mofetil;** review, 285
- Mycoses;** amphotericin B; FDA approvals, 2426
- Myocardial infarction**  
 aspirin; prophylaxis, 1949, 1984  
 disease management; protocols, Nov 15 suppl S9  
 methamphetamine; abuse, 586  
 reteplase; FDA approvals, 12  
 thrombolytic agents; comparisons, Nov 15 suppl S27; outcome markers, Nov 15 suppl S23; pharmacists' role, Nov 15 suppl S3
- N**
- Nadroparin calcium;** thrombophlebitis; overview, 1995
- Nafcillin;** adverse reactions; comparisons, 1176
- Nafcillin sodium;** incompatibilities; polyvinyl chloride, 1068
- n-PA;** mechanism of action; thrombolytics, Nov 15 suppl S17
- Nasal preparations;** mupirocin calcium; review, 2185
- National Academy of Sciences;** nutrition; protocols, 2438
- National Association of Boards of Pharmacy**  
 examinations; pharmacists' competence, 2433  
 generic drugs; narrow therapeutic index, 1630  
 meetings; 1997, 1932
- National Committee for Quality Assurance**  
 accreditation; managed care systems, 1528  
 managed care systems; data collection, 2551
- National Council on Patient Information and Education;** television; medication errors, 1486
- National Heart, Lung, and Blood Institute;** protocols; asthma therapy, 862
- National Institute for Occupational Safety and Health;** guidelines; latex allergies, 1688
- National Institutes of Health**  
 hospital pharmacy; gene-therapy handling, 1604  
 protocols; antivirals, 1681; hepatitis C, 1140  
 United States Public Health Service; pharmaceutical services, 766
- Nausea**  
 antiemetics; Medicare policies, 830  
 granisetron; comparisons, 2478  
 ondansetron; comparisons, 2478  
 propofol; toxicity, 1953  
 therapy; pharmacists' protocols, 680
- Needles;** contamination; hospital policies, 258
- Negligence;** pharmacists, hospital; liability, 1152
- Nelfinavir mesylate;** approvals; FDA, 1233
- Neoplasm vaccines;** adults; research, 379
- Neoplasms**  
 aminoglycosides; pharmacokinetic calculations, 541  
 fentanyl; transdermal patches, 87  
 gemcitabine; review, 162
- Neuralgia;** famciclovir; herpes zoster, 1180
- Neurological manifestations;** vincristine sulfate; toxicity, 1755
- Neuropathies;** amifostine; prophylaxis, 787
- Neutropenia**  
 amphotericin B; mycoses, 2426  
 cefepime hydrochloride; toxicity, 2621
- New Periodicals,** 107, 476, 601, 729, 1002, 2639
- News,** 12, 116, 234, 342, 490, 613, 743, 862, 1012, 1140, 1233, 1376, 1477, 1572, 1681, 1785, 1922, 2033, 2151, 2269, 2426, 2544, 2652, 2786
- Aggressive lipid-lowering therapy beneficial after bypass grafting,** say researchers, 626
- Americans at risk from self-medication, survey reveals,** 2664
- Antidotes dangerously understocked in Colorado, Montana, and Nevada,** 16
- Antipsychotic choices now include quetiapine,** 2547
- APhA approves Guidelines for Pharmacy-Based Immunization Advocacy and Administration,** 2553
- APhA house of delegates considers issues from assisted suicide to collaborative practice,** 1025
- Appointments and Promotions,** 347, 625, 874, 1145, 1388, 1782, 2050, 2290, 2800
- Ardeparin cleared for marketing,** 1575
- As patients embrace herbal remedies, dearth of scientific evidence frustrates clinicians,** 2656
- Behavior change by injection drug users cuts rate of HIV infection, study shows,** 748
- Book correction notice,** 504, 629, 1481
- BPS has new bylaws, first executive director,** 141
- BPS, others ponder high failure rate on pharmacotherapy exam,** 1015
- Broad plan essential for tuberculosis elimination, say researchers,** 361
- Bromfenac marketed for short-term pain relief,** 2151
- California, Arizona laws permit medical use of marijuana,** 126
- California coalition aims for 'SMART' medication use by seniors,** 2282
- CDC advises institutions on responding to vancomycin-resistant staphylococci,** 1925
- CDC guidelines focus on prevention of nosocomial pneumonia,** 1022
- CDC sets interim strategy for hepatitis A control,** 625
- CDC study documents growing problem of pneumococcal resistance,** 744
- Cervastatin approval expands HMG-CoA reductase inhibitor choices,** 1793
- Changes in hospital ownership proliferate, with uncertain effect on communities,** 1150
- Community pharmacists' interventions may reduce health care costs,** 1388
- Consensus panel advocates prolonged interferon treatment for chronic hepatitis C,** 1140
- Consumers receive written information with most prescriptions, report indicates,** 1381
- Digitalis Investigation Group study shows only modest effects for digoxin in heart failure,** 869
- Drug information centers pools resources,** 1930
- Drug information industry reacts to private-sector plan for useful content,** 1572
- Drug-resistant tuberculosis remains public health menace,** 2437
- Early efforts of ASHP helped shape USP problem reporting system,** 1240
- Educating parents, providing measuring devices could eliminate pediatric dosage errors, researchers show,** 2289
- Elderly outpatients can discontinue most medications and have no adverse events, study shows,**

- but caution is needed, 2787
- Ertad to become critical care medicine fellow, 2668
- Erythromycin resistance in Finland declines after reduction in macrolide use, 2436
- Evidence-Based Practice Centers receive initial assignments, 2668
- FDA cites new data in decision to bar genetic conjugated estrogens, 1376
- FDA announces plan to halt marketing of terfenadine, 342
- FDA announces tighter regulation of oral levothyroxine products, 2151
- FDA approvals include two new AIDS drugs, pediatric labeling for two protease inhibitors, 1233
- FDA pharmacist recognized for role in tobacco initiative, 2050
- FDA posts record number of drug approvals in 1996, 494
- FDA program frames better medication use as women's health issue, 2288
- FDA proposes constraints on ephedrine dietary supplements, 1578
- FDA proposes plan for phasing out CFC-containing drug products, 1021
- FDA proposes tiered approach to regulation of tissue, cell therapies, 877
- FDA seeks help in evaluating consequences of therapeutic interchange, 1149
- FDA seeks new-drug applications for 'morning-after' contraception, 874
- Failure to implement U.S. needle-exchange program has cost many lives and dollars, study says, 1149
- Federal panel backs early, aggressive HIV therapy, 1681
- Fenfluramine and dexfenfluramine withdrawn from market, 2269
- Free vaccines, insurance status influence immunization by physicians, 2554
- Gastroenterologists issue guidelines on ulcerative colitis management, 1390
- Gilead issues new warnings about zidovudine nephrotoxicity, 12
- Gouveia named *AJHP* Field Editor; Sellers joins headquarters staff, 2666
- Growth hormone-releasing hormone product cleared for marketing, 2547
- Heart groups issue comprehensive myocardial-infarction practice guidelines, 16
- HMG-CoA reductase inhibitors reduce stroke risk, total mortality, 2152
- HMO patients receive less costly end-of-life care, 2552
- HMOs grow in number, enrollment, 19
- HMO utilization found similar between enrollees with and without prior health insurance, 1390
- Hospital data compared by HMO and system ownership, 2044
- Hospital program boosts vaccination rates among preschoolers, 2154
- Hospitals re-examining procedures for preventing cancer chemotherapy errors, shows survey, 750
- Implantable defibrillator prevails in study of device versus drugs, 1236
- Imported products ease i.v. multivitamin shortage, 1789
- In nursing facilities, cost of drug-related problems tops cost of drugs, 2664
- In nursing homes, psychotropic drug use changed after OBRA '87, 2787
- In Remington medal talks, Hepler and Strand give prognosis for pharmaceutical care, 1012
- Intensive insulin therapy is good value, say researchers, 116
- Intranasal antihistamine gains marketing approval, 234
- Isolates of partially vancomycin-resistant *S. aureus* reported in United States, 2434
- JCPP forms working group on continued competence, 2433
- Joint Commission to require performance data, 743
- Liposomal formulation of amphotericin B approved for marketing, 2426
- Low infant infection rate halts study of perinatal HIV transmission, 1018
- Lyons receives Donald E. Francke medal, 243
- Mail-order pharmacies send out clinical services, 613
- Many physicians use PDR for overdose management, study shows, 626
- Medicare reforms affect hospitals, outpatient settings, 2433
- Mibefradil release expands calcium-channel-blocker choices, 2033
- Minority communities benefit from pharmacy student involvement, 354
- More pharmacists administering vaccines, 490
- Museum exhibit gives pharmacy students lessons in history and in meeting the public, 1236
- NABP resolves to strengthen pharmacists' role, ensure competence, 1932
- National goals for child immunization being met, but shortfalls remain at state and local levels, 2280
- NCQA data show wide variability in health plan performance, 2551
- New bisphosphonate approved for Paget's disease, 1145
- New diabetes drug targets insulin resistance, 623
- New EVP Manasse outlines challenges to pharmacy, 1477
- New guidelines address pediatric issues in antiretroviral therapy, 2652
- New guidelines from rheumatologists association focus on glucocorticoid-induced osteoporosis, 744
- New guidelines proposed for use of RSV immune globulin, 1025
- New immunization schedule reflects shift in poliovirus vaccination policy, 347
- New interferon approved for chronic hepatitis C, 2656
- New pneumococcal-vaccine recommendations include strategies for increasing vaccine use, 1688
- New rules will standardize labeling for dietary supplements, 2561
- New safety information emerges from postmarketing use of ritonavir, 126
- News Briefs, 15, 141, 243, 361, 497, 629, 748, 877, 1026, 1240, 1386, 1488, 1583, 1686, 1789, 1932, 2156, 2282, 2440, 2552, 2655, 2802
- New studies add to evidence on causes, impact of adverse drug events, 498
- NIOSH recommends steps for reducing work-related exposure to latex, 1688
- North Carolina board of pharmacy releases figures from mandatory reports of drug-related deaths, 2434
- Optimal needle lengths determined for deltoid immunization in adults, 1691
- Over half of physician office visits for colds, URIs, and bronchitis lead to antimicrobial prescriptions, 2436
- Pamipexole marketed for Parkinson's disease, 1922
- Parents need help with children's doses of nonprescription drugs, study suggests, 2288
- Patient education, early anti-inflammatory therapy are keys to better asthma care, say new federal guidelines, 862
- Perioperative atenolol may lower risk of death after noncardiac surgery, say researchers, 237
- Personal use of drug samples frequent at physician office, 2155
- Pharmacist intervention in depression is focus of \$3 million research grant, 2668
- Pharm.D. degree, specialty certification boost earnings of PHS pharmacists, 1236
- Physicians are concerned about generic drug bioequivalence, but often unaware of FDA standards, 2799
- Poison control centers may save money, not just lives, 370
- Policies on product selection, drug donation, AIDS care and prevention approved by international pharmacy group, 2800
- Practice guidelines cover management of Alzheimer's disease, 1481
- Private-sector plan for patient information approved, 352
- Procedures announced for phaseout of baccalaureate program accreditation, 2439
- Program on medication misuse airs on PBS, 1486
- Proposed regulations would mandate pediatric testing for many drugs, 2152
- Protease inhibitors may raise blood glucose levels, FDA warns, 1575
- Report characterizes progress of health-system integration, 238
- Report links appetite suppressants with heart disease, 1785
- Report reframes diabetes diagnosis, 1926
- Report shows continued integration of health systems, with trend toward contracting, 2786
- Report unveils new approach to nutrient recommendations, 2438
- Residents and preceptors hold regional conference, 2054
- Retepase set to enter thrombolytic market, 12
- Ropinivole approved for Parkinson's disease, 2655
- Routine vaccine review at 11-12 years recommended, 494
- Study offers preliminary information on benefits of postmenopausal hormones in various risk groups, 1927
- Study shows minorities receive inadequate relief, assessment of cancer-related pain, 2792
- Study suggests antioxidants slow decline in Alzheimer's disease, 1478
- Study suggests link between antineoplastic drug handling and infertility in health care workers, 1931
- Survey shows continued need to educate public about folic acid and birth defects, 2439
- Thalidomide heals HIV-related oral ulcers, but caution is required, 1485
- Thalidomide recommended for approval under tight restrictions, 2270
- Tiagabine approved for partial seizures, 2544
- Topical retinoid introduced for plaque psoriasis, acne vulgaris, 2037
- Treatment recommendations for invasive pneumococcal infections updated; resistance is behind change, 747
- Tuckson calls pharmacists to reach out to communities, 234
- Two products join ranks of smoking cessation treatments, 1478
- Upcoming Meetings, 16, 238, 513, 750, 1015, 1243, 1486, 1927, 2154, 2440, 2656
- Upswing in prescribing errors detected during nine-year study, 2044
- Upward trend in teenage drug use continues, 365
- With 20,000 technicians certified, PTCB begins recertification process, 1486
- With Value Health acquisition, Columbia enters benefit management arena, 513
- News media;** television; medication errors, 1486
- Newsletters;** drug information; pharmacists, 1762
- Nicotin;** approvals; FDA, 1478
- Nifedipine;** myocardial infarction; methamphetamine toxicity, 586
- Nitrogen;** enteral nutrition; formulations, 2239
- Nitroglycerin** incompatibilities; dextrose, 1417
- myocardial infarction; methamphetamine toxicity, 586
- Nomenclature;** similarities; computer models, 1161; ritonavir, 126
- Norepinephrine bitartrate;** incompatibilities; dextrose, 1417
- North Carolina;** regulations; drug deaths, 2434
- Nurses** ambulatory care; hypertension clinics, 564
- education; i.v. to oral conversion, 524
- patient-focused care; team, 2174
- professional relations; pharmacists, 1262
- protocols; insulin, 1046
- workload; USP quality control, 1240
- workload; i.v. administration systems, 1614; methodology, 171
- Nursing homes;** data collection; system ownership, 2044
- Nutrition** diet; dietary reference intakes, 2438; patient information, 564
- dietary supplements; labeling, 2561
- enteral; nitrogen, proteins, 2239; pediatrics, 1335
- parenteral; automated compounding, 678; compounding, 904; device-related infections, 1897; incompatibilities, 181, 570, 1295; interactions, 2515; multivitamin shortage, 1789; pediatrics, 1335; personnel competence, 1412; propofol, 694
- pediatrics; pharmacists' ethics, 687
- O**
- Obesity** aminoglycosides; pharmacokinetics, 2201
- anorexics; labeling, 1785
- dexfenfluramine hydrochloride; review, 2059
- Oddis, J.;** history; ASHP, 1804; pharmacy, 1815
- Ointments;** mupirocin calcium; review, 2185
- Oklahoma Society of Health-System Pharmacists;** history; C. Lyons, 1095
- Omeprazole;** stability; compounding, 1833
- Ondansetron** nausea; comparisons, 2478
- palliative care; costs, 1191
- Ondansetron hydrochloride**

incompatibilities; containers, 915; dexamethasone, 1065

toxicity; comparisons, 1172

#### Opiates

abuse; adolescents, 365  
incompatibilities; Y-site injections, 181  
meperidine hydrochloride; incompatibilities, 205  
pain; pharmacist consultation, 2451

**Orange syrup**; sweetening agents; ursodiol suspensions, 1401

#### Organizations

American Association of Colleges of Pharmacy; pharmacists' competence, 2433  
American Council on Pharmaceutical Education; accreditation standards, 2439

American Pharmaceutical Association; immunization guidelines, 2553; meetings, 1012; policies, 1025

American Society of Health-System Pharmacists; accreditation standards, 2099; advertising policies, 2181; antitubercular protocols, 428; aspirin protocols, 1984; evidence-based practice centers, 2668; guidelines, 314; H. Manasse, 1477; J. Oddis, 1815; J. Oddis endowment, 1804; latex allergies, 2517; managed care residencies, 2055; membership satisfaction, 1037; mentoring programs, 1701; niacin protocols, 2815; pharmaceutical education, 2169; pharmacists' competence, 2433; pharmacotherapy examinations, 1015; protocols, 299; quality control reports, 1240; recruitment, 1260; residencies, 1521; *S. pneumoniae* resistance, 575; strategic planning, 1889; WWW, 1273

health care; coalitions, 2282  
International Pharmaceutical Federation; meetings, 2800

Joint Commission of Pharmacy Practitioners; pharmacists' competence, 2433

medical; myocardial infarction, Nov 15 suppl 53  
National Association of Boards of Pharmacy; pharmacists' competence, 2433; resolutions, 1932

National Council on Patient Information and Education; medication errors, 1486

National Heart, Lung, and Blood Institute; asthma protocols, 862

pharmacy; history, 1095; immunization programs, 490

Pharmacy Technician Certification Board; technician recertification, 1486

**Osmolality**; roentgenographic agents; cost-benefit analysis, 1395

**Otitis media**; antibiotics; cost-benefit analysis, 2736

#### Outcomes

clinical; ACE inhibitors, 264; ambulatory care databases, 1973; depression, 2668; divalproex vs. valproic acid, 1716; i.v. to oral conversion, 524; pharmacists' interventions, 1591; protocols, 1395

economics; divalproex vs. valproic acid, 1716; i.v. to oral conversion, 524

patient care; JCAHO standards, 743; managed care pharmacists, 1049

pharmaceutical care; research, 1434

quality assurance; DUE criteria, 2000, 2002; managed care accreditation, 1528; tramadol, 696

therapeutic; anti-infective use, 1837; clinical information systems, 1505, 1515; pharmaceutical care, 554; thrombolytic agents, Nov 15 suppl 523

**Outpatients**, see **Patients; outpatients**

**Ovarian neoplasms**; docetaxel; overview, Dec 15 suppl 519

**Oxacillin**; adverse reactions; comparisons, 1176

**Oxacillin sodium**; incompatibilities; polyvinyl chloride, 1068

**Oxapropzin**; adverse reactions; status asthmaticus, 199

## P

#### Packaging

anticonvulsants; costs, 1716

drugs; USP standards, 1633

injections; preservatives, 2006

prescriptions; mail order, 520

#### Facilities

incompatibilities; polyvinyl chloride, 566

labeling; revisions, 2128

pharmacoconomics; comparisons, Dec 15 suppl 511

**Paget's disease**; tiludronate disodium; FDA approvals, 1145

#### Pain

analgesics and antipyretics; pharmacists' role, 2451

bromfenac sodium; FDA approvals, 2151

disease management; NABP resolutions, 1932

fentanyl; transdermal patches, 87

fentanyl citrate; i.v. injections, 87

lidocaine, combination, prilocaline; comparisons, 388

tetracaine; comparisons, 388

tramadol; review, 643

tramadol hydrochloride; DUE, 696

#### Palliative care

aldesleukin; toxicity, 1191

pharmacists, hospital; pharmaceutical care, 753

#### Parasympatholytic agents

basal ganglia diseases; antipsychotic toxicity, 2461

ipratropium bromide; status asthmaticus, 199

**Parasympathomimetic agents**; donepezil hydrochloride; review, 2805

#### Parenterals, see Injections

#### Parkinson's disease

antipsychotic agents; toxicity, 2461

pramipexole dihydrochloride; FDA approvals, 1922

ropinirol hydrochloride; FDA approvals, 2655

#### Patches transdermal

dosage; reduced, 1759

fentanyl; abuse, 85; dosage, 87

#### Patient care

clinical pharmacists; role, 1280

computers; technology, 269

consultation; ASHP guidelines, 431

continuity; AIDS, 1407

costs; propofol, 1953

health maintenance organizations; computerized databases, 1510

hospital pharmacy; contract services, 37

managed care systems; formularies, 1041; pharmacists' opportunities, 1049

pharmaceutical care; practice trends, 639

pharmaceutical services; clinical care plans, 314

pharmacists; job performance, 2680; United States Air Force, 783

pharmacists, hospital; United States Navy, 778

pharmacists, institutional; clinical information systems, 1505, 1515

standards; outcomes, 743

terminal care; home health care, 2230

#### Patient education

antibiotics; pharmacists' role, 2457

attention deficit disorder with hyperactivity; pharmacists' role, 2685

computers; clinical information systems, 1505

diabetes mellitus; Medicare reimbursement, 2433

resistance; television, 1486

home health care; low-molecular-weight heparins, 1995

latex; allergies, 1071

pharmacists; depression, 2668

pharmacists, institutional; ASHP guidelines, 431

prescription drugs; advertising, 2181

self-care; asthma protocols, 862

#### Patient-focused care

anti-infective agents; DUE, 1837

computers; pharmacists' role, 263

pharmacists, hospital; pharmaceutical services, 1262

pharmacists, institutional; clinical information systems, 1501

team; hospitals, 2174

#### Patient information

aspirin; myocardial infarction, 1949

computers; clinical information systems, 1501, 1505

confidentiality; drug abuse, 1053

consultation; ASHP guidelines, 431; computers, 1515; drug-food interactions, 405; HMO pharmacists, 2449; hospital pharmacists, 564, 1702; mail order, 520; maintenance therapy, 2084; myocardial infarction, 1984; niacin, 2803; pharmacists, 1262, 1497, 2434, 2451, 2664; pharmacists' protocols, 680; pharmacists' rounds, 670; pharmacy students, 1727; sustained-action medications, 2403; tuberculosis, 375

dietary supplements; labeling, 2561

drug histories; allergy documentation, 1627; penicillin allergies, 2457

guidelines; writing, 1572

leaflets; anticonvulsant compliance, 2585

medical histories; mail order, 613

prescription drugs; advertising, 2181

prescriptions; survey, 1381

profile; computerized databases, 1510

regulations; private sector, 352

#### Patients

attitudes; managed care, 1049

clinical studies; costs, 1742

guidelines; Internet information, 757

inpatients; tramadol, 696

managed care systems; laws, 1752; National Committee for Quality Assurance, 2551

outpatients; antiemetics, 830; Medicare reimbursement, 2433; oncology clinics, 680; tramadol, 696

pharmaceutical services; satisfaction measurement, 2721

selection; antivirals, 1681; aspirin prophylaxis, 1984; i.v. to oral conversion, 524; thrombolytic agents, Nov 15 suppl 59

#### Pediatrics

antibiotics; otitis media, 2736

anti-infective agents; rational therapy, 295

antivirals; HIV infections, 2652

attention deficit disorder with hyperactivity; diagnosis, 2685

hospital pharmacy; latex policies, 2516

human immunodeficiency virus; laboratory tests, 1646

lidocaine, combination, prilocaline; phlebotomy pain, 388

nefinavir mesylate; labeling, 1233

neonates; HIV infections, 1018; parenteral nutrition, 570

nutrition; pharmacists' ethics, 687; reference books, 1335

ritonavir; labeling, 1233

sermorelin acetate; FDA approvals, 2547

sodium phosphate dibasic; overdose, 2488

tetracaine; phlebotomy pain, 388

**Peer review**; pharmacists, hospital; clinical interventions, 1722

#### Penicillin

allergies; patient histories, 2457

amoxicillin; otitis media, 2736

incompatibilities; polyvinyl chloride, 1068

methicillin; resistance, 2185

resistance; *S. pneumoniae*, 527, 575

**Penicillin G potassium**; incompatibilities; polyvinyl chloride, 1068

**Penicillin G sodium**; incompatibilities; polyvinyl chloride, 1068

#### Penicillins

nafcillin; adverse reactions, 1176

oxacillin; adverse reactions, 1176

penicillin; allergies, 2457; resistance, 575; *S. pneumoniae* resistance, 527

piperacillin sodium, combination, tazobactam sodium; interactions, 2704

**Pentoxifylline**; stability; suspensions, 1301

#### Personnel

hospitals; latex allergies, 1071; needle-stick policies, 258

industry, pharmaceutical; *AJHP* policies, 30

#### Personnel, pharmacy

administration; ambulatory care, 1584; code of conduct, 142; e-mail, 886

errors; compounding, 904

guidelines; gene-therapy handling, 1604

hospitals; administration, 1076

pharmacists; job performance, 2680

supportive; certification, 2562; emergency rooms, 1702; help desk, 1941; i.v. syringe checking, 1611; needle-stick policies, 258; professional competence, 1412; recertification, 1486; United States Air Force, 783; United States Army, 773; United States Navy, 778

**Pertussis vaccines**; adults; research, 379

#### Pharmaceutical care

ambulatory care; cost-benefit analysis, 554

history; twentieth century, 1805

home health care; AIDS, 1407

hospital pharmacy; impact, 48; practice trends, 639; survey, 653

interventions; antihypertensive programs, 2079

personnel, pharmacy; professional competence, 1412

pharmaceutical services; quality assurance, 1434

pharmacists; aspirin prophylaxis, 1949; future, 1012; Healthy People 2000, 2169; human dignity, 2733; NABP meetings, 1932

pharmacists, hospital; outcomes, 1591; palliative care, 753;

pharmacists, institutional; future, 2503

pharmacy, community; disease management, 32

pharmacy, institutional; clinical care plans, 314

residencies; self-renewal programs, 2116

**Pharmaceutical education**, see **Education, pharmaceutical**

**Pharmaceutical services**

ambulatory care; administration, 1584; psycho-pharmacy clinic, 2717  
 clinical; antihypertensive programs, 2079; mail order, 613; staff development, 1794  
 clinical pharmacists; primary care, 1280  
 cognitive; computer documentation, 1515  
 community; customer satisfaction, 531; disease management, 32  
 Department of Veterans Affairs; administration, 761  
 formularies; HMOs, 1941  
 health maintenance organizations; computerized databases, 1510; hospital rounds, 670; mail order, 520  
 home health care; enoxaparin, 1968; vasopressin infusion, 2230  
 hospitals; ambulatory care, 2719; clinical interventions, 1722; clinical studies, 1742; disasters, 1110; dosage checking, 545; DUE, 1837; emergency rooms, 1702; hypertension clinics, 564; ICU algorithms, 1841; insulin protocols, 1046; intervention documentation, 1727; interventions, 392; latex allergies, 1071; i.v. to oral conversion, 524; outsourcing, 37, 41, 43, 45, 48, 52; patient care team, 2174; patient-focused care, 1262; pediatric nutrition, 1335; practice trends, 639; quality assurance, 2238; regional consolidation, 1076; reimbursement, 2433; strategic planning, 1196; survey, 653  
 immunization; APHA guidelines, 2553; pharmacist education, 490  
 infections; monitoring, 1897  
 integrated health care; economics, 2207  
 intensive care units; pharmacists' interventions, 2811  
 managed care systems; clinical information systems, 1501, 1505; patient education, 1497; pharmacists' opportunities, 1049  
 neoplasms; pharmacists' protocols, 680  
 palliative care; hospital pharmacists, 753  
 patient education; ASHP guidelines, 431  
 prisons; training, 674  
 team; twenty-first century, 1865  
 United States Air Force; administration, 783  
 United States Army; administration, 773  
 United States Navy; administration, 778  
 United States Public Health Service; pharmacists, 766  
**Pharmacia & Upjohn**; television; medication errors, 1486  
**Pharmacists**  
 alternative medicine; toxicity monitoring, 1707  
 careers; mentoring programs, 1701  
 compounding; medication errors, 1449  
 consultation; drug deaths, 2434; myocardial infarction, 1984; pain management, 2451  
 demographics; pharmacotherapy examinations, 1015  
 Department of Veterans Affairs; role, 761  
 drug information; medicinal plants, 2656  
 education, pharmaceutical; immunization programs, 490  
 ethics; physician-assisted suicide, 1025  
 home health care; vasopressin infusion, 2230  
 hours; economics, 558  
 Hunter, J.; tobacco regulations, 2050  
 interventions; ACE inhibitors, 264  
 job performance; work styles, 2680  
 managed care systems; formulary systems, 1041  
 patient education; television, 1486  
 patient information; nonprescription drugs, 2664; prescription drugs, 2181  
 pharmaceutical care; aspirin prophylaxis, 1949; economics, 554; future, 1012; Healthy People 2000, 2169; NABP meetings, 1932  
 pharmacoeconomics; databases, 2601  
 practice; technicians' role, 2562  
 professional competence; examinations, 2433  
 professionalism; resignation, 1946  
 rational therapy; myocardial infarction, Nov 15 suppl 53  
 role; AIDS prevention, 2800; antibiotic resistance, 2457; asthma prescribing, 2197; depression, 2668; health care, 1477; hyperactivity education, 2685; immunization, 2553; Internet information, 757; niacin monitoring, 2803; niacin therapy, 2815; Olympic Games, 1053; outcomes research, 1434; patient consultation, 2084; professional practice, 1827; *S. pneumoniae* resistance, 527; tuberculosis, 375; twenty-first century, 1865  
 United States Air Force; role, 783  
 United States Army; role, 773  
 United States Navy; role, 778

United States Public Health Service; role, 766  
 writing; newspapers, 1762

**Pharmacists, clinical, see Clinical pharmacists****Pharmacists, community**

Internet; information, 34  
 reimbursement; services, 32  
 reports; USP quality control, 1240  
**Pharmacists, hospital**  
 ambulatory care; hypertension clinics, 564  
 committees; ethics, 2007  
 communication; attitudes, 584  
 computers; intervention documentation, 1727  
 contract services; role, 41  
 decision-making; formularies, Nov 15 suppl 55  
 drug information; database comparisons, 2592  
 education, pharmaceutical; administration, 1076  
 emergency services; disasters, 1110  
 ethics; infant formula kits, 687  
 history; C. Lyons, 1095  
 Internet; information, 34  
 interventions; ambulatory care, 2719; costs, 392; documentation, 1596; dosage checking, 545; drug-food interactions, 405; i.v. to oral conversion, 524; outcomes, 1591; peer review, 1722; physicians' acceptance, 397  
 job description; advertising, 1260  
 liability; overview, 1152  
 patient education; latex allergies, 1071  
 patient-focused care; team, 2174  
 pharmaceutical care; palliative care, 753  
 pharmaceutical services; patient-focused care, 1262  
 prescribing; oncology clinics, 680  
 professional competence; assessment, 1412  
 professional relations; physicians, 1584  
 quality assurance; health care, 2238  
 reports; USP quality control, 1240  
 residents; job satisfaction, 1521  
 role; alteplase monitoring, 2213; anti-infective DUE, 1837; emergency rooms, 1702; i.v. syringe checking, 1611; outsourcing conflicts, 52  
 safety; needle-stick policies, 258  
 services; clinical care plans, 314  
 staff development; clinical skills, 48; training programs, 1794  
 workload; i.v. administration systems, 1614  
 writing; reference books, 1335

**Pharmacists, institutional**

clinical pharmacy; training, 674  
 computers; clinical information systems, 1515  
 consultation; ASHP guidelines, 431; indigent patients, 2449  
 disease management; managed care systems, 2217  
 health maintenance organizations; computerized databases, 1510; help desk, 1941; hospital rounds, 670  
 history; Boston Dispensary, 1097  
 home health care; AIDS, 1407; enoxaparin monitoring, 1968  
 interventions; psychopharmacy clinic, 2717  
 managed care; Internet, 34  
 managed care systems; opportunities, 1049  
 patient care; clinical information systems, 1505  
 patient education; managed care systems, 1497  
 patient-focused care; clinical information systems, 1501  
 practice; future, 2503  
 prisons; anticonvulsant compliance, 2585  
 role; computer systems, 263  
 services; clinical care plans, 314  
**Pharmacodynamics**  
 databases; health care, 2601  
 docetaxel; clinical studies, Dec 15 suppl 516  
 enoxaparin; comparisons, 1185  
**Pharmacoeconomics**  
 docetaxel; comparisons, Dec 15 suppl 511  
 heparin; comparisons, 1185  
 paclitaxel; comparisons, Dec 15 suppl 511  
 propofol; review, 1953  
 purchasing; 1997 projections, 153  
 United States Army; administration, 773  
**Pharmacokinetics**  
 amifostine; review, 787  
 aminoglycosides; patients' weight, 2201  
 amphotericin B; liposomes, 2426  
 angiotensin-converting-enzyme inhibitors; review, 2689  
 ardeparin sodium, 1575  
 azelastine hydrochloride, 234  
 aztreonam; critical illness, 537  
 bromfenac sodium; overview, 2151  
 bupropion hydrochloride; smoking cessation, 1478  
 cerivastatin sodium; overview, 1793  
 delavirdine mesylate; FDA approvals, 1233

dexfenfluramine hydrochloride; review, 2059  
 docetaxel; clinical studies, Dec 15 suppl 516; overview, Dec 15 suppl 57  
 donepezil hydrochloride; review, 2805  
 gencitabine; review, 162  
 gentamicin; Bayesian calculations, 541; piperacillin-tazobactam interactions, 2704  
 interferon alfacon-1; overview, 2656  
 levofloxacin; review, 2569  
 metformin hydrochloride; review, 893  
 mifepradil dihydrochloride; overview, 2033  
 mycophenolate mofetil; review, 285  
 nelfinavir mesylate; FDA approvals, 1233  
 nicotine; inhalers, 1478  
 pharmaceutical services; patient-focused care, 1262  
 pramipexole dihydrochloride; overview, 1922  
 quetiapine fumarate; overview, 2547  
 reteplase; FDA approvals, 12  
 ropinorol hydrochloride; overview, 2655  
 sermorelin acetate; overview, 2547  
 tazarotene; overview, 2037  
 tiagabine hydrochloride; overview, 2544  
 tiludronate disodium, 1145  
 tramabycin; Bayesian calculations, 541  
 tramadol; review, 643  
 troglitazone, 623  
 trovafloxacin mesylate; review, 2569

**Pharmaceutical standards**

injections; labeling, 2006  
 United States Pharmacopeia; pharmacy practice, 1633

**Pharmaceutical therapy; specialties; examinations, 101****Pharmacy**

administration; recruitment, 1260; staff performance, 2680; technicians' certification, 2562  
 computers; medical logic modules, 281  
 history; J. Oddis, 1804, 1815; twenty-first century, 1865  
 practice; history, 1827; H. Manasse, 1477; outsourcing conflicts, 52; patient consultation, 2084; pharmaceutical care, 2733; professional issues, 1877; USP standards, 1633  
 reimbursement; antiemetics, 830  
 state boards; North Carolina, 2434  
 students; clinical interventions, 1727; community service, 354; mentoring programs, 1701; public relations, 1236; residencies, 92, 1521

**Pharmacy and therapeutics committee**

hospitals; ICU algorithms, 1841  
 mental retardation facilities; therapeutic substitution, 1716

**Pharmacy benefit management companies**

administration; Department of Veterans Affairs, 761  
 contract services; integrated health care, 2207  
 health maintenance organizations; administration, 19  
 ValueRx; mergers, 513

**Pharmacy, clinical, see Clinical pharmacy****Pharmacy, community**

chain stores; customer satisfaction, 531; patient information, 1381  
 Independents; customer satisfaction, 531  
 managed care systems; laws, 1752  
 services; disease management, 32; immunization programs, 490; integrated health care, 2207; patient satisfaction, 2721  
 United States Public Health Service; services, 76

**Pharmacy, education, see Education, pharmaceutical****Pharmacy Ethics, 687****Pharmacy, institutional**

administration; psychopharmacy clinic, 2717  
 anticonvulsants; costs, 1716  
 computers; pharmacists' role, 263  
 costs; purchasing, 153  
 health maintenance organizations; clinical information systems, 1515; computerized databases, 1510  
 home health care; enoxaparin, 1968  
 managed care systems; ambulatory care databases, 1973; clinical information systems, 1501, 1505; formularies, 1041; quality assurance, 1528  
 patient education; ASHP guidelines, 431  
 practice; future, 2503; history, 1097  
 prescriptions; mail order, 520  
 prisons; training, 674  
 services; clinical care plans, 314; HMO formularies, 1941; integrated health care, 2207; patient education, 1497  
 United States Public Health Service; services, 766

**Pharmacy, institutional, hospital**

administration; ambulatory care, 1584; clerkships, 1727; clinical training programs, 1794; code of

- conduct, 142; controlled substances, 630, 1392; cost control, 1196; decision-making, 2491; drug administration routes, 200; drug expenditures, 2302; e-mail, 886; i.v. compounding, 904; i.v. syringe checking, 1611; pharmacists' liability, 1152
- altpase; forms, 1447
- ambulatory care; Medicare reimbursement, 2433
- anti-infective agents; DUE, 1837
- clinical pharmacists; economics, 2079; interventions, 1623
- computers; dosage checking, 545; information systems, 269
- contract services; HMOs, 670; impact, 43
- decentralized; drug information databases, 2592; emergency rooms, 1702; i.v. to oral conversion, 524
- Department of Veterans Affairs; services, 761
- drug distribution systems; contract services, 37, 41, 52; outsourcing, 45; outsourcing models, 48
- drug information centers; telecommunication networks, 1930
- emergency services; disasters, 1110
- errors, medication; methodology, 171
- ethics; committees, 2007
- formuleries; ACE inhibitors, 2689; amifostine, 787; cost-benefit analysis, 95
- history; C. Lyons, 1095; twentieth century, 1805
- integrated health care; U.S., 238
- intensive care units; pharmacists' interventions, 2811
- interventions; costs, 392
- policies and procedures; gene-therapy handling, 1604; latex allergies, 2516; needle sticks, 258
- protocols; insulin dosage, 1046
- quality assurance; clinical interventions, 1722; DUE criteria, 2000, 2002; personnel competence, 1412; tramadol, 696
- reports; drug deaths, 2434; USP quality control, 1240
- residencies; self-renewal programs, 2116
- residents; job satisfaction, 1521
- services; ambulatory care, 2719; clinical care plans, 314; clinical pharmacists, 1280; clinical studies, 1742; hypertension clinics, 564; ICU algorithms, 1841; immunization programs, 490; infection monitoring, 1897; latex allergies, 1071; palliative care, 753; patient satisfaction, 2721; patient-focused care, 1262, 2174; pediatric nutrition, 1335; pharmacists' interventions, 1591; practice trends, 639; quality assurance, 2238; regional consolidation, 1076; survey, 653; United States Air Force, 783
- standards; latex allergies, 2517
- technology; information, 274
- United States Army; services, 773
- United States Navy; services, 778
- Pharmacy personnel, see Personnel, pharmacy**
- Pharmacy services, see Pharmaceutical services**
- Pharmacy Technician Certification Board;** technicians; recertification requirements, 1486
- Phenobarbital;** adverse reactions; cross-sensitivity, 2616
- Phenoxymethamine hydrochloride;** incompatibilities; vehicles, 2073
- Phentermine;** toxicity; heart diseases, 1785
- Phenytoin;** toxicity; emergency room visits, 295
- Phenytoin sodium;** adverse reactions; cross-sensitivity, 2616
- Phlebography;** thrombophlebitis; diagnosis, 66
- Phlebotomy**
- lidocaine, combination, prilocaline; pain, 388
- tetracaine; pain, 388
- Phosphate binders;** aluminum hydroxide; sodium phosphate toxicity, 2488
- Phosphorus;** dosage; dietary reference intakes, 2438
- Physicians**
- communication; drug administration routes, 200
- disease management; managed care systems, 2217
- documentation; drug allergies, 1627
- drug information; medicinal plants, 2656
- education; ACE inhibitors, 264; i.v. to oral conversion, 524; pharmacy students, 1727
- managed care systems; laws, 1752
- patient information; nonprescription drugs, 2664
- prescribing; ambulatory care, 2719; analgesics, 2451; antibiotics, 2457; aspirin prophylaxis, 1949; dosage, 545; HMOs, 1510; managed care systems, 1041; pharmacists' interventions, 392, 397
- professional relations; hospital pharmacists, 1584; pharmacists, 1097, 1262
- reports; USP quality control, 1240
- role; suicide, 1025
- Physicians' Desk Reference;** databases; comparisons, 2592
- Physician's GenRx;** databases; comparisons, 2592
- Piperacillin sodium;** combination, tazobactam sodium; interactions, 2704
- Placental transfer**
- globulin immune; HIV infections, 1018
- human immunodeficiency virus immune globulin; HIV infections, 1018
- zidovudine; HIV infections, 1018
- Planning and design**
- hospital pharmacy; Department of Veterans Affairs, 761
- pharmacy, institutional; mail order, 520
- Plants;** medicinal; drug information, 2656; labeling regulations, 2561
- Plasticizers;** diethylhexyl phthalate; containers, 566; leaching, Dec 15 suppl 57
- Plastics**
- chlorobutanol; acetylcysteine incompatibilities, 549
- incompatibilities; pentoxifylline suspensions, 1301; pyrimethamine suspensions, 2714; tacrolimus suspensions, 178
- polyisoprene; fluorouracil incompatibilities, 1845
- polypropylene; fluorouracil incompatibilities, 1845; incompatibilities, 1106; midazolam incompatibilities, 913; propafenone incompatibilities, 1293
- polyvinyl chloride; antibiotic incompatibilities, 1068; dexamethasone-ondansetron incompatibilities, 1065; docetaxel injections, Dec 15 suppl 57; fluorouracil incompatibilities, 1845; incompatibilities, 2204; insulin-ranitidine incompatibilities, 1304; plasticizer leaching, 566; propafenone incompatibilities, 1293
- Platelet aggregation inhibitors**
- aspirin; myocardial infarction, 586, 1984, Nov 15 suppl 59
- coronary disease; stents, 437
- Plethysmography;** thrombophlebitis; diagnosis, 66
- Pneumococcal infections**
- immunization; ASHP position statement, 575
- rational therapy; pharmacists' role, 527
- Pneumococcal vaccines**
- immunization; adults, 379
- Streptococcus pneumoniae*; penicillin-resistant, 575
- use; pharmacists' role, 527
- Pneumonia;** sulfamethoxazole, combination, trimethoprim; *P. carinii*, 1545
- Poisoning;** drugs; suicides, 295
- Policies and procedures, see Administration**
- Politics;** Hungary; health care, 1207
- Polyethylene;** containers; acetylcysteine incompatibilities, 549
- Polyisoprene**
- containers; incompatibilities, 915
- incompatibilities; fluorouracil, 1845
- Polymers;** polystyrene; propafenone incompatibilities, 1293
- Polyoxyl 40 hydrogenated castor oil;** vehicles; paclitaxel incompatibilities, 566
- Polypropylene;** incompatibilities; caffeine citrated, 1106; fluorouracil, 1845; midazolam, 913; propafenone, 1293
- Polysorbate 80;** vehicles; docetaxel injections, 566
- Polystyrene;** incompatibilities; propafenone, 1293
- Polyvinyl chloride**
- containers; bupivacaine-morphine incompatibilities, 61; ceftriaxone-metronidazole, 424; dexamethasone-ondansetron incompatibilities, 1065; docetaxel injections, Dec 15 suppl 57; incompatibilities, 915, 1417; insulin-ranitidine incompatibilities, 1304; thiopeta incompatibilities, 2588
- incompatibilities; antibiotics, 1068; antineoplastic, 566; bumetanide, 422; fluorouracil, 1845; i.v. injections, 2204; meropenem, 412; propafenone, 1293
- Postmarketing surveillance**
- protease inhibitors; hyperglycemia, 1575
- ritonavir; labeling, 126
- Potency;** levothyroxine sodium; FDA regulations, 2151
- Powders**
- captopril; incompatibilities, 2483
- phenoxymethamine hydrochloride; compounding, 2073
- Pramipexole dihydrochloride;** approvals; FDA, 1922
- Precipitation**
- amphotericin B; remifentanyl incompatibilities, 2192
- amscrine; granisetron incompatibilities, 56
- ceftriaxone sodium; incompatibilities, 424
- cefprozilacin lactate; incompatibilities, 1193
- doxorubicin hydrochloride; incompatibilities, 2708
- fluorouracil; incompatibilities, 1845
- iron; parenteral nutrition, 570
- metronidazole hydrochloride; incompatibilities, 424
- propafenone hydrochloride; incompatibilities, 1293
- propofol; incompatibilities, 1287
- warfarin sodium; incompatibilities, 2599
- Prednisone;** dermatitis; losartan adverse reactions, 1333
- Pregnancy**
- contraceptives, oral; emergency use, 874
- globulin immune; HIV infections, 1018
- human immunodeficiency virus immune globulin; HIV infections, 1018
- zidovudine; HIV infections, 1018
- Prescribing**
- cannabis; laws, 126
- divalproex; mental retardation facilities, 1716
- drugs; expenditure reports, 2302; palliative care, 1191
- pharmacists; Department of Veterans Affairs, 761; pharmacists, hospital; hypotensive agents, 564; oncology clinics, 680
- physicians; ACE inhibitors, 264; ambulatory care, 2719; analgesics, 2451; antibiotics, 2457; aspirin prophylaxis, 1949; asthma, 2197; dosage, 545; HMOs, 1510; managed care systems, 1041
- valproic acid; mental retardation facilities, 1716
- Prescriptions**
- costs; low-income patients, 1702
- discharge; patient consultation, 1262
- drugs; advertising, 2181, 2596; compliance, 2503; death, 2434; HMO formularies, 1941; molecular weight, 1449; patient information, 352, 1572, 2664; prescription to nonprescription, 1207
- integrated health care; U.S., 238
- mail order; clinical services, 613; HMOs, 520
- patient information; survey, 1381
- pharmacy, community; services, 531
- pharmacy, institutional; clinical information systems, 1515
- Preservatives**
- chlorobutanol; acetylcysteine incompatibilities, 549
- injections; storage, 2006
- Prilocaine;** combination, lidocaine; comparisons, 388
- Primary care**
- clinical pharmacists; role, 1280
- depression; pharmacists' role, 2668
- hypertension; pharmacists' role, 564
- pharmaceutical services; antihypertensive programs, 2079
- Primers,** 66, 1071, 1420, 1528, 1973, 2207, 2491, 2601, 2721
- Prison**
- anticonvulsants; compliance, 2585
- pharmacy, institutional; services, 674
- Product development;** vaccines; adults, 379
- Product withdrawal**
- dexfenfluramine hydrochloride; toxicity, 2269
- fenfluramine hydrochloride; toxicity, 2269
- pseudoephedrine hydrochloride, combination, terfenadine; toxicity, 342
- terfenadine; toxicity, 342
- Professional competence**
- personnel, pharmacy; assessment, 1412
- pharmacists; APHA policies, 1025; JCPP working groups, 2433; NABP resolutions, 1932
- pharmacists, hospital; recruitment, 1260
- pharmacists, institutional; clinical pharmacy, 674
- technicians; certification, 2562
- Professionalism**
- personnel, pharmacy; code of conduct, 142
- pharmacists; mentoring programs, 1701; resignation, 1946
- Professional relations**
- nurses; pharmacists, 2174
- pharmacists; physicians, 1097; resignation, 1946
- pharmacists, hospital; patient-focused care, 1262; physicians, 1584
- Professions;** pharmacy; qualifications, 1827
- Propafenone hydrochloride;** incompatibilities; diluents, containers, 1293

**Propellants**; chlorofluorocarbons; FDA regulations, 1021

**Propofol**  
dosage schedules; parenteral nutrition, 694  
emulsions; nutritional implications, 2515  
incompatibilities; Y-site injections, 1287  
pharmacoeconomics; review, 1953

**Propoxyphene**; concomitant therapy, 85

**Propranolol**; akathisia; antipsychotic toxicity, 2461

**Propylene**; copolymers; ethylene, 2204

**Propylene glycol**; incompatibilities; phenoxybenzamine, 2073

**Proteins**; enteral nutrition; labeling, 2239

## Protocols

see also **Guidelines**

algorithms; ICU, 1841

alteplase; cardiovascular disorders, 1447; cerebrovascular disorders, 2213

American Society of Health-System Pharmacists; ACE inhibitors, 299; niacin, 2815; *S. pneumoniae* resistance, 575; tuberculosis, 428

analgesics and antipyretics; pain, 2451

antibiotics; resistance prevention, 2457

anti-inflammatory agents; asthma, 862

antineoplastic agents; pharmacists, 680

antivirals; HIV infections, 1681, 2652

aspirin; myocardial infarction prophylaxis, 1984

computers; medical logic modules, 281

disease management; community pharmacy, 32

fentanyl; i.v. to transdermal, 87

hospital pharmacy; latex allergies, 2516

interferons; hepatitis C, 1140

nutrition; National Academy of Sciences, 2438; pediatrics, 1335

pharmaceutical services; clinical care plans, 314

propofol; fat emulsions, 2515

roentgenographic agents; cost-benefit analysis, 1395

sulfamethoxazole, combination, trimethoprim; desensitization, 1545

thrombolytic agents; myocardial infarction, Nov 15 suppl 53

tramadol hydrochloride; DUE, 696

urokinase; DUE criteria, 2000, 2002

vaccines; adolescents, 494

vincristine sulfate; dosage, 1755

**Pruritus**; azelastine hydrochloride; FDA approvals, 234

**Pseudoephedrine hydrochloride**; combination, terfenadine; product withdrawal, 342

**Psoriasis**; tazarotene; FDA approvals, 2037

**Psychopharmacy**; ambulatory care; clinic, 2717

**Psychotherapeutic agents**  
algorithms; ICU, 1841

ambulatory care; pharmaceutical services, 2717

**Psychotherapy**; attention deficit disorder with hyperactivity, 2685

**Psychotic disorders**; quetiapine fumarate; FDA approvals, 2547

**Publications**; *American Journal of Health-System Pharmacy*; policies, 30

**Public Broadcasting Service**; television; medication errors, 1486

**Public health**  
HIV infections; home tests, 2232

hospitals; quality assurance, 2238

United States; Healthy People 2000, 2169

**Public Health Service**; pharmacists; awards, 2050

**Public relations**  
organizations; health care, 2282

students; museum exhibits, 1236

**Purchasing**  
drugs; AIDS buyers' clubs, 2122

group; drug cost projections, 153

hospital pharmacy; wholesalers, 45

**PVC**, see **Polyvinyl chloride**

**Pyrimethamine**; stability; suspensions, 2714

## Q

### Quality assurance

drug distribution systems; medication errors, 171

drug information centers; databases, 1763

health care; hospitals, 2238; informatics, 274

home health care; HMOs, 1968

hospital pharmacy; administration, 1076; clinical interventions, 1722; contract services, 48; DUE criteria, 2000, 2002; survey, 653; tramadol, 696

hospitals; latex allergies, 1071

immunization; pharmacists' role, 2553

injections; syringe checking, 1611

managed care systems; accreditation, 1528; disease management, 2217; formularies, 1041

National Committee for Quality Assurance; managed care systems, 2551

personnel, pharmacy; professional competence, 1412

pharmaceutical services; clinical care plans, 314; patient satisfaction, 2721; pharmaceutical care, 1434

pharmacy, community; customer satisfaction, 531

**Quality control**, see **Control, quality**

**Quality improvement**, see **Quality assurance**

**Quality of life**  
antiemetics; comparisons, 2478

docetaxel; comparisons, Dec 15 suppl S11

paclitaxel; comparisons, Dec 15 suppl S11

pain; pharmacists' role, 2451

prescription drugs; advertising, 2596

**Questions and Answers**, 30, 1037, 1260, 1701, 2169

Drug review articles and industry ties, 30

Healthy People 2000, 2169

Monitoring member satisfaction, 1037

Overemphasis on credentials in personnel ads, 1260

PALs program, 1701

**Quetiapine fumarate**; approvals; FDA, 2547

**Quinolones**  
ciprofloxacin lactate; incompatibilities, 1193

levofloxacin; review, 2569

trovafloxacin mesylate; review, 2569

## R

**Rabies vaccines**; immunization; adults, 379

**Radiopharmaceuticals**  
administration; needle-stick policies, 258

United States Pharmacopeia; standards, 1633

**Ranitidine hydrochloride**; incompatibilities; insulin human, 1304

**Rational therapy**  
analgesics and antipyretics; pain, 2451

angiotensin-converting-enzyme inhibitors; pharmacists' interventions, 264

antibiotics; ASHP position statement, 575; resistance, 2457

anti-infective agents; DUE, 1837

$\beta$ -agonists; asthma, 2197

drugs; emergency room visits, 295; clinical pharmacists, 1280

myocardial infarction; protocols, Nov 15 suppl S9; pharmacists' role, Nov 15 suppl S3

niacin; hyperlipidemia, 2803, 2815

pneumococcal infections; pharmacists' role, 527

polypharmacy; pharmacists' interventions, 2719

prescription drugs; advertising, 2181

roentgenographic agents; cost-benefit analysis, 1395

vincristine sulfate; toxicity, 1755

**Recombinant t-PA**, see **Alteplase**

**Reconstitution**, see **Drugs; reconstitution**

**Records**  
hospital pharmacy; controlled substances, 630, 1392; wholesalers, 45

medical; adolescents, 494; allergies, 1627; patient-focused care, 1262

**Recruitment**; pharmacists; advertising, 1260

**Reference books**; nutrition; pediatrics, 1335

**References**  
patient information; writing guidelines, 1572

prescription drugs; advertising, 2596

**Regulations**  
clinical studies; administration, 1742

controlled substances; documentation, 1392

dietary supplements; labeling, 2561

estrogens, conjugated; generic, 1376

Food and Drug Administration; AIDS buyers' clubs, 2122; anorexics labeling, 1785; dietary supplements, 1707; ephedrine, 1578; gene therapy, 877; Internet, 757; levothyroxine, 2151; oral contraceptives, 874; paclitaxel labeling, 2128; thalidomide marketing, 2270

hospital pharmacy; pharmacists' liability, 1152; service outsourcing, 45

imports; multivitamins, 1789

inhalers; chlorofluorocarbons, 1021

International Olympic Committee; drug abuse, 1053

managed care systems; integrated health care, 1752

Medicare; antiemetic reimbursement, 830

North Carolina; drug deaths, 2434

patient information; private sector, 352; written, 1381

substitution; NABP resolutions, 1932

tobacco; FDA, 2050

**Reimbursement**  
Balanced Budget Act of 1997; Medicare, 2433

health-benefit programs; innovative therapy, 572

integrated health care; pharmaceutical services, 2207

pharmacists, community; disease management, 32

pharmacy; Medicare policies, 830

pharmacy, institutional; computer programs, 1505

third party; clinical studies, 1742

**Release**; drugs; membranes, 1759

**Remifentanyl hydrochloride**; incompatibilities; Y-site simulation, 2192

**Renal artery obstruction**; angiotensin-converting-enzyme inhibitors; contraindications, 1552

**Replacement solutions**  
calcium chloride; bradycardia, 2488

emergency kits; disasters, 1110

heart arrest; therapy, 85

sodium chloride; hyperphosphatemia, 2488

**Reports**  
adverse reactions; patient-focused care, 1262

allergies; documentation, 1627

American Society of Health-System Pharmacists; strategic planning, 1889

control, quality; USP, 1240

death; drug related, 2434

drugs; costs, 2302

drugs, adverse reactions; dietary supplements, 1707; therapeutic interchange, 1149

integrated health care; U.S., 238

managed care systems; quality assurance, 1528

**Research**  
anticoagulants; history, 1992

health care; databases, 2601

history; museum exhibits, 1236

hospitals; university affiliated, 1711

latex; allergies, 2517

marketing; membership satisfaction, 1037

outcomes; pharmaceutical care, 1434

thrombolytic agents; history, 1992

United States Public Health Service; pharmacists' role, 766

vaccines; adults, 379

**Residencies**, see **Education, pharmaceutical; residencies**

**Resistance**  
antibiotics; bacteria, 2457

anti-infective agents; *Enterococcus*, *Staphylococcus* species, 1420

antituberculars; ASHP protocols, 428

docetaxel; overview, Dec 15 suppl S2

methicillin; *S. aureus*, 2185

penicillin; *S. pneumoniae*, 527, 575

tuberculosis; patients' compliance, 375

**Respiratory smooth-muscle relaxants**; theophylline; roentgenographic toxicity, 587

**Retepase**  
approvals; FDA, 12

mechanism of action; thrombolytics, Nov 15 suppl S17

myocardial infarction; comparisons, Nov 15 suppl S27

**Retired Persons Services**; clinical pharmacy; mail order, 613

**Rhinitis**; azelastine hydrochloride; FDA approvals, 234

**Ritonavir**; labeling; pediatrics, 1233; toxicity, 126

**Roentgenographic agents**  
interactions; metformin, 587

protocols; cost-benefit analysis, 1395

**Ropinirole hydrochloride**; approvals; FDA, 2655

## S

### Safety

guidelines; gene-therapy handling, 1604

needs; hospital policies, 258

**Salaries**  
managed care systems; administrators, 1049

pharmacists; residents, 1521; U.S. Public Health Service, 1236; Wisconsin, 558

**Saliva levels**; antibodies; HIV tests, 2232

**Salts**; drugs; compounding errors, 1449

**Samples**; nutrition; pediatrics, 687

**Schools**; pharmacy; accreditation standards, 2439; drug information centers, 1930

**Scintigraphy**; thrombophlebitis; diagnosis, 66

**Sedimentation:** pentoxifylline; suspensions, 1301

#### Seizures

phenytoin sodium; cross-sensitivity, 2616  
tiagabine hydrochloride; FDA approvals, 2544

**Selenium:** parenteral nutrition; iron dextran incompatibilities, 570

#### Self-study Materials, 853, 1464

Pharmacoeconomics and Outcomes: Applications for Patient Care, Module 2: Assessment of Economic Outcomes, 853

Pharmacotherapy: A Patient-Focused Approach, 1464

**Senior Medication Awareness Training Program:** errors, medication; California, 2282

**Sermorelin acetate:** approvals; FDA, 2547

#### Serums

globulin immune; HIV infections, 1018  
human immunodeficiency virus immune globulin; HIV infections, 1018

**Sex:** patients; aspirin prophylaxis, 1984

#### Simple syrup

see also **Sucrose**

Incompatibilities; tacrolimus, 178

#### Skeletal muscle relaxants

algorithms; ICU, 1841

cisatracurium besylate; incompatibilities, 1735

**Skilled-nursing facilities:** reimbursement; laws, 2433

#### Smoking

cessation; bupropion, nicotine, 1478

patient information; hospital pharmacists, 564

#### Sociology

HIV infections; home tests, 2232

low income; patient consultation, 2449; patients, 1702; students' community service, 354

pharmaceutical care, 2733

pharmacists, hospital; terminal patients, 753

#### Sodium bicarbonate

heart arrest; therapy, 85

incompatibilities; ciprofloxacin, 1193

vehicles; omeprazole compounding, 1833

#### Sodium chloride

diluents; antibiotics, 1068; antineoplastic incompatibilities, 566; bupivacaine-morphine incompatibilities, 61; ceftriaxone-metronidazole, 424; cidofovir injections, 2204; ciprofloxacin incompatibilities, 1193; cisatracurium incompatibilities, 1735; dexamethasone-ondansetron incompatibilities, 1065; doxorubicin, 2708; drug stability, 915; granisetron incompatibilities, 56; incompatibilities, 1295; insulin-ranitidine incompatibilities, 1304; meperidine, 205; propofol emulsions, 1287; remifentanyl incompatibilities, 2192

hyperphosphatemia; sodium phosphate toxicity, 2488

incompatibilities; acetylcysteine, 549; meropenem, 412; midazolam, 913; propafenone, 1293; thiopental, 258

**Sodium deoxycholate:** solubilizing agents; amphotericin B, 2426

**Sodium phosphate dibasic:** toxicity; errors, 2488

**Software Review, Time Matters, Version 2.208,** 728

**Solubilizing agents:** sodium deoxycholate; amphotericin B, 2426

**Solutions, ophthalmic:** acetylcysteine sodium; incompatibilities, 549

**Somatotropin:** wasting syndrome; AIDS, 2618

**Soybean oil:** incompatibilities; amphotericin B, 683

#### Specialties

oncology; pharmacists' protocols, 680

pharmacists; certification, 1236

pharmacotherapy; examinations, 1015

pharmacy; APHA policies, 1025; certification, 1260; residents' satisfaction, 1521

#### Spectrum microbial

levofloxacin; review, 2569

trovafloxacin mesylate; review, 2569

**Sports:** drug abuse; pharmacists' role, 1053

#### Stability

acetylcysteine sodium; ophthalmic solutions, 549

amphotericin B; incompatibilities, 683

bumetanide; injections, 422

bupivacaine hydrochloride; incompatibilities, 61

caffeine citrated; incompatibilities, 1106

captopril; oral liquids, 2483

ceftriaxone sodium; metronidazole incompatibilities, 424

cidofovir; incompatibilities, 2204

ciprofloxacin lactate; Y-site injections, 1193

cisatracurium besylate; Y-site injections, 1735

dacarbazine; temperature, 915

dexamethasone sodium phosphate; incompatibilities, 1065

docetaxel; overview, Dec 15 suppl 57

dopamine hydrochloride; incompatibilities, 1417

doxorubicin hydrochloride; liposomes, 2708; temperature, 915

epinephrine hydrochloride; incompatibilities, 1417

filgrastim; incompatibilities, 185

fluorouracil; incompatibilities, 1845

granisetron hydrochloride; incompatibilities, 56; oral liquids, 1404

injections; incompatibilities, 64, 181

insulin human; i.v., Y-site injections, 1304

iron dextran; parenteral nutrition, 570

ketamine hydrochloride; meperidine incompatibilities, 205

levothyroxine sodium; FDA regulations, 2151

meperidine hydrochloride; ketamine incompatibilities, 205

meropenem; incompatibilities, 412

metronidazole hydrochloride; ceftriaxone incompatibilities, 424

midazolam hydrochloride; incompatibilities, 913

morphine sulfate; incompatibilities, 61

nitroglycerin; incompatibilities, 1417

norepinephrine bitartrate; incompatibilities, 1417

omeprazole; compounding, 1833

ondansetron hydrochloride; incompatibilities, 1065; temperature, 915

parenteral nutrition; injections, 1295

penicillins; incompatibilities, 1068

pentoxifylline; suspensions, 1301

phenoxybenzamine hydrochloride; incompatibilities, 2073

polyvinyl chloride; plasticizer leaching, 566

propafenone hydrochloride; injections, 1293

propofol; Y-site injections, 1287

pyrimethamine; incompatibilities, 2714

ranitidine hydrochloride; i.v., Y-site injections, 1304

remifentanyl hydrochloride; incompatibilities, 2192

sumatriptan succinate; suspensions, 1619

tacrolimus; suspensions, 178

thiopental; incompatibilities, 2588

tobramycin sulfate; incompatibilities, 1068

ursodiol; compounding, 1401

vinorelbine sulfate; temperature, 915

**Stadlanders Pharmacy:** clinical pharmacy; mail order, 613

#### Staff development

hospital pharmacy; anti-infective DUE, 1837; clinical skills, 48; clinical training programs, 1794

pharmacists; Department of Veterans Affairs, 761

pharmacists, institutional; training, 674

#### Standards

accreditation; pharmacy schools, 2439

American Society of Health-System Pharmacists; residencies, 2055, 2099

computers; program languages, 281

education, pharmaceutical; NABP resolutions, 1932

health care; information, 274

Joint Commission on Accreditation of Healthcare Organizations; patient care outcomes, 743

managed care systems; quality assurance, 1528

pharmacy; latex allergies, 2517

quality assurance; personnel competence, 1412

United States Pharmacopeia; pharmacy practice, 1633

**Staphylococcal infections:** mupirocin calcium; review, 2185

**Staphylococcus aureus:** resistance; methicillin, 2185; vancomycin, 2457

**Staphylococcus species:** resistance; anti-infective agents, 1420

#### Statistics

hospitals; HMO ownership, 2044

integrated health care; survey, 2786; U.S., 238

**Status asthmaticus:** oxaprozin; adverse reactions, 199

**Stents:** coronary disease; thrombolytic agents, 437

**Sterile products:** compounding; technicians, 1702

#### Steroids, cortico-

allergies; latex, 2516; sulfamethoxazole-trimethoprim, 1545

dexamethasone sodium phosphate; incompatibilities, 1065

incompatibilities; doxorubicin, 2708

inhalers; chlorofluorocarbons, 1021

prednisone; dermatitis, 1333

triamcinolone acetonide; dermatitis, 1333

**Stevens-Johnson syndrome:** phenytoin sodium; adverse reactions, 2616

#### Storage

acetylcysteine sodium; incompatibilities, 549

amphotericin B; incompatibilities, 683

bumetanide; injections, 422

bupivacaine hydrochloride; incompatibilities, 61

caffeine citrated; incompatibilities, 1106

captopril; incompatibilities, 2483

ceftriaxone sodium; incompatibilities, 424

cidofovir; incompatibilities, 2204

cisatracurium besylate; Y-site injections, 1735

dacarbazine; incompatibilities, 915

dexamethasone sodium phosphate; incompatibilities, 1065

docetaxel; incompatibilities, 566; overview, Dec 15 suppl 57

doxorubicin hydrochloride; incompatibilities, 915

filgrastim; incompatibilities, 185

fluorouracil; incompatibilities, 1845

granisetron hydrochloride; incompatibilities, 56; stability, 1404

injections; incompatibilities, 64, 181; preservatives, 2006

insulin human; incompatibilities, 1304

iron dextran; parenteral nutrition, 570

ketamine hydrochloride; meperidine incompatibilities, 205

meperidine hydrochloride; ketamine incompatibilities, 205

meropenem; incompatibilities, 412

metronidazole hydrochloride; incompatibilities, 424

midazolam hydrochloride; incompatibilities, 913

morphine sulfate; incompatibilities, 61

omeprazole; stability, 1833

ondansetron hydrochloride; incompatibilities, 915, 1065

pacitaxel; incompatibilities, 566

penicillins; incompatibilities, 1068

pentoxifylline; suspensions, 1301

phenoxybenzamine hydrochloride; incompatibilities, 2073

propafenone hydrochloride; incompatibilities, 1293

pyrimethamine; incompatibilities, 2714

ranitidine hydrochloride; incompatibilities, 1304

sumatriptan succinate; suspensions, 1619

tacrolimus; suspensions, 178

thiopental; incompatibilities, 2588

ursodiol; suspensions, 1401

vinorelbine sulfate; incompatibilities, 915

**Strand, L.; pharmacy:** future, 1012

#### Strategic planning

American Society of Health-System Pharmacists; reports, 1889

Department of Veterans Affairs; pharmaceutical services, 761

hospital pharmacy; contract services, 48; informatics, 274

hospitals; cost control, 1196; university affiliated, 1711

pharmaceutical services; emergency rooms, 1702

**Streptococcus pneumoniae:** resistance; penicillin, 527, 575

#### Students

drug abuse; survey, 365

medical; residencies, 92

**Substance Abuse and Mental Health Services Administration:** United States Public Health Service; pharmaceutical services, 766

#### Substitution

generic; levothyroxine, 2151

generic drugs; narrow therapeutic index, 1630

therapeutic; ACE inhibitors, 2689; adverse drug reactions, 1149; divalproex vs. valproic acid, 1716; FIP guidelines, 2800; NABP resolutions, 1932

#### Sucrose

see also **Simple syrup**

incompatibilities; captopril, 2483; phenoxybenzamine, 2073; pyrimethamine, 2714

#### Suicides

pharmacists; physician-assisted, 1025

poisoning; emergency room visits, 295

**Sulfamethoxazole:** combination, trimethoprim; allergies, 1545; otitis media, 2736

**Sulfonamides:** sulfamethoxazole, combination, trimethoprim; allergies, 1545; otitis media, 2736

**Sumatriptan succinate:** stability; suspensions, 1619

**Surface area:** patients; docetaxel pharmacokinetics, Dec 15 suppl 516

#### Surgery

arterial occlusive diseases; comparisons, 1963

aztreonam; pharmacokinetics, 537

controlled substances; documentation, 1392

## Annual Index

- enoxaparin; hip prosthesis, 1185  
heparin; hip prosthesis, 1185
- Surgical supplies;** administration sets; emergency kits, 1110; fluorouracil incompatibilities, 1845; needle contamination, 258
- Suspending agents**  
incompatibilities; compounding, 178; ursodiol suspensions, 1401  
methylcellulose; pyrimethamine suspensions, 2714
- Suspensions**  
pentoxifylline; stability, 1301  
pyrimethamine; stability, 2714  
sulfamethoxazole, combination, trimethoprim; HIV infections, 1545  
sumatriptan succinate; stability, 1619  
tacrolimus; compounding, 178  
ursodiol; stability, 1401
- Sustained-action medications**  
pentoxifylline; suspension compounding, 1301  
tablets; patient information, 2403
- Sweetening agents**  
orange syrup; ursodiol stability, 1401  
sucrose; pyrimethamine suspensions, 2714  
syrups; sumatriptan suspensions, 1619
- Sympatholytic agents**  
 $\beta$ -blockers; myocardial infarction, Nov 15 suppl S9  
metoprolol; antipsychotic toxicity, 2461  
phenoxylbenzamine hydrochloride; incompatibilities, 2073  
propranolol; antipsychotic toxicity, 2461
- Sympathomimetic agents**  
albuterol; emergency room visits, 295; status asthmaticus, 199  
albuterol sulfate; sustained-action, 2403  
 $\beta$ -agonists; DUR, 2197  
dopamine hydrochloride; incompatibilities, 1417  
ephedrine; FDA regulations, 1578  
epinephrine; heart arrest, 85  
epinephrine hydrochloride; incompatibilities, 1417  
etilefrine hydrochloride; sustained-action, 2403  
inhalers; chlorofluorocarbons, 1021  
norepinephrine bitartrate; incompatibilities, 1417  
pseudophedrine hydrochloride, combination, terfenadine; product withdrawal, 342
- Syringes**  
injections; error checking, 1611  
ketamine hydrochloride; stability, 205  
meperidine hydrochloride; stability, 205  
polypropylene; incompatibilities, 1106; midazolam incompatibilities, 913; propafenone incompatibilities, 1293
- Syrups;** sweetening agents; sumatriptan suspensions, 1619
- T**
- Tablets**  
captopril; incompatibilities, 2483  
granisetron hydrochloride; liquid compounding, 1404  
pentoxifylline; suspension compounding, 1301  
pyrimethamine; suspension compounding, 2714  
sustained-action medications; patient information, 2403
- Tacrolimus;** stability; suspensions, 178
- Tazarotene;** approvals; FDA, 2037
- Tazobactam sodium;** combination, piperacillin sodium; interactions, 2704
- Tyramine**  
health care; memory disorders, 92  
home health care; terminal care, 2230  
hospitals; clinical pharmacists, 2811; pharmacists' role, 1591  
nutrition; reference books, 1335  
patient-focused care; hospitals, 2174; pharmacists' role, 1262  
pharmacists; twenty-first century, 1865  
primary care; clinical pharmacists, 1280
- Team hospitals;** hospitals; cost control, 1196
- Technicians, pharmacy, see Personnel, pharmacy; supportive**
- Technology**  
computers; e-mail, 886; health care, 263  
drug information; pharmacists' role, 2503  
health care; computers, 269; informatics, 274
- Telecommunication**  
drug information centers; networks, 1930  
pharmacists; hospital; attitudes, 584  
pharmacy, institutional; clinical information systems, 1505; HMO formularies, 1941
- Television**  
education, pharmaceutical; immunization programs, 490  
errors, medication; PBS programs, 1486
- Temperature**  
acetylcysteine sodium; incompatibilities, 549  
antineoplastic agents; incompatibilities, 915  
ceftriaxone sodium; incompatibilities, 424  
cidofovir; incompatibilities, 2204  
dexamethasone sodium phosphate; incompatibilities, 1065  
dextrose; portable infusion pumps, 1277  
fluorouracil; incompatibilities, 1845  
granisetron hydrochloride; stability, 1404  
meropenem; incompatibilities, 412  
metronidazole hydrochloride; incompatibilities, 424  
midazolam hydrochloride; incompatibilities, 913  
nafcillin sodium; incompatibilities, 1068  
omeprazole; stability, 1833  
ondansetron hydrochloride; incompatibilities, 1065  
oxacillin sodium; incompatibilities, 1068  
penicillin G potassium; incompatibilities, 1068  
pentoxifylline; stability, 1301  
propafenone hydrochloride; incompatibilities, 1293  
pyrimethamine; suspension stability, 2714  
tacrolimus; suspensions, 178  
thiotea; incompatibilities, 2588  
tobramycin sulfate; incompatibilities, 1068  
ursodiol; stability, 1401
- Teratogenicity;** thalidomide; toxicity, 2270
- Terfenadine;** product withdrawal; toxicity, 342
- Tests, laboratory**  
anticoagulants; institutional pharmacists, 1968  
blood; thrombophlebitis, 66  
dextrose; blood levels, 1058  
drug abuse; Olympic Games, 1053  
HIV infections; non-blood-based, 2232  
human immunodeficiency virus; ribonucleic acid levels, 1646
- Tetracaine;** pain; comparisons, 388
- Texas;** hospitals; ownership, 2238
- Thalidomide;** marketing; FDA regulations, 2270
- Theophylline;** prophylaxis; roentgenographic agents toxicity, 587
- Therapeutic interchange, see Substitution, therapeutic**
- Therapy Consultation,** 87, 694, 1545, 1759, 2510, 2616
- Thermography;** thrombophlebitis; diagnosis, 66
- Thiamine;** parenteral nutrition; deficiency, 1789
- Thiamine deficiency;** vitamins; shortage, 1789
- Thiopental sodium;** incompatibilities; i.v. additives, 64
- Thiotea;** incompatibilities; sodium chloride, 2588
- Thrombolytic agents**  
alteplase; cardiovascular disorders, 1447; cerebrovascular disorders, 2213; mechanism of action, Nov 15 suppl S17; myocardial infarction, 586, Nov 15 suppl S27  
clinical studies; outcome markers, Nov 15 suppl S23  
coronary disease; stents, 437  
myocardial infarction; pharmacists' role, Nov 15 suppl S3; protocols, Nov 15 suppl S9  
n-PA; mechanism of action, Nov 15 suppl S17  
research; history, 1992  
reteplase; FDA approvals, 12; mechanism of action, Nov 15 suppl S17; myocardial infarction, Nov 15 suppl S27  
TNK-t-PA; mechanism of action, Nov 15 suppl S17  
urokinase; comparisons, 1963; DUE criteria, 2000, 2002; overview, 1988
- Thrombophlebitis**  
ardeparin sodium; FDA approvals, 1575  
diagnosis, 66  
enoxaparin; comparisons, 1185  
enoxaparin sodium; home health care, 1968  
heparin; comparisons, 1185  
heparins; low molecular weight, 1995  
thrombolytic agents; clinical studies, 1992  
urokinase; DUE criteria, 2002; regional infusion, 1988
- Thrombosis**  
anticoagulants; overview, 1992  
thrombolytic agents; overview, 1992  
urokinase; overview, 1988
- Thyroid drugs;** levothyroxine sodium; FDA regulations, 2151
- Tigabine hydrochloride;** approvals; FDA, 2544
- Tiludronate disodium;** approvals; FDA, 1145
- Time;** pharmacists, institutional; AIDS prophylaxis, 1407
- Time studies;** drug administration systems; cefotaxime vs. ceftriaxone, 1614
- Tinzaparin sodium;** thrombophlebitis; overview, 1995
- TNK-t-PA;** mechanism of action; thrombolytics, Nov 15 suppl S17
- Tobacco;** regulations; FDA, 2050
- Tobramycin;** pharmacokinetics; Bayesian calculations, 541; patients' weight, 2201
- Tobramycin sulfate;** incompatibilities; filgrastim, 185; polyvinyl chloride, 1068
- Tomography;** thrombophlebitis; diagnosis, 66
- Topical preparations**  
lidocaine, combination, prilocaine; phlebotomy pain, 388  
mupirocin calcium; review, 2185  
tetracaine; phlebotomy pain, 388  
triamcinolone acetonide; dermatitis, 1333
- Toxicity**  
see also **Drugs, adverse reactions**  
albendazole; liver, blood, 319  
aldesleukin; palliative care, 1191  
alteplase; clinical studies, 2213  
amifostine; review, 787  
amphotericin B; liposomes, 2426  
angiotensin-converting-enzyme inhibitors; pharmacists' interventions, 264; renal artery obstruction, 1552; review, 2689  
anorexia; heart diseases, 1785  
antidepressants; geriatrics, 2510  
antineoplastic agents; amifostine therapy, 787; antiemetic comparisons, 2478; antiemetic reimbursement, 2433; antiemetics, 830; pharmacists' protocols, 680  
antipsychotic agents; basal ganglia diseases, 2461  
antivirals; HIV infections, 1681  
ardeparin sodium, 1575  
aspirin; dosage, 1949; myocardial infarction prophylaxis, 1984  
azelastrone hydrochloride; side effects, 234  
bromfenac sodium; overview, 2151  
bupropion hydrochloride; smoking cessation, 1478  
cefepime hydrochloride; neutropenia, 2621  
cerivastatin sodium; overview, 1793  
cidofovir; kidney failure, 12  
cisapride; interactions, 320  
delavirdine mesylate; FDA approvals, 1233  
dexfenfluramine hydrochloride; product withdrawal, 2269; review, 2059  
dietary supplements; reports, 1707  
divalproex sodium; substitution, 1716  
docetaxel; dosage, Dec 15 suppl S16; overview, Dec 15 suppl S2, S19  
donepezil hydrochloride; review, 2805  
drug abuse; newspapers, 1762  
drugs; clinical care plans, 314; clinical information systems, 1505; clinical pharmacists, 1280; death, 2434; education, 1053; emergency room visits, 295; restricted formularies, 1041  
drugs, nonprescription; consumer information, 2664  
fenfluramine hydrochloride; product withdrawal, 2269  
fentanyl; transdermal patches, 85  
gemcitabine, 162  
gene therapy; FDA regulations, 877  
ginseng; warfarin interactions, 692  
granisetron hydrochloride; comparisons, 1172  
heparins; low molecular weight, 1995  
injections; pain, 388  
interferon alfa-2a, 190  
interferon alfacon-1; overview, 2656  
levofloxacin; review, 2569  
levothyroxine sodium; potency, 2151  
lidocaine, combination, prilocaine; side effects, 388  
medical devices; infections, 1897  
medicinal plants; drug information, 2656  
metformin; interactions, 587  
metformin hydrochloride; review, 893  
methamphetamine; myocardial infarction, 586  
mifepristone dihydrochloride; overview, 2033  
mupirocin calcium; review, 2185  
mycophenolate mofetil, 285  
nafcillin; home health care, 1176  
nelfinavir mesylate; FDA approvals, 1233  
niacin; monitoring, 2803, 2815  
nicotine; inhalers, 1478  
nutrition; dietary reference intakes, 2438  
ondansetron hydrochloride; comparisons, 1172  
oxacillin; home health care, 1176  
pramipexole dihydrochloride; overview, 1922  
prescription drugs; patient information, 2664  
propofol; hypertriglyceridemia, 2515; review, 1953  
protease inhibitors; hyperglycemia, 1575

pseudoephedrine hydrochloride, combination, terfenadine; product withdrawal, 342  
 quetiapine fumarate; overview, 2547  
 reteplase; side effects, 12  
 ritonavir; labeling, 126  
 roentgenographic agents; prophylaxis, 587  
 ropinirole hydrochloride; overview, 2655  
 sermorelin acetate; overview, 2547  
 sodium phosphate dibasic; pediatrics, 2488  
 somatropin, 2618  
 tazarotene; overview, 2037  
 terfenadine; product withdrawal, 342  
 tetracaine; erythema, 388  
 thalidomide; FDA regulations, 2270  
 tiagabine hydrochloride; overview, 2544  
 tiludronate disodium; overview, 1145  
 tramadol; review, 643  
 tramadol hydrochloride; DUE, 696  
 tretinoin, 190  
 troglitazone, 623  
 trovafloxacin mesylate; review, 2569  
 urokinase; DUE criteria, 2000, 2002; overview, 1988  
 valproic acid; substitution, 1716  
 vasopressin; injections, 2230  
 vincristine sulfate; dosage, 1755  
 warfarin sodium; ginseng interactions, 692; interactions, 320  
**Tramadol**; pain; review, 643  
**Tramadol hydrochloride**; use; evaluation, 696  
**Tranquilizers**; abuse; adolescents, 365  
**Transplantation**; bone marrow; drug incompatibilities, 181  
**Tretinoin**; carcinoma; renal cell, 190  
**Triamcinolone acetate**; dermatitis; losartan adverse reactions, 1333  
**Trimethoprim**; combination, sulfamethoxazole; allergies, 1545; otitis media, 2736  
**Troglitazone**; approvals; FDA, 623  
**Trophamine**; incompatibilities; iron dextran, 570  
**Trovafloxacin mesylate**; bacterial infections; review, 2569  
**Tuberculosis**  
 patient information; pharmacists' interventions, 375  
 resistance; ASHP protocols, 428  
**Tubing**; polyvinyl chloride; fluorouracil incompatibilities, 1845  
**Turbidity**  
 amphotericin B; griseofulvin incompatibilities, 56  
 cefoperazone sodium; remifentanyl incompatibilities, 2192  
 chlorpromazine hydrochloride; remifentanyl incompatibilities, 2192  
 doxorubicin hydrochloride; incompatibilities, 2708  
 thiotepa; incompatibilities, 2588  
 warfarin sodium; incompatibilities, 2599  
**Typhoid vaccines**; immunization; adults, 379

**U**

**Ultrasonography**; thrombophlebitis; diagnosis, 66  
**United Kingdom**; pharmacists; hospitals; interventions, 397  
**United States**; cannabis; laws, 126  
**United States Agency for Health Care Policy and Research**; administration; evidence-based practice centers, 2668  
**United States Air Force**; pharmaceutical services; administration, 783  
**United States Army**; pharmaceutical services; administration, 773  
**United States Navy**; pharmaceutical services; administration, 778  
**United States Pharmacopeia**  
 reports; quality control, 1240

standards; injection labeling, 2006; pharmacy practice, 1633  
**United States Public Health Service**  
 pharmacists; careers, 1236; role, 766  
 Department of Health and Human Services;  
 Healthy People 2000, 2169  
 drug abuse; students' survey, 365  
 health maintenance organizations; administration, 19  
 integrated health care; administration, 19  
 pharmacy; history, 1805  
 regulations; AIDS buyers' clubs, 2122  
**Universities**; health professions; hospitals, 1711  
**Urine levels**; antibodies; HIV tests, 2232  
**Urokinase**  
 arterial occlusive diseases; comparisons, 1963  
 thrombosis; overview, 1988  
 use; evaluation, criteria, 2000, 2002  
**Ursodiol**; stability; compounding, 1401

## V

**Vaccines**  
 adults; immunization, 379  
 pharmacists; administration, 490  
 pneumococcal; ASHP position statement, 575; use, 527  
 protocols; adolescents, 494  
**Valproic acid**; substitution; mental retardation facilities, 1716  
**Value Health**; mergers; Columbia/HCA Healthcare, 513  
**Vancomycin**; resistance; *S. aureus*, 2457  
**Varicella vaccines**; adults; immunization, 379  
**Vasodilating agents**; nitroglycerin; myocardial infarction, 586  
**Vasopressin**; gastrointestinal hemorrhage; home infusion, 2230  
**Vehicles**  
 cherry syrup; griseofulvin stability, 1404  
 citric acid; phenoxylbenzamine incompatibilities, 2073  
 fat emulsions; propofol, 2515  
 glycerin; ursodiol stability, 1401  
 methylcellulose; captopril incompatibilities, 2483  
 polyoxyl 40 hydrogenated castor oil; paclitaxel incompatibilities, 566  
 polysorbate 80; docetaxel incompatibilities, 566  
 propofol; fat emulsions, 694  
 propylene glycol; phenoxylbenzamine incompatibilities, 2073  
 simple syrup; incompatibilities, 178  
 sodium bicarbonate; omeprazole compounding, 1833  
 sodium chloride; acetylcysteine incompatibilities, 549  
 sucrose; captopril incompatibilities, 2483; phenoxylbenzamine incompatibilities, 2073; pyrimethamine suspensions, 2714  
 syrups; sumatriptan suspensions, 1619  
 water for injection; captopril incompatibilities, 2483  
 water; captopril incompatibilities, 2483; pentoxifylline suspensions, 1301; phenoxylbenzamine incompatibilities, 2073  
**Vendors**; selection; contract services, 43  
**Ventricular dysfunction**; angiotensin-converting-enzyme inhibitors; pharmacists' interventions, 264; protocols, 299  
**Vials**  
 closures; latex, 2516  
 multiple dose; unpreserved, 2006  
 paclitaxel; labeling, 2128  
**Vincristine sulfate**  
 incompatibilities; containers, 915  
 toxicity; dosage, 1755

**Viscosity**; dextrose; portable infusion pump, 1277  
**Vitamin D**; dosage; dietary reference intakes, 2438  
**Vitamins**  
 dosage; dietary reference intakes, 2438  
 labeling; FDA regulations, 2561  
 multiple; parenteral nutrition, 570; shortage, 1789  
**Volume**; paclitaxel; labeling, 2128  
**Volume of distribution**, see **Drugs, body distribution**  
**Vomiting**  
 antiemetics; Medicare policies, 830  
 granisetron; comparisons, 2478  
 ondansetron; comparisons, 2478  
 propofol; toxicity, 1953  
 therapy; pharmacists' protocols, 680

## W

**Warfarin**; concomitant therapy, 1968  
**Warfarin sodium**  
 incompatibilities; i.v. additives, 2599  
 interactions; acarbose, 1551; cisapride, 320; ginseng, 692  
**Wastage**; controlled substances; documentation, 1392  
**Waste disposal**  
 fentanyl; transdermal patches, 85  
 injections; preservatives, 2006  
**Wasting syndrome**; somatropin; AIDS, 2618  
**Water**  
 control, quality; USP standards, 1633  
 incompatibilities; captopril, 2483; phenoxylbenzamine, 2073  
 vehicles; pentoxifylline suspensions, 1301  
**Water for injection**  
 diluents; antibiotics, 1068; incompatibilities, 64; warfarin incompatibilities, 2599  
 incompatibilities; captopril, 2483; meropenem, 412  
**Weight**  
 injections; compounding, 678  
 patients; aminoglycoside pharmacokinetics, 2201; creatinine clearance, 2505  
**Wholesalers**; contract services; hospital pharmacy, 45  
**Wisconsin**; pharmacists; survey, 558  
**Women**  
 health care; FDA programs, 2288; psychopharmacy clinic, 2717  
 pharmacists; hours, 558; residency satisfaction, 1521  
**Workload**  
 hospital pharmacy; methodology, 171  
 nurses; insulin protocols, 1046; i.v. administration, 1614  
 students; clinical documentation, 1727  
**World Wide Web**  
 Agency for Health Care Policy and Research; evidence-based practice centers, 2668  
 American Society of Health-System Pharmacists; information, 1273; latex allergies, 2517  
**Wounds and injuries**; personnel, pharmacy; needle sticks, 258  
**Writing**  
 patient information; guidelines, 1572  
 pharmacists; newspapers, 1762  
 publications; drug information, 30

## Z

**Zidovudine**; HIV infections; pregnancy, 1018

## Author Index

## A

- Abdel-Rahman, Susan M.** Stability of pentoxifylline in an extemporaneously prepared oral suspension, 1301
- Abramowitz, Paul W.** Multidisciplinary approach to reducing costs in a health system, 1196
- Adams, Jack P.** see Marshall, Judith M., 1412
- Aifano, Sandra L.** see Stump, Lisa S., 1447
- Allain, Patrick** see Corbion, Valérie, 1845
- Allen, Loyd V. Jr.** see Stiles, M. Lou, 1068
- Ambados, Fotios** Compatibility of ketamine hydrochloride and meperidine hydrochloride (letter), 205
- Ambrose, Peter J.** Doping control in sports—a perspective from the 1996 Olympic Games, 1053
- Amin, Biren** Position statement from infectious diseases society (letter), 2822
- Ammons, Dwayne K.** Prioritizing pharmacy services in the emergency department (Frontline Pharmacist), 1702
- Anaizi, Nasr H.** Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution, 549
- Andersen, Scott R.** Accuracy of technicians versus pharmacists in checking syringes prepared for a dialysis program, 1611
- Anderson, Phillip O.** see Lee, Hanneli A., 1759
- Andrus, Derek S.** Book review, 1462
- Antolovich, Gabrielle** see Taniguchi, George, 1762
- Arenberg, Steven** Monitoring member satisfaction (Questions and Answers), 1037
- Arend, Jonathan** see Gray, Thomas M., 1262
- Armistead, John A.** see Boyko, William L., 1591
- Armstrong, Edward P.** Ambulatory care databases for managed care organizations, 1973
- Armstrong, Edward P.** see also Else, Barbara A., 2601
- Aronovitch, Sharon** see Gauthier, Isabelle, 405
- Asensio, Juan** see Cornwell, Edward E. III, 537
- Au, Adrienne Lam** Important points to note when preparing nutritional admixtures for latex-sensitive patients (letter), 2128

## B

- Bahal, Surendra M.** Visual compatibility of warfarin sodium injection with selected medications and solutions, 2599
- Bailey, Leonard C.** Stability of ceftriaxone sodium and metronidazole hydrochloride, 424
- Bailey, Thomas C.** see McMullin, S. Troy, 545
- Baker, Mary B.** see Trissel, Lawrence A., 1295
- Baldinger, Sandra L.** Cost savings from having a clinical pharmacist work part-time in a medical intensive care unit, 2811
- Baluch, William M.** Implementing a clinical information system in a managed care setting. Clinical information system in a mixed-model HMO, 1515
- Barber, Nick D.** Predicting the rate of physician-accepted interventions by hospital pharmacists in the United Kingdom, 397
- Barber, Nicholas D.** see also Dean, Bryony S., 2491
- Barbour, Paul J.** see Brouker, Mark E., 1794
- Barker, Kenneth N.** see Flynn, Elizabeth Allan, 904
- Barletta, Francis P.** see Okeke, C. Claudia, 1633
- Barrachina, Fernando** see Mateu-de Antonio, Javier, 2515
- Barriso, Patricia** see Chandler, Christine, 1280
- Basmarjian, Patrick A.** see Lennon, David B., 1392
- Batty, Ros** see Barber, Nick D., 397
- Bauer, Steve** see Yee, Donald K., 670
- Baxter, Steve** see May, Marcus W., 630
- Bayles, Britt C.** Pharmaceutical services in the United States Navy, 778
- Beal, Frederick C.** Work styles (Frontline Pharmacist), 2680
- Beall, Howard D.** see Fish, Douglas N., 1619
- Beard, Karen M.** see Hoyt, Douglas B., 1752
- Beckett, Brian E.** see Hill, W. Chris, 1208

- Belgado, Bernadette S.** Evaluation of electronic drug information resources for answering questions received by decentralized pharmacists, 2592
- Belson, J. Joseph** see Okeke, C. Claudia, 1633
- Beltz, Elizabeth A.** see Mutnick, Alan H., 392
- Belzberg, Howard** see Cornwell, Edward E. III, 537
- Berger, Michael J.** see Fan-Havard, Patty, 1407
- Berne, Thomas V.** see Cornwell, Edward E. III, 537
- Berning, Shaun E.** see Peloquin, Charles A., 700, 1208
- Bernstein, Gail** see Farley, P. Anne, 2478
- Berod, Thierry** Pharmacist's role in rescue efforts after plane crash in Indian Ocean (letter), 1110
- Bertino, Joseph S. Jr.** Intranasal mupirocin for outbreaks of methicillin-resistant *Staphylococcus aureus*, 2185
- Bever, Kristine A.** Dextenfluramine hydrochloride: an anorexigenic agent, 2059
- Blumenschein, Karen** see Neudeck, Brien L., 1963
- Boike, Steven C.** Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults, 1172
- Bond, Jack A.** see Lacy, Melinda K., 1837
- Bonhomme-Faivre, Laurence** see Paule, Bernard, 190
- Book, Mary Ellen** Supplying starter kits of infant formula. Position 1: director should accept the proposal, 687
- Boothman, J. Lyle** see Johnson, Jeffrey A., 554
- Bosso, John A.** Controlling pneumococcal resistance to penicillin (editorial), 527
- Bosso, John A.** see also Hall, Philip D., 185
- Bottaro, Samuel D. II** see Williams, Roger F., 773
- Boyko, William L. Jr.** Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital, 1591
- Bradford, Gregory S.** see Hill, W. Chris, 1208
- Branthaver, Beth** Determination of cost-effective treatment of acute otitis media from HMO records, 2736
- Briesacher, Becky** Patient satisfaction with pharmaceutical services at independent and chain pharmacies, 531
- Brody, Robert V.** see Dong, Betty J., 564
- Brossard, Denis** see Corbion, Valérie, 1845
- Brouker, Mark E.** Inhouse clinical training program for staff pharmacists (Management Consultation), 1794
- Brugger, Catherine H.** see Farnsworth, Terry L., 586
- Brundage, Dianne** Guiding patients to better pain relief (Frontline Pharmacist), 2451
- Bruno, R.** Advances in the management of cancer: review of docetaxel. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of Phase I and Phase II trials, Dec 15 suppl S16
- Brushwood, David B.** Challenging denial of coverage for innovative therapy, 572
- Buckler, Victoria** see Kale-Pradhan, Pramodini B., 2201
- Burgot, Gwenola** see Le Guévello, Pierre, 1449
- Burke, Cassandra E.** Order form for restricting vancomycin prescribing (letter), 1893
- Bush, Paul W.** see Kale-Pradhan, Pramodini B., 2201
- Bussey, Henry I.** see Haines, Stuart T., 66
- Butts, John D.** see Yerasi, Ash B., 85
- Butts, John D.** see Yerasi, Ash B., 85
- Byerly, Wesley G.** Book review, 1913

## C

- Camamo, James M.** see Grant, Kathryn L., 1395
- Camamo, James** see also Maloney, Marie, 1841
- Campagna, Keith D.** Key factors influencing pharmacists' drug therapy decisions, 1307
- Campbell, Thomas M.** Improving drug use in a capitated program for the poor (Managed Care Forum), 2449
- Canaday, Bruce R.** Anticonvulsant cross-sensitivity, 2616
- Cano, Steven B.** Book review, 224
- Cantrill, Judith A.** Accuracy of drug allergy documentation, 1627
- Cantu, Thomas G.** Fact versus opinion in the judgment on fosphenytoin articles (letter), 1653
- Caouette, Marc L.** see Williams, Roger F., 773
- Carhuapoma, Juan** see Dumo, Peter, 2213
- Carleton, Bruce** see McCormack, James P., 2505

- Carlson, Steve** Once-daily aminoglycoside therapy (letter), 2824
- Carson, Stanley W.** see Cranor, Carole W., 1716
- Ceccato, Attilio** see Evard, Brigitte, 1065
- Chaffee, Betty J.** Low-molecular-weight heparins for treatment of deep vein thrombosis, 1995
- Chan, Debora Schotik** Multidisciplinary handbook on pediatric nutritional support (letter), 1335
- Chan, Debora Schotik** see also Chan, Jessica H. M., 1897
- Chan, Eli** see Lye, Michelle Y. F., 2483
- Chan, Eli W. Y.** see also Lim, Lee-Yong, 2073
- Chan, Jessica H. M.** Computer program for tracking incidence of intravascular-device-related infections in patients receiving parenteral nutrition (letter), 1897
- Chan, Sui Y.** see Lye, Michelle Y. F., 2483
- Chan, Sui-Yung** see also Lim, Lee-Yong, 2073
- Chan-on-Teung, Françoise** see Berod, Thierry, 1110
- Chandler, Christine** Pharmacists on a primary care team at a Veterans Affairs medical center, 1280
- Chandler, Mary H. H.** see Radomski, Kristine M., 541
- Chang, Barbara** see Dedden, Phil, 1968
- Chapman, Robert L.** see Chavez, Mary L., 2635
- Chatelain, Fred** see Goldwater, Shannon H., 200
- Chavez, Mary L.** In search of literature on alternative therapies, 2635
- Chevverry, Claire** see Le Guévello, Pierre, 1449
- Chiu, Ming Fung** Visual compatibility of injectable drugs used in the intensive care unit, 64
- Chow, Moses S. S.** see Baldinger, Sandra L., 2811
- Chow, Moses S. S.** see also Quercia, Robert A., 1404, 1833
- Christen, Catherine** see Johnson, Cary E., 61
- Clifton, G. Dennis** Antithrombotic therapy after intracoronary stent placement, 437
- Coffey, Edward L. Jr.** see Keith, Matthew R., 674
- Coley, S. Crystal** Performance of three portable infusion-pump devices set to deliver 2 mL/hr, 1277
- Colgan, Kevin** see Farley, P. Anne, 2478
- Collette, David R.** Fact versus opinion in the judgment on fosphenytoin articles (letter), 1654
- Collette, David R.** Reactions to fosphenytoin editorial and review article (letter), 442
- Collins, Ted** see Sleath, Betsy, 2197
- Connor, Sharon E.** see Lewis, Richard K., 2084
- Cook, Steven E.** see Patel, Piyush R., 412
- Cooke-Ariel, Hannah** Promoting use of angiotensin-converting-enzyme inhibitors (editorial), 264
- Cooper, Janet** see McCormack, James P., 2505
- Corbion, Valérie** Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint, 1845
- Corey, Ron** see Briesacher, Becky, 531
- Corliss, Don A.** Computer-assisted help desk for handling drug benefits (Managed Care Forum), 1941
- Cornish, Laura A.** Stability of bumetanide in 5% dextrose injection, 422
- Cornwell, Edward E. III** Pharmacokinetics of aztreonam in critically ill surgical patients, 537
- Cottrell, W. Neil** see Cantrill, Judith A., 1627
- Cousins, David** Reliability and validity of hospital pharmacists' clinical intervention data, 1596
- Cox, Emily R.** see Else, Barbara A., 2601
- Cramer, Richard L.** see Collette, David R., 442, 1654
- Cranor, Carole W.** Clinical and economic impact of replacing divalproex sodium with valproic acid, 1716
- Crauste-Manciet, Sylvie** see Corbion, Valérie, 1845
- Crinnion, Cara** see Maloney, Marie, 1841
- Cruz, Julia M.** see Owens, Dwight, 683
- Curtiss, Frederic R.** Lessons learned from projects in disease management in ambulatory care, 2217
- Cuyegkeng, Thomas X.** see Gong, William C., 92

## D

- Dahl, Terrence C.** see Ennis, Richard D., 2204
- Dahlgren, Amy Frazier** Adverse drug reactions in home care patients receiving nafcillin or oxacillin, 1176
- Dahlgren, Amy Frazier** Two cases of possible

- cefepime-induced neutropenia (letter), 2621  
**Daniels, Charles E.** see Abramowitz, Paul W., 1196  
**Daniels, Charles E.** see also DeCederfelt, Hope J., 1604  
**Dapolite, Lori A.** see Horne, Allen L., 680  
**Darlington, Margaret Raburn** Hypoprothrombinemia induced by warfarin sodium and cispripide (letter), 320  
**Davis, Angela Stafford** Streamlining outpatient drug therapy at a Veterans Affairs medical center, 2719  
**Davis, George A.** see Radomski, Kristine M., 541  
**Davis, Nan H.** Change from zolpidem to clorazepate won't solve the patient's problem (letter), 588  
**Davis, William C.** Home infusion of vasopressin for gastrointestinal bleeding, 2230  
**De Peri, Charles Jr.** Software review, 728  
**Dean, Bryony S.** Mathematical modeling of pharmacy systems, 2491  
**DeCederfelt, Hope J.** Handling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department, 1604  
**DeCederfelt, Richard O.** see DeCederfelt, Hope J., 1604  
**DeChristoforo, Robert** AIDS buyers' clubs, 2122  
**Deedden, Phil** Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin, 1968  
**Delattre, Luc** see Evrard, Brigitte, 1065  
**Delporte, Jean-Pierre** see Evrard, Brigitte, 1065  
**Demetriades, Demetrios** see Cornwell, Edward E. III, 537  
**Dempsey, Cindy L.** see Farley, P. Anne, 2478  
**Denis, Pierre** see Mazza, David J., 566  
**Dentinger, Paul J.** see Anazi, Nasr H., 549  
**Dernanowski, Kevin R.** see Paavola, Fred G., 766  
**Dickson, Mike** see Reeder, C. E., 653  
**Dobler, George L.** see Bahal, Surendra M., 2599  
**Doering, Paul L.** see Belgado, Bernadette S., 2592  
**Dole, Ernest J.** Book review, 333  
**Dong, Betty J.** Pharmacist provision of preventive health care services in a hypertension clinic, 564  
**Dumo, Peter** Thrombolysis in acute ischemic stroke, 2213  
**Dunagan, W. Claiborne** see McMullin, S. Troy, 545  
**Dupuis, L. Lee** Stability of propafenone hydrochloride in i.v. solutions, 1293  
**Dydek, George J.** see Williams, Roger F., 773
- E**
- Early, John J.** see Cranor, Carole W., 1716  
**Echaves, Steven A.** see Dong, Betty J., 564  
**Echevarria, Roberto** see Williams, Roger F., 773  
**Eckardt, John R.** Advances in the management of cancer: review of docetaxel. Antitumor activity of docetaxel, Dec 15 suppl S2  
**Eckel, Fred M.** Outsourcing drug distribution services. Outsourcing: at odds with pharmacy's professional foundation, 52  
**Egberts, A.C.G.** see Kan, H.J.M. van, 388  
**Eichelberger, Bernadette** Implementing a clinical information system in a managed care setting. Building clinical decision-support systems to profile physician practice and develop guidelines in a staff-model HMO, 1510  
**Eichelberger, Bernadette** see also Branthaver, Beth, 2736  
**Eidem, Leslie A.** see Lacy, Melinda K., 1837  
**El-Rachidi, Amne** see Pram, Yashoda V., 913  
**Else, Barbara A.** Data sources for pharmacoeconomic and health services research, 2601  
**Endean, Eric D.** see Neudeck, Brian L., 1963  
**Ennis, Richard D.** Stability of cidofovir in 0.9% sodium chloride injection for five days, 2204  
**Erkkila, Denise** see Murray, Kim M., 2588  
**Ernst, Erika J.** see Ernst, Michael E., 2569  
**Ernst, Michael E.** Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? 2569  
**Erstad, Brian L.** see Maloney, Marie, 1841  
**Everson-Mays, Robyn E.** Restarting trimethoprim-sulfamethoxazole after a hypersensitivity reaction in patients infected with the human immunodeficiency virus, 1545  
**Evrard, Brigitte** Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection, 1065
- F**
- Fabián, L.** Nonprescription drugs in Hungary (letter), 1207  
**Fagan, Susan C.** see Dumo, Peter, 2213  
**Fan, Chengde** see Quercia, Robert A., 1404, 1833  
**Fan-Havard, Patty** Continuity of pharmaceutical services for patients with AIDS in the transition from hospital to home, 1407  
**Farley, P. Anne** Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers, 2478  
**Farnsworth, Terry L.** Myocardial infarction after intranasal methamphetamine (letter), 586  
**Felkey, Bill G.** Health system informatics, 274  
**Felkey, Bill G.** Implementing a clinical information system in a managed care setting. Building the clinical workstation: software for the health-system pharmacist, 1505  
**Ferrière, Françoise** see Paule, Bernard, 190  
**Fish, Douglas N.** Stability of sumatriptan succinate in extemporaneously prepared oral liquids, 1619  
**Fishwick, Jeffrey J.** Weight-based accuracy of parenteral nutrient solutions prepared with an automated compounder, 678  
**Fitzsimmons, Dana S.** Our professional responsibility after hospitals change ownership (letter), 2238  
**Fleming, Ronald A.** see Owens, Dwight, 683  
**Flynn, Elizabeth Allan** Observational study of accuracy in compounding i.v. admixtures at five hospitals, 904  
**Forrester, Collier W.** see Davis, Angela Stafford, 2719  
**Foster, Jessica A.** see Jacobson, Pamela A., 178  
**Foster, Thomas S.** see Wermeling, Daniel P., 1742  
**Foster-Nora, Jessica A.** Amifostine for protection from antineoplastic drug toxicity, 787  
**Fowler, Joan Barnett** Book review, 471  
**Fox, Janet L.** see Fish, Douglas N., 1619  
**Fox, Janet L.** see also Nolan, Paul E. Jr., 1304  
**Fox, Janet L.** see also Stewart, James T., 915  
**Fraser, Brent D.** Stability of caffeine citrate injection in polypropylene syringes at room temperature (letter), 1106  
**Freeman, Cheryl H.** see Yee, Donald K., 670  
**Frenia, Maureen L.** see Smith, Kelly M., 295  
**Friedmann, Yrena** Involving network pharmacies in disease management programs (Managed Care Forum), 32  
**Frighetto, Luciana** Tracking and reporting drug expenditures (Management Consultation), 2302  
**Fry, Paula Duncan** Planning the basics of a mail-service pharmacy (Managed Care Forum), 520  
**Frye, Carla B.** Methylphenidate for depression in the elderly, medically ill patient, 2510  
**Fudin, Jeffrey** Quicker dosage adjustment for transdermal fentanyl, 87  
**Fumoleau, Pierre** Advances in the management of cancer: review of docetaxel. Efficacy and safety of docetaxel in clinical trials, Dec 15 suppl S19
- G**
- Gabriel, Caroline M.** Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus, 1191  
**Gallivan, Stephen** see Dean, Bryony S., 2491  
**Gandhi, Ashesh J.** see Phillips, Beth Byles, 2613  
**Gannon, Richard H.** see Baldinger, Sandra L., 2811  
**Gaspard, Olivier** see Evrard, Brigitte, 1065  
**Gates, Dennis M.** Book review, 472  
**Gauthier, Isabelle** Comparison of programs for preventing drug-nutrient interactions in hospitalized patients, 405  
**Gerrett, David** see Cousins, David, 1596  
**Gibson, John** see Bayles, Britt C., 778  
**Gilbert, Doward L. Jr.** Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration, 1193  
**Gilbert, Doward L. Jr.** see also Trissel, Lawrence A., 56, 1287, 1295, 1735, 2192, 2708  
**Gill, Mark A.** see Cornwell, Edward E. III, 537  
**Goetsch, Roger** Home collection and non-blood-based methods of testing for the human immunodeficiency virus, 2232  
**Goldberg, Laurence A.** Book review, 852  
**Goldwater, Shannon H.** Smoothing the path for i.v.-to-oral conversion (letter), 200  
**Gombotz, Wayne R.** see Murray, Kim M., 2588  
**Gong, William C.** Book review, 1366  
**Gong, William C.** Memory disorders consultation service (letter), 92  
**Goodwin, S. Diane** see Fish, Douglas N., 1619  
**Gora-Harper, Mary Lea** Book review, 1464  
**Gouveia, William A.** The power and perils of e-mail (Management Consultation), 886  
**Gouveia, William A.** see also Pill, Michael W., 1097  
**Grabenstein, John D.** Status and future of vaccines for adults, 379  
**Grady, Lee T.** see Okeke, C. Claudia, 1633  
**Grant, Kathryn L.** Adverse events and cost savings three years after implementation of guidelines for outpatient contrast-agent use, 1395  
**Gray, Thomas M.** Pharmacists in patient-focused care (Frontline Pharmacist), 1262  
**Gray, Vivian A.** see Okeke, C. Claudia, 1633  
**Green, John** Recapping needles in the pharmacy (Frontline Pharmacist), 258  
**Green, Laurence** see DeCederfelt, Hope J., 1604  
**Green, Susan K.** see Fan-Havard, Patty, 1407  
**Greiner, Deborah L.** see Branthaver, Beth, 2736  
**Grimes, George J.** see DeCederfelt, Hope J., 1604  
**Gubbins, Paul O.** see Penzak, Scott R., 2744  
**Guenette, Amy J.** Book review, 106  
**Gura, Kathleen M.** Book review, 1000  
**Gura, Kathleen M.** see also McDermott, John S., 2516  
**Guthrie, M. Kelly** see Davis, Angela Stafford, 2719
- H**
- Haddad, Ann M. Ryan** Possible losartan-induced rash (letter), 1333  
**Haefeli, Walter E.** see Schuerch, Leander V., 2403  
**Hagan, Robert L.** see Mallett, Mark S., 1401  
**Hailemeskel, Bisrat** Estimating aminoglycoside dosage requirements in patients with low serum creatinine concentrations (letter), 986  
**Hailemeskel, Bisrat** Severe asthmatic reaction to contraindicated anti-inflammatory drug (letter), 199  
**Haines, Stuart T.** Diagnosis of deep vein thrombosis, 66  
**Hall, Gregory E.** see Bayles, Britt C., 778  
**Hall, Philip D.** Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration, 185  
**Han, Nina H.** see Lewis, Kelly S., 643  
**Hanish, Lynn R.** Standardizing regimens for sliding-scale insulin (Frontline Pharmacist), 1046  
**Hanish, Lynn R.** User-friendly weight-based heparin protocol for initial infusion (letter), 699  
**Harris, William L. Jr.** Book review, 2775  
**Hasegawa, Elizabeth A. J.** Can we talk? 584  
**Hatal, Janie K.** see Lennon, David B., 1392  
**Hatton, Randy C.** see Belgado, Bernadette S., 2592  
**Haupt, Bridget A.** see Kanmaz, Tina J., 1623  
**Hawkins, David W.** Antithrombotic drugs for thromboembolic disorders: a lesson in evidence-based medicine, 1992  
**Hawkins, David W.** Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement, 1185  
**Hawkins, Patti R.** The pharmacist as a health education coordinator (Managed Care Forum), 1497  
**Heeren, David L.** see Sauer, Barbara L., 1727  
**Heide, Peter Edgar** Precipitation of amphotericin B from i.v. fat emulsion (letter), 1449  
**Hepler, Charles D.** Where is the evidence for formula effectiveness? (letter), 95  
**Higby, Gregory J.** American pharmacy in the twentieth century, 1805  
**Hille, D.** see Bruno, R., Dec 15 suppl S16  
**Hill, W. Chris** Miracle is not the same as luck (letter), 1208  
**Hipple, Thomas F.** see Nahata, Milap C., 2714  
**Hirsch, Jack** see Hawkins, David W., 1992  
**Hitt, Catherine M.** Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime, 1614  
**Hitt, Catherine M.** Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily, 2704  
**Ho, Paul C. L.** see Lim, Lee-Yong, 2073  
**Ho, Paul C.** see also Lye, Michelle Y.F., 2483  
**Ho, Sherman S. M.** Comparison of two brands of

## Annual Index

- test strips for self-monitoring of blood glucose, 1058
- Hoffman, Richard M.** see Wieland, Linda D., 1062
- Holder, Geoffrey** see Schuerch, Leander V., 2403
- Holdford, David A.** Improving the quality of outcomes research involving pharmaceutical services, 1434
- Holloman, Lisa C.** Management of acute extrapyramidal effects induced by antipsychotic drugs, 2461
- Holloway, William** see Burke, Cassandra E., 1893
- Hood, Kerri A.** Mycophenolate mofetil: a unique immunosuppressive agent, 285
- Hopell, Alan** Book review, 1562
- Hopell, Alan** Reactions to fosphenytoin editorial and review article (letter), 445
- Horne, Allen L.** Protocol for pharmacist management of antineoplastic drug-induced adverse effects in outpatients, 680
- Hostettler, Charles** see Bayles, Britt C., 778
- Hoyer, Gifford L.** see Nolan, Paul E. Jr., 1304
- Hoyt, Douglas B.** Regulating managed care in an integrated health system environment, 1752
- Hudson, Teresa** Book review, 1909
- Hui, Yuk Fung** Gemcitabine: a cytidine analogue active against solid tumors, 162
- Hurd, David D.** see Owens, Dwight, 683
- Huse, Daniel M.** Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia, 1180
- I**
- Icaza, Luis** see Taniguchi, George, 696, 2007
- Ignoffo, Robert J.** Medicare reimbursement for oral antiemetics in management of chemotherapy-induced emesis (letter), 830
- Ilson, Bernard** see Boike, Steven C., 1172
- Ivey, Marianne F.** see Boyko, William L., 1591
- J**
- Jacobi, Judith** An aspirin a day: advice that makes sense (editorial), 1949
- Jacobson, Pamela A.** Stability of tacrolimus in an extemporaneously compounded oral liquid, 178
- Jagers, Leslie Dotson** Healthy People 2000 (Questions and Answers), 2169
- Jambulingam, Thanigavelan** see Mott, David A., 558
- Janda, Sue M.** Book review, 2831
- Janetzky, Katherine** Probable interaction between warfarin and ginseng, 692
- Janetzky, Katherine** see also Morreale, Anthony P., 1551
- Janich, Julia A.** see Marshall, Judith M., 1412
- Janis, Lesley W.** see Wieland, Linda D., 1062
- Jermala, Donna M.** Psychopharmacology medication clinic in a managed care women's health setting, 2717
- Jewesson, Peter J.** see Frighetto, Luciana, 2302
- Joerg, Kenneth H.** Supplying starter kits of infant formula. Position 2: director should decline the proposal, 688
- Johnson, Cary E.** Compatibility of bupivacaine hydrochloride and morphine sulfate, 61
- Johnson, Cary E.** see also Cornish, Laura A., 422
- Johnson, Cary E.** see also Jacobson, Pamela A., 178
- Johnson, James R.** see Campbell, Thomas M., 2449
- Johnson, Jeffrey A.** Drug-related morbidity and mortality and the economic impact of pharmaceutical care, 554
- Johnson, Ruth A.** see Sens, Bonnie L., 1071
- Johnson, Steven B.** see Maloney, Marie, 1841
- Johnston, Kerry R.** see Fudin, Jeffrey, 87
- Jorkasky, Diane K.** see Boike, Steven C., 1172
- K**
- Kahn, Michael G.** see McMullin, S. Troy, 545
- Kakuda, Thomas N.** Somatropin for treating AIDS-related wasting syndrome, 2618
- Kalash, Leslie D.** Reports of labeling problems do get action (letter), 2128
- Kale-Pradhan, Pramodini B.** Effect of body weight on aminoglycoside pharmacokinetics in patients with hypoalbuminemia, 2201
- Kan, H.J.M. van** Tetracaine versus lidocaine-prilocaine for preventing venipuncture-induced pain in children, 388
- Kanmaz, Tina J.** Comparison of manual and barcode systems for documenting pharmacists' interventions, 1623
- Kanyok, Thomas P.** Combating tuberculosis (editorial), 375
- Katz, Joshua A.** see Roth, Marc S., 694
- Kaul, Alan F.** Criteria for use of regional urokinase infusion for deep vein thrombosis, 2002
- Kaul, Alan F.** Criteria for use of regional urokinase infusion for peripheral and arterial occlusion, 2000
- Kaul, Alan F.** see also Tomera, John F., 1988
- Keith, Matthew R.** Book review, 2534
- Keith, Matthew R.** Clinical training program for distributive pharmacists, 674
- Keith, Matthew R.** see also Seals, Tarrow D., 2585
- Kelly, David M.** see Davis, William C., 2230
- Kelly, Edward T. III** see Baldinger, Sandra L., 2811
- Kelly, H. William** see Sleath, Betsy, 2197
- Kelly, Michael W.** see Klepser, Teresa B., 893
- Kendall, James D.** Fact versus opinion in the judgment on fosphenytoin articles (letter), 1652
- Kendrach, Michael** Book reviews, 223, 1130
- Kepple, Stephen R.** Book review, 724
- Kern, Jack W.** see Cornwell, Edward E. III, 537
- Kessler, John M.** The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction. Decision analysis in the formulary process, Nov 15 suppl 55
- Kienle, Patricia C.** Consolidation of pharmacy departments in a regional health system, 1076
- Killian, Aaron D.** Measuring human immunodeficiency virus type 1 RNA viral load, 1646
- Kilwein, John H.** Book review, 852
- Kim, Mia C.** see Trissel, Lawrence A., 2192
- King, Deanne T.** see Stewart, James T., 915
- King, Jeffrey H.** see Sauer, Barbara L., 1727
- Kirsch, Arlene J.** see Huse, Daniel M., 1180
- Kizer, Kenneth W.** see Ogden, John E., 761
- Klepser, Michael E.** see Ernst, Michael E., 2569
- Klepser, Teresa B.** Metformin hydrochloride: an antihyperglycemic agent, 893
- Knight, Alfred B.** see Jermain, Donna M., 2717
- Knisel, Virginia** see Au, Adrienne Lam, 2128
- Knowlton, Heather L.** Benefits of a board-certified technician (Management Consultation), 2562
- Kolar, G. Ron** Outsourcing drug distribution services. Outsourcing: route to a new pharmacy practice model, 48
- Kozma, Chris M.** see Reeder, C. E., 653
- Krasowski, Joseph A.** see Okeke, C. Claudia, 1633
- Kraynak, Maura A.** Advances in the management of cancer: review of docetaxel. Pharmaceutical aspects of docetaxel, Dec 15 suppl 57
- Krueger, Kem P.** see Hawkins, David W., 1185
- Kubica, Anthony J.** Book review, 1130
- Kucukarslan, Suzan** see Fan-Havard, Patty, 1407
- Kucukarslan, Suzan N.** see also Schommer, Jon C., 2721
- Kulper, Randy** see Seabold, James A., 1732
- Kulis-Gobitaille, Catherine** see Farley, P. Anne, 2478
- Kupiak, David M.** see Fudin, Jeffrey, 87
- Kurz, Andy** see Hailemeskel, Bisrat, 986
- L**
- Lacy, Melinda K.** Development of a patient-focused, interdisciplinary antimicrobial management program involving staff pharmacists, 1837
- Lambert, Bruce L.** Predicting look-alike and sound-alike medication errors, 1161
- Lambert, Bruce L.** see also Lewis, Richard K., 2084
- Lamsam, Grace D.** Human dignity and pharmaceutical care, 2733
- Landis, Nancy Tarleton** California, Arizona laws permit medical use of marijuana (News), 126
- Landis, Nancy Tarleton** California coalition aims for 'SMART' medication use by seniors (News), 2282
- Landis, Nancy Tarleton** FDA pharmacist recognized for role in tobacco initiative (News), 2050
- Landis, Nancy Tarleton** FDA program frames better medication use as women's health issue (News), 2288
- Landis, Nancy Tarleton** More pharmacists administering vaccines (News), 490
- Landis, Nancy Tarleton** Museum exhibit gives pharmacy students lessons in history and in meeting the public (News), 1236
- Langley, Paul C.** see Hawkins, David W., 1185
- Lasack, Nancy L.** see Lewis, Richard K., 2084
- Laub, James J.** see Libby, Elizabeth A., 2079
- Laurila, Terry L.** see Fan-Havard, Patty, 1407
- Lazarus, Herman L.** Outsourcing drug distribution services. Outsourcing: a success story, 43
- Le Guévello, Pierre** Medication errors and drug hydrates (letter), 1449
- Lebecqz, A.** see Bruno, R., Dec 15 suppl S16
- LeDoux, Jane H.** see Nolan, Paul E. Jr., 1304
- Lee, Hannell A.** Giving partial doses of transdermal patches, 1759
- Lee, Tara J.** see Bahal, Surendra M., 2599
- Leff, Richard D.** see Coley, S. Crystal, 1277
- Legg, Julie** see Fan-Havard, Patty, 1407
- Lenderink, A. W.** see Kan, H.J.M. van, 388
- Lennon, David B.** Involving anesthesiology in drug control (Management Consultation), 1392
- Lesar, Timothy S.** see Gauthier, Isabelle, 405
- Lewis, Kelly S.** Tramadol: a new centrally acting analgesic, 643
- Lewis, Richard K.** Patient counseling—a focus on maintenance therapy, 2084
- Libby, Elizabeth A.** Economic and clinical impact of a pharmacy-based antihypertensive replacement program in primary care, 2079
- Lien, Tho** see Sleath, Betsy, 2197
- Lim, Lee-Yong** Stability of phenoxybenzamine hydrochloride in various vehicles, 2073
- Lim, Lee Y.** see also Lye, Michelle Y.F., 2483
- Lindley, Celeste** see McCune, Jeannine S., 1755
- Lisi, Donna M.** Ethical issues for pharmacists in managed care (Managed Care Forum), 1041
- Liu, Xinchun** see Quercia, Robert A., 1833
- Loewen, Peter E.** E-mail for conducting surveys (letter), 1334
- Loh, Fang K.** see Neudeck, Brien L., 1963
- Lopez, Larry M.** The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction. Clinical trials in thrombolytic therapy, part 2: the open-artery hypothesis and RAPID-1 and RAPID-2, Nov 15 suppl S27
- Loucas, Vivian A.** see Pram, Yashoda V., 913
- Luscombe, David** see Cousins, David, 1596
- Lye, Michelle Y. F.** Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids, 2483
- Lyons, Carl D.** Organizational opportunities and rewards, 1095
- Lyons, Sheila** see Hall, Philip D., 185
- M**
- Ma, Marla** see Johnson, Cary E., 61
- Macres, Mark G.** see Andersen, Scott R., 1611
- Magnus, Gary H.** Leaving a job on an up note (Frontline Pharmacist), 1946
- Magnus, Gary H.** Surfing the Net for pharmacy sites (Frontline Pharmacist), 34
- Magnus, Gary H.** Useful Internet sites (letter), 1450
- Mallett, Mark S.** Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid, 1401
- Mallon, Treacy A.** see Brouker, Mark E., 1794
- Malone, Margaret** see Gauthier, Isabelle, 405
- Malone, Robert J.** see Fishwick, Jeffrey J., 678
- Maloney, Marie** Development of algorithms for treating patients in the intensive care unit, 1841
- Malters, Patricia** see Farnsworth, Terry L., 586
- Manasse, Henri R. Jr.** Continuing the momentum, 1877
- Manuchehiri, Firouzeh** see Armstrong, Edward P., 1973
- Manzi, Shannon French** see Sin, G. Paul, 1209
- Marder, Stephen R.** see Holloman, Lisa C., 2461
- Marra, Carlo A.** see Frighetto, Luciana, 2302
- Marshall, Judith M.** Practical, ongoing competency-assessment program for hospital pharmacists and technicians, 1412
- Martin, Arlene B.** see Roth, Marc S., 694
- Martinez, Juan F.** see Gilbert, Edward L. Jr., 1193
- Martinez, Juan F.** see also Trissel, Lawrence A., 56, 1287, 1295, 1735, 2192, 2708
- Mateu-de Antonio, Javier** Propofol infusion and nutritional support (letter), 2515

**Matheson, Charles** Fact versus opinion in the judgment on fosphenytoin articles (letter), 1654

**Matheson, Charles** Reactions to fosphenytoin editorial and review article (letter), 441

**May, Marcus W.** Computerized system for controlled-substances distribution (Management Consultation), 630

**Mayhew, Susan L.** Compatibility of iron dextran with neonatal parenteral nutrient solutions, 570

**Mazzo, David J.** Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials, 566

**McAdams, June Wingert** see Smith, Kelly M., 295

**McCament-Mann, Leslie** see Sleath, Betsy, 2197

**McComb, R. Carter** see Abramowitz, Paul W., 1196

**McCormack, James P.** Simple approach to dosage adjustment in patients with renal impairment, 2505

**McCune, Jeannine S.** Appropriateness of maximum-dose guidelines for vincristine, 1755

**McDaniel, Michael R.** Book review, 2774

**McDermott, John S.** Procedures for preparing injectable medications for latex-sensitive patients (letter), 2516

**McGee, Christine** Book review, 2254

**McGinnes, Michaelle** see Bahal, Surendra M., 2599

**McLendon, Michael L.** see May, Marcus W., 630

**McManus, Claire** More on mechanisms of bacterial resistance (letter), 2747

**McManus, M. Claire** Mechanisms of bacterial resistance to antimicrobial agents, 1420

**McMullin, S. Troy** Automated system for identifying potential dosage problems at a large university hospital, 545

**McNally, Karen M.** Failure-mode and effects analysis in improving a drug distribution system, 171

**McNew, Janet L.** see Davis, Angela Stafford, 2719

**Mehl, Bernard** Projecting future drug expenditures—1997, 153

**Metzger, Scott D.** see Hailemeskel, Bisrat, 199

**Milkovich, Gary** see Goldwater, Shannon H., 200

**Miller, Gloria** Book review, 2138

**Miller, Jane L.** Drug review articles and industry ties (Questions and Answers), 30

**Miller, Jane L.** FDA cites new data in decision to bar generic conjugated estrogens (News), 1376

**Miller, Jane L.** Thalidomide recommended for approval under tight restrictions (News), 2270

**Minor, James R.** see DeChristoforo, Robert, 2122

**Minor, James R.** see also Gabriel, Caroline M., 1191

**Minor, James R.** see also Goetsch, Roger, 2232

**Mirralto, Jay M.** see Trissel, Lawrence A., 1295

**Montgomery, Patricia A.** see Cornish, Laura A., 422

**Moore, Richard A.** Useful Internet sites (letter), 1450

**Moran, Errol L.** see Williams, Roger F., 773

**Morisco, Richard S.** see Nahata, Milap C., 2714

**Morreale, Anthony P.** Probable interaction of warfarin and acarbose (letter), 1551

**Morreale, Anthony P.** see also Janetzky, Katherine, 692

**Mott, David A.** Path model of Wisconsin pharmacists' hours supplied to the labor market, 558

**Muniz, Andrew** see Ogden, John E., 761

**Murphy, Christine** Bulk packages of injectable products (letter), 2006

**Murphy, Christine C.** see also Fishwick, Jeffrey J., 678

**Murphy, John E.** Service as the prime directive: 'make it so', 1865

**Murphy, John E.** see also VanDenBerg, Chad, 1521

**Murray, Kim M.** Stability of thiotape (lyophilized) in 0.9% sodium chloride injection, 2588

**Musallam, Nabil A.** see Sauer, Barbara L., 1727

**Mutnick, Alan H.** Cost savings and avoidance from clinical interventions, 392

**Myers, Charles E.** Chasing the curve of innovation: trends from the 1996 survey (editorial), 639

**Myers, Charles E.** Overemphasis on credentials in personnel ads (Questions and Answers), 1260

**Myers, Charles E.** Procedures for preparing injectable medications for latex-sensitive patients (letter), 2517

## N

**Nagel, Dennis** see Dedden, Phil, 1968

**Nahata, Milap C.** Stability of pyrimethamine in a liquid dosage formulation stored for three months, 2714

**Nahata, Milap C.** see also Abdel-Rahman, Susan M., 1301

**Najari, Zohre** Compatibility of commonly used bone marrow transplant drugs during Y-site delivery, 181

**Nakahiro, Randall K.** see Ho, Sherman S. M., 1058

**Namanny, Michael D.** see Hailemeskel, Bisrat, 199, 986

**Neal-Janifer, Anissia** see Goldwater, Shannon H., 200

**Neudeck, Brian L.** Intra-arterial urokinase versus surgery for acute peripheral arterial occlusion, 1963

**Newlin, Michael H.** see Campagna, Keith D., 1307

**Nguyen-Huu, Jean-Jacques** see Mazzo, David J., 566

**Nicolau, David P.** see Hitt, Catherine M., 1614, 2704

**Nightingale, Charles H.** see Hitt, Catherine M., 1614, 2704

**Nolan, Don B.** Metformin, contrast media, and theophylline (letter), 2008

**Nolan, Don B.** Recognizing a nurse as team leader (Frontline Pharmacist), 2174

**Nolan, Don B.** Theophylline option for attenuating contrast media-induced nephrotoxicity in patients on metformin (letter), 587

**Nolan, Paul E. Jr.** Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection, 1304

**Noid, Edward G.** Trends in health information systems technology, 269

**Nyfelser, Juerg** see Schuerch, Leander V., 2403

## O

**O'Connor, Paul** Book review, 2256

**O'Malley, Colleen** Quality measurement for health systems: accreditation and report cards, 1528

**O'Malley, Colleen** Training pharmacists for careers in managed care (editorial), 2055

**Oddis, Joseph A.** Providing leadership in a time of transition, 1873

**Ogden, John E.** Pharmaceutical services in the Department of Veterans Affairs, 761

**Okamoto, Mark P.** see Ho, Sherman S. M., 1058

**Okeke, C. Claudia** USP standards and activities affecting pharmacy practice, 1633

**Olsen, Keith M.** see Peddicord, Tom E., 1417

**Orosz, Stephen T. Jr.** see Bailey, Leonard C., 424

**Orr, Jane** Fact versus opinion in the judgment on fosphenytoin articles (letter), 1654

**Orr, Jane** Reactions to fosphenytoin editorial and review article (letter), 442

**Ostrander, John** Book review, 1218

**Owens, Dwight** Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion, 683

## P

**Paavola, Fred G.** Pharmaceutical services in the United States Public Health Service, 766

**Pacheco, Raquel** see Sesin, G. Paul, 1209

**Page, Maxwell A.** see McNally, Karen M., 171

**Pagniez, Sophie** see Mazzo, David J., 566

**Pahre, Steven N.** Preparing for the last visit with a dying patient (Frontline Pharmacist), 753

**Paloucek, Frank P.** Reactions to fosphenytoin editorial and review article (letter), 449

**Pankey, Susan** see Murray, Kim M., 2588

**Pashayan, Odette P.** see Gong, William C., 92

**Patel, Kalpana B.** see Hitt, Catherine M., 2704

**Patel, Piyush R.** Stability of meropenem in intravenous solutions, 412

**Pathak, Dev** see Fan-Havard, Patty, 1407

**Pathak, Dev S.** see also Rothenrich, Elizabeth A., 2596

**Patterson, Albert A.** see Ogden, John E., 761

**Paul, W. Larry** see Okeke, C. Claudia, 1633

**Paule, Bernard** Interferon alpha-2a plus tretinoin

in patients with metastatic renal cell carcinoma: a pilot study, 190

**Pearson, Robert E.** see Flynn, Elizabeth Allan, 904

**Peddicord, Tom E.** Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection, 1417

**Peikwijk, N. J. ter** see Kan, H.J.M. van, 388

**Peloquin, Charles A.** Advice on treatment of drug-resistant tuberculosis (letter), 700

**Peloquin, Charles A.** Advice on treatment of *Mycobacterium avium* complex infection (letter), 1208

**Penzak, Scott R.** More on mechanisms of bacterial resistance (letter), 2744

**Perez, Edith A.** Standardized antiemetic regimens (letter), 2404

**Perez, Michelle M.** see Johnson, Cary E., 61

**Perleman, Jeffrey M.** Fatal hyperphosphatemia after oral phosphate overdose in a premature infant, 2488

**Peroutka, Julie A.** see Mutnick, Alan H., 392

**Perry, Paul J.** see Bever, Kristine A., 2059

**Peters, Daniel A.** see Mallett, Mark S., 1401

**Peterson, Andrew M.** see Kanmaz, Tina J., 1623

**Philips, Pamela** see Abramowitz, Paul W., 1196

**Phillips, Beth Bryles** Epoprostenol in the treatment of congestive heart failure, 2613

**Piccoro, Lance T.** see Wermeling, Daniel P., 1742

**Pill, Michael W.** The Boston Dispensary: in 1796 and today, 1097

**Piper, John** see Burke, Cassandra E., 1893

**Piscitelli, Stephen C.** see Gabriel, Caroline M., 1191

**Piscitelli, Stephen C.** see also Goetsch, Roger, 2232

**Pittman, Robert E.** see Paavola, Fred G., 766

**Polkonen, John Arden** Syntax: the emerging standard language for representing medical knowledge in computer system, 281

**Ponder, Garratt W.** see Stewart, James T., 915

**Powell, Michael F.** Self-study material review, 853

**Prater, Yashoda V.** Stability of midazolam hydrochloride in syringes and i.v. fluids, 913

**Probasco, Robert J.** Book review, 1367

**Prosser, Tony** Inconsistencies in labeling of enteral nutrition products (letter), 2239

**Puckett, William H.** Outsourcing drug distribution services. Outsourcing: taking the first step, 45

**Pugh, Mark C.** Book review, 2139

## Q

**Quasny, Holly** Metformin, contrast media, and theophylline (letter), 2007

**Quercia, Robert A.** Stability of griseofulvin hydrochloride in an extemporaneously prepared oral liquid, 1404

**Quercia, Robert A.** Stability of omeprazole in an extemporaneously prepared oral liquid, 1833

**Quick, M. W.** see Mayhew, Susan L., 570

**Quintillani, Richard** see Hitt, Catherine M., 1614

## R

**Radomski, Kristine M.** General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patients, 541

**Ramirez, Denis J.** see Ogden, John E., 761

**Rapp, Robert P.** see Neudeck, Brian L., 1963

**Ray, Max D.** Letters from the edge, 1827

**Ray, Max D.** Pharmacy residency training: proposal for a fourth wave, 2116

**Reeder, C. E.** ASHP national survey of pharmacy practice in acute care settings—1996, 653

**Reents, Stan** see Prosser, Tony, 2239

**Rego, Louis** see De Peri, Charles Jr., 728

**Rego, Louis P.** see also Smith, Adrienne L., 319

**Reichley, Richard M.** see McMullin, S. Troy, 545

**Reilly, Mary Jo** see Talley, C. Richard, 1815

**Reitz, Jeffrey** see Hui, Yuk Fung, 162

**Restino, Maryann S.** see Owens, Dwight, 683

**Ridout, Deborah A.** see Barber, Nick D., 397

**Riesenberg, Mark C.** see Fishwick, Jeffrey J., 678

**Rijnvos, W.P.M.** see Kan, H.J.M. van, 388

**Riva, A.** see Bruno, R., Dec 15 suppl S16

**Roberts, Bernard (Bob) L.** Jr. Decentralizing an

## Annual Index

- I.V.-to-oral conversion program (Frontline Pharmacist), 524  
**Roberts, Bernard L.** see also Boyko, William L., 1591  
**Roberts, Neal** see Ammons, Dwayne K., 1702  
**Rosum, Robert W.** Planning for an ambulatory care service (Management Consultation), 1584  
**Roth, Marc S.** Nutritional implications of prolonged propofol use, 694  
**Rothermich, Elizabeth A.** References for health-related quality-of-life claims in prescription drug advertisements, 2596  
**Rozenberg-Ben-Dror, Karine** see Chandler, Christine, 1280  
**Rudant, Eric** see Paule, Bernard, 190  
**Rusho, William J.** see Najari, Zohre, 181  
**Russell, Fran** see Fan-Havard, Patty, 1407  
**Ryan, Michael L.** Book review, 2416

## S

- Sakami, Duane** Financial risk management of pharmacy benefits, 2207  
**Sanborn, Michael D.** Book review, 597  
**Sangst, Sujit S.** Pharmacists should be recognized as providers of nonprescription drug information (letter), 2127  
**Santelli, John P.** see Mehl, Bernard, 153  
**Santelli, John P.** see also Reeder, C. E., 653  
**Santella, Robert N.** see Singh, Preman J., 2609  
**Sauer, Barbara L.** Computerized documentation of activities of Pharm.D. clerkship students, 1727  
**Sawyer, William T.** see Cranor, Carole W., 1716  
**Schabinbaum, Sandra** see Huse, Daniel M., 1180  
**Schmitt, Brian** see Chandler, Christine, 1280  
**Schneider, Philip J.** Outsourcing drug distribution services. Outsourcing: a key to professional survival, 41  
**Schoier, Susan G.** see Haddad, Ann M. Ryan, 1333  
**Scholz, Robert L.** Changing department culture through a code of conduct (Management Consultation), 142  
**Schommer, Jon C.** Measuring patient satisfaction with pharmaceutical services, 2721  
**Schroeder, Donna J.** see Tsourounis, Candy, 1763  
**Schuerch, Leander V.** Haunting medicines (letter), 2403  
**Schuna, Arthur A.** Safe use of niacin, 2803  
**Schwartz, Michael A.** Restructuring the academic health center for the twenty-first century, 1711  
**Schwartz, Mitchell Lee** see Chiu, Ming Fung, 64  
**Schwinghammer, Terry L.** A case in point (letter), 2404  
**Scott, Felicia** Book review, 1002  
**Seaboldt, James A.** Comparison of information obtained from a Usenet newsgroup and from drug information centers, 1732  
**Seals, Tarrow D.** Influence of patient information leaflets on anticonvulsant drug compliance in prison, 2585  
**Segars, Larry W.** Additional contraindication to use of angiotensin-converting-enzyme inhibitors (letter), 1552  
**Sest, Bonnie L.** Latex allergy, 1071  
**Sesin, G. Paul** Advice on treatment of *Mycobacterium avium* complex infection (letter), 1209  
**Shaeffer, Gregory K.** Book review, 1001  
**Shane, Rita** The health care puzzle: where does pharmacy fit? 2503  
**Shapiro, David W.** see Dong, Betty J., 564  
**Shaw, Pamela K.** see Coley, S. Crystal, 1277  
**Shillington, Alicia A.** see Farley, P. Anne, 2478  
**Shintani, Ellen Y.** Donepezil: an anticholinesterase inhibitor for Alzheimer's disease, 2805  
**Siden, Rivka** see Foster-Nora, Jessica A., 787  
**Simon, Pamela A.** Book review, 2415  
**Singh, Preman J.** Gastrointestinal prokinetic agents for enhancing drug response in gastroparesis, 2609  
**Sleath, Betsy** Effect of including both physicians and pharmacists in an asthma drug-use review intervention, 2197  
**Slimowitz, Richard** Book review, 2017  
**Sloan, Nancy E.** see Mutnick, Alan H., 392  
**Sloskey, Gary E.** see Au, Adrienne Lam, 2128  
**Smalling, Richard W.** The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes, Nov 15 suppl S17

- Smith, Adrienne L.** Albendazole monitoring (letter), 319  
**Smith, Howard S.** see Fudin, Jeffrey, 87  
**Smith, Kelly M.** Drug-related problems in emergency department patients, 295  
**Smith, Shonda** see Holdford, David A., 1434  
**Smolarek, Richard T.** see Zimmerman, Christopher R., 1722  
**Somani, Shabir M.** see Abramowitz, Paul W., 1196  
**Sorenson, Mark K.** see Mutnick, Alan H., 392  
**St. Peter, John V.** see Andersen, Scott R., 1611  
**St. Peter, Wendy L.** see Andersen, Scott R., 1611  
**Stamm, Pamela L.** see Campbell, Thomas M., 2449  
**Steffen, William M.** Important issues to consider in pursuing prescribing authority for pharmacists (letter), 987  
**Sterba, Kenneth J.** see Mutnick, Alan H., 392  
**Stevenson, James G.** see Zimmerman, Christopher R., 1722  
**Stewart, James T.** Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags, 915  
**Stiles, M. Lou** Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium, and tobramycin sulfate in polyvinyl chloride drug reservoirs, 1068  
**Stringer, Kathleen A.** The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction. Clinical trials in thrombolytic therapy, part 1: outcome markers that go beyond mortality reduction, Nov 15 suppl S23  
**Stump, Lisa S.** Facilitating emergency use of alteplase for stroke (letter), 1447  
**Sulak, Patricia J.** see Jermain, Donna M., 2717  
**Summerfield, Marc R.** see Scholz, Robert L., 142  
**Sunderland, V. Bruce** see McNally, Karen M., 171  
**Surber, Christian** see Schuerch, Leander V., 2403  
**Swartz, Marsha A.** see Lacy, Melinda K., 1837  
**Swenson, Chad F.** see Anaizi, Nasr H., 549

## T

- Tagliente, Thomas M.** Pharmacoeconomics of propofol in anesthesia, 1953  
**Talbert, Robert L.** The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction. strategies for the management of acute myocardial infarction: selecting patients for thrombolytic therapy, Nov 15 suppl S9  
**Talbert, Robert L.** The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction. Introduction, Nov 15 suppl S3  
**Talley, C. Richard** ASHP's Web site (editorial), 1273  
**Talley, C. Richard** Direct-to-consumer prescription drug advertising (editorial), 2181  
**Talley, C. Richard** The Joseph A. Oddis Endowment (editorial), 1804  
**Talley, C. Richard** Joseph A. Oddis: influences and achievements, 1815  
**Talley, C. Richard** Making software work for pharmacy (editorial), 1501  
**Talley, C. Richard** Managed care backlash (editorial), 1049  
**Talley, C. Richard** Outsourcing drug distribution (editorial), 37  
**Talley, C. Richard** Patient-centered computing (editorial), 263  
**Talley, C. Richard** Promoting rational thought about ADHD, 2685  
**Talley, C. Richard** Slowing the emergence of multidrug-resistant pathogens, 2457  
**Talley, C. Richard** Trouble on the Internet (editorial), 757  
**Tan, Lai-Li** see Lim, Lee-Yong, 2073  
**Taniguchi, George** Bioethics committee activities (letter), 2007  
**Taniguchi, George** Criteria for use of tramadol hydrochloride in adult inpatients and outpatients, 696  
**Taniguchi, George** Pharmacist as newspaper columnist (letter), 1762  
**Theodorou, Dimitrios** see Cornwell, Edward E. III, 537  
**Thomas, John D.** see Williams, Roger F., 773  
**Thomas, L.** see Bruno, R., Dec 15 suppl S16  
**Thompson, Cheryl A.** Adverse reactions to alter-

native medicine (editorial), 1707

- Thompson, Cheryl A.** As patients embrace herbal remedies, dearth of scientific evidence frustrates clinicians (News), 2656  
**Thompson, Cheryl A.** Drug information centers pool resources (News), 1930  
**Thompson, Cheryl A.** Drug information industry reacts to private-sector plan for useful content (News), 1572  
**Thompson, Cheryl A.** Mail-order pharmacies send out clinical services (News), 613  
**Todd, Mark W.** see Smith, Kelly M., 295  
**Toledo-Binette, Charlotte** see Fudin, Jeffrey, 87  
**Tomera, John F.** Regional thrombolytic infusion for peripheral arterial occlusion and deep vein thrombosis: tried and true, 1988  
**Tomera, John F.** see also Kaul, Alan F., 2000, 2002  
**Trinh, Bo** see Yee, Donald K., 670  
**Trissel, Lawrence A.** Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration, 1735  
**Trissel, Lawrence A.** Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration, 2708  
**Trissel, Lawrence A.** Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration, 56  
**Trissel, Lawrence A.** Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration, 1295  
**Trissel, Lawrence A.** Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration, 1287  
**Trissel, Lawrence A.** Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration, 2192  
**Trissel, Lawrence A.** see also Gilbert, Doward L. Jr., 1193  
**Trissel, Lawrence A.** see also Tyler, Linda S., 831  
**Trope, Angela** see Dupuis, L. Lee, 1293  
**Tsourounis, Candy** Implementation of a computerized drug information database (letter), 1763  
**Tyler, Linda S.** Comparing cefmetazole compatibility data from different sources (letter), 831  
**Tyring, Stephen** see Huse, Daniel M., 1180

## U

- Uchida, Kathryn M.** see Shintani, Ellen Y., 2805

## V

- Vaida, Allen J.** Book review, 2016  
**Van Ackere, Ann** see Dean, Bryony S., 2491  
**VanDenBerg, Chad** Satisfaction among residents in ASHP-accredited pharmacy residency programs, 1521  
**Venl, Joan H.** see Yee, Donald K., 670  
**Ventch, Robert M.** Supplying starter kits of infant formula. Analysis and commentary, 689  
**Venkateswaran, Thirunellai G.** see Stewart, James T., 915  
**Verme-Gibhoney, Catherine** Oral angiotensin-converting-enzyme inhibitors, 2689  
**Vigil, Justina M.** see Wieland, Linda D., 1062  
**Vincze, Zoltán** see Fábán, L., 1207  
**Vogel, Susan** see Gabriel, Caroline M., 1191

## W

- Walker, Roger G.** see Sauer, Barbara L., 1727  
**Walter, William V.** see Trissel, Lawrence A., 1295  
**Warner, David J.** see Peddicord, Tom E., 1417  
**Warren, Flynn W.** see Stewart, James T., 915  
**Webb, Lauren** see Peddicord, Tom E., 1417  
**Weidie, Paul J.** see Everson-Mays, Robyn E., 1545  
**Weizer, Michele** Book review, 1668  
**Wermeling, Daniel P.** Financial impact of clinical research on a health system, 1742  
**West, Nina J.** see Jacobson, Pamela A., 178  
**White, Eugene V.** Office-practiced pharmacy (letter), 2824  
**White, Sara J.** Making pharmaceutical care a possible dream, 1862  
**Whitney, Harvey A. K.** New address for publisher (letter), 1110  
**Whorton, Kevin P.** see Wittmer, David R., 434

**Wieland, Linda D.** Relationship between home glucose testing and hemoglobin A<sub>1c</sub> in type II diabetes patients, 1062

**Williams, Karl G.** Liability for expanded responsibilities (Management Consultation), 1152

**Williams, Richard** see Smith, Adrienne L., 319

**Williams, Roger F.** Pharmaceutical services in the United States Army, 773

**Wingfield, Cynthia L.** see Davis, Angela Stafford, 2719

**Witmer, David R.** ASHP oncology pharmacy work force survey, 434

**Witmer, David R.** Book review, 1219

**Witmer, David R.** PALs program (Questions and Answers), 1701

**Woker, David R.** see Bayles, Britt C., 778

**Woller, Thomas W.** see Abramowitz, Paul W., 1196

**Wong, Barry** see Dupuis, L. Lee, 1293

**Wong, Miki** see Chan, Debora Schotik, 1335

**Woodward, Billy W.** see Jermain, Donna M., 2717

## Y

**Yee, Donald K.** Involvement of HMO-based pharmacists in clinical rounds at contract hospitals, 670

**Yee, Gary C.** Advances in the management of cancer: review of docetaxel. Cost-utility analysis of taxane therapy, Dec 15 suppl S11

**Yee, William** Self-study material review, 1464

**Yerasi, Ash B.** Disposal of used fentanyl patches, 85

**Young, James H.** Pharmaceutical services in the United States Air Force, 783

**Yow, Kah L.** see Lye, Michelle Y.F., 2483

**Yow, Kah-Lai** see also Lim, Lee-Yong, 2073

**Yu, Winnie** see Cornwell, Edward E. III, 537

**Yui, Darren** see Hall, Phillip D., 185

**Yurkowski, Peter J.** see Boyko, William L., 1591

## Z

**Zarembski, Dawn G.** see Hood, Kerri A., 285

**Zariffa, Nérine** see Boike, Steven C., 1172

**Zawada, Edward T.** see Singh, Premam J., 2609

**Zhang, Jinghua** see Quercia, Robert A., 1404

**Zhu, Zhu** see Hitt, Catherine M., 2704

**Zietlow, Kimberly** Book review, 472

**Zilz, David A.** Diversification of revenue and management of expense keys to record-setting year, 1868

**Zimmerman, Christopher R.** Peer review and continuous quality improvement of pharmacists' clinical interventions, 1722

**Zumbrunnen, Troy L.** see Peddicord, Tom E., 1417

## Advertising Index

## A

**Abbott Laboratories**  
Positions Available, 592

**Abbott Laboratories, Hospital Products Division**  
ADD-Vantage, 883, 1109, 1259, Jul 15 IBC, 2327, 2669  
FirstChoice Premixes, Jan 15 IFC, 339, 619, 949, May 15 IBC, 1373, 1655, 1783, Sep 15 IBC, 2279, 2541, Dec 1 IBC, Dec 15 IBC

**Advocate Health Care**  
Position Available, 2829

**Agency for Health Care Policy and Research**  
Institutional, 261

**Agouron Pharmaceuticals, Inc.**  
Viracept, 1934-1936, 2038-2040, 2241-2243, 2285-2287, 2519-2521, 2649-2651

**Akron General Medical Center**  
Position Available, 837

**Alabama Oncology, LLC**  
Position Available, 459, 1458

**Allegheny University Hospitals**  
Position Available, 328

**Allegheny University Hospitals, Hahnemann**  
Position Available, 2014

**Alpha Therapeutic Corporation**  
Venoglobulin-S, 941-942, 1031-1032, 1263-1264, 1479-1480, 2283-2284

**Alza/US Bioscience**  
Exhibitor's Theater, 929

**American Association of Diabetes Educators**  
Certificate Program, 149

**American Council on Pharmaceutical Education**  
Position Available, 1558

**American Lung Association**  
Institutional, 2054

**American Pain Society**  
16th Annual Scientific Meeting, 1583, 1687

**American Pharmaceutical Association**  
Certificate Program, 149  
National Pharmacy Week, 1764, 2037

**American Regent Laboratories, Inc.**  
Dexferum, 220-222, 348-350, 712-714, 870-872, 1146-1148, 1356-1358, 1482-1484, 1894-1896, 2034-2036, 2330-2332, 2548-2550, 2750-2752

**American Society of Health-System Pharmacists**  
AHFS Drug Information 97, 11, 211, 298, 455, 553, 638, 749, 1045, 1394, 2458, Nov 15 IBC, 2675  
AHFS Drug Information 98, 2785  
A/JHP Reprints, 98, 421, 716, 1118, 1836, 1983, 2098, 2320, 2517, 2622, 2743  
Applied Therapeutics: The Clinical Use of Drugs, Sixth Edition, 1768  
ASHP Advantage, 2265, 2315, 2375  
ASHP Annual Meeting '97: Education and Exhibits, 588, 723, 754, 921  
ASHP Membership, 38, 376, 528, 711, Apr 1 IBC, 997, 1950, 2686  
ASHP Second Annual Leadership Conference on Pharmacy Practice Management, 1657, 1789

ASHP Section of Clinical Specialists, 1473, 1775, 2551, 2553  
ASHP Section of Home Care Practitioners, 1129, 1314, 1387  
ASHP Software, 89, 1117, 1766, 2381  
ASHP Videotapes, 2137  
ASHP Web Site, 1350, 1389, 1520, 1629, 2124, 2740  
Basic Skills in Interpreting Laboratory Data, 205, 1057, 1209, 1445, 2003, 2301  
Career Opportunities on the Web, 1456  
CiteSearch, 601  
Clinical Pharmacokinetics Pocket Reference, 23, 148, 1075  
Clinical Pharmacology: An Electronic Drug Reference and Teaching Guide, 800  
Clinical Skills Program, 717, 1124, 1379, 2037, 2678  
CliniTrend, 294  
The Complete Guide to the 1997-98 Home Care Survey Process: Home Care and Long Term Care Pharmacies, 1962  
Concepts in Clinical Pharmacokinetics: A Self-Instructional Course, Second Edition, 141, 265, 440, 513, 623, 962, 1622, 1898, 2179, 2509  
Concepts in Immunology and Immunotherapeutics, Third Edition, 2053, 2196, 2620, 2716  
DataKinetics, 1375, 1498, 1651, 2017, 2665  
Drug Information on CD-ROM, 1669  
Drugs in Pregnancy and Lactation, Fourth Edition, 1764  
Guidelines for Administration of Intravenous Medications to Pediatric Patients, 1150, 1465, 1907, 2417, 2561  
Handbook of Clinical Drug Data, 1997-1998, Eighth Edition, 1768  
Handbook on Injectable Drugs, Ninth Edition, 321, 884, 1793  
Home Care 97, 1100, 1344  
Home Health Care Practice, Second Edition, 1962  
Home Infusion Software, 198, 427, 691, 999, 1365, 1487, 1773, 1999, 2212, 2448, 2810  
Infusion Technology Manual, A Self-Instructional Approach, 29  
International Pharmaceutical Abstracts, 1190, 1488, 2072, 2455, 2748  
Managing Oral Anticoagulation Therapy, 2477, 2591  
MedAxon, 25, 125, Feb 1 IBC, Mar 15 IBC, 848, 1003, 1125, 1463, 2253  
Medication Teaching Manual, 387, 701, 1157  
Medication Teaching Manual, Spanish Translation, 1704, 2514  
MedTeach for Windows, 107, 225, 697, 1105, 1563, 2078  
Midyear Clinical Meeting, 1761, 1901, 2005, 2129  
Neofax 1997: A Manual of Drugs Used in Neonatal Care, Tenth Edition, 1764, 1907, 2417  
New Publications, 1768  
Outcomes, 1267, 1460, 1502  
Pharmacoeconomics and Outcomes: Applications for Patient Care, 1385, 1632, 1942  
Pharmacotherapy: A Pathophysiologic Approach, Third Edition, 1768  
Pharmacy Resources, 1489  
Pharmacy Technician Workbook: A Self-Instructional Approach, 903, 1656, 2814  
Pocket Guide to Injectable Drugs, 146, 477, 574, 729, 847, 1391, 2791  
Pocket Guide to Injectable Drugs, Ninth Edition, 100, 328

Position Available, 99, 459, 590, 595, 715, 716, 837, 843, 992, 993, 1118, 1123, 1216, 1355, 1456, 1459, 1557, 1659, 1666, 1767, 1771, 1903, 1904, 2010, 2135, 2632  
Preparing the Pharmacy for a Joint Commission Survey, 3rd Edition, 31, 189, 318, 475, 942, 1258, 1947  
Project Catalyst, 2761  
PSAP II-Pharmacotherapy Self-Assessment Program, 888, 1465, 2502, 2824  
Quality Assurance of Pharmacy-Prepared Sterile Products Videotape and Workbook, 33, 1001  
Résumés and Personal Statements for Health Professionals, 2417  
Stedman's Concise Medical Dictionary, 2490  
Student Membership, 2043, 2257, 2379, 2634  
Understanding Medical Terms: A Guide for Pharmacy Practice, 2490

**Amgen Inc.**  
Neupogen, Jan 15 IFC, 109, Mar 15 IFC, 603, May 15 IFC, 1133, Jul 15 IFC, 1565, Sep 15 IFC, 2019, 2347  
Symposium

**Amicam Management Services**  
Position Available, 2247

**Antelope Valley Hospital**  
Positions Available, 1554

**Apothecon, A Bristol-Myers Squibb Company**  
Injectable Products, 238-239, 850-851, 1238-1239, 1694-1695  
Stadol, 367-368  
Stadol Injectable, 251-252, 491-492, 627-628, Apr 1 IFC, 731, 931-932, 1027-1028, 1137-1138, 1361-1362, Jun 15 IFC, 1369

**Appalachian Regional Healthcare**  
Positions Available, 704, 1665

**Arventure, LLC**  
Position Available, 2526

**ASHP Research and Education Foundation**  
Anticoagulation Management Service Traineeship Program, 2623  
Awards Program, 366  
Clinical Pharmacy Dialysis Service Traineeship Program, 257, 698  
Institutional, 91, 225, 889, 1127, 1454, 1704  
The Joseph A. Oddis Endowment, 1453, 1770, 1826, 2626  
Stem Cell Transplantation Traineeship Program, 2823

**Astra Merck Inc.**  
Position Available, 1767

**Astra USA, Inc.**  
Xylocaine 10% Spray, 880-882

**Aultman Hospital**  
Position Available, 1458

**Aurora Health Care**  
Position Available, 1659

**AutoMed Technologies**  
Institutional, 1227

## B

**Baptist Health System (Birmingham)**  
Position Available, 1556

**Baptist Health System (San Antonio)**  
Positions Available, 844, 2013

**Baptist St. Anthony's Health System**  
Position Available, 2246, 2408, 2765

**Bayer Corporation, Pharmaceutical Division**  
Adalat CC, 13-14, 495-496, 1013-1014, 1241-1242, 2345-2346, 2453-2454

**Baylor Senior Health Centers**  
Positions Available, 2763

**Baylor University Medical Center**  
Position Available, 1214, 1343, 2524, 2771

**Baystate Health Systems**  
Position Available, 1556, 1905

**B. Braun Medical Inc.**  
Institutional, 887, 971, 2339, Nov 15 IFC, 2537

**Biopharm USA Limited**  
Leeches, 869, 2301

**Board of Pharmaceutical Specialties**  
Institutional, 1243

**Boehringer Ingelheim**  
Combivent, 1943-1944

**Boehringer Mannheim Corporation**  
CoaguChek, 1265  
CoaguChek System, 637, 969  
Retavase, 117-124, 463-470, 505-512, 951-954, 1153-1156

**Bristol Laboratories Oncology Products, A Bristol-Myers Squibb Company**

Etopophos, 266-268, 758-760, 1050-1052, 1274-1276, 1708-1710  
Fungizone, 255-256  
Monopril, 2293-2295  
Paraplatin, 39-40, 1951-1952, 2687-2688  
Symposium, 2365  
Taxol, 245-246, 529-530, 745-746, 1245-1246, 1503-1504, 2183-2184, 2459-2460

**Bullhead Community Hospital**  
Position Available, 324

## C

**California Society of Health-System Pharmacists**  
Seminar '97, 1777

**Carolinas Healthcare System**  
Position Available, 2408

**Cary Medical Center**  
Position Available, 2131

**Children's Health Care Minneapolis**  
Position Available, 1664

**Children's Hospital (San Diego)**  
Positions Available, 1558

**Children's Hospital and Medical Center (Seattle)**  
Position Available, 2134

**Children's National Medical Center (Washington)**  
Position Available, 1353

**Cleveland Clinic Foundation**  
Positions Available, 706, 837, 995, 2630

**Clinical Laboratory Management Association**  
Congress on Integrated Clinical Systems Management, 105  
1998 Congress on Integrated Health Care Systems Management, 2627

**Columbia Chippenham Medical Center/Johnston-Willis Hospital**  
Position Available, 208

**Columbia/HCA Healthcare Corporation**  
Position Available, 1666, 2135, 2631

**Columbia Sunrise Hospital and Medical Center**  
Positions Available, 994, 995

**Community Health Plan/Kaiser Permanente**  
Position Available, 1664

**Concord Hospital**  
Position Available, 1458, 1666, 2525

**Cortex Communications**  
Exhibitors' Theater, 929

Symposia, 2291, 2355

## D

**Department of Veterans Affairs**  
Positions Available, 327

**Department of Veterans Affairs (Albuquerque)**  
Positions Available, 2631

**Department of Veterans Affairs (Richmond)**  
Positions Available, 97, 989, 1119, 1339, 2753

**Diebold, Inc.**  
Institutional, 1247, 1571, 2341, 2679

**Diversified Pharmaceutical Services, Inc.**  
Position Available, 2246

**Duke University Medical Center**  
Position Available, 459, 2132

**Dunhill of Warwick**  
Positions Available, 96, 322, 594, 844, 1126

**Dunhill Professional Search of Madison**  
Positions Available, 206, 322, 450, 594, 716, 844, 996, 1126, 1215, 1359, 1459, 1558, 1658, 1771, 1906, 1904, 2014, 2135

**Du Pont Merck Corporate**  
Coumadin, 136-138

**Du Pont Pharma**  
Coumadin, 446-448, 614-616

## E

**Eastern Maine Medical Center**  
Position Available, 1120, 1554, 2754

**E. Fougera & Co., A Division of Altana Inc.**  
Institutional, 2147, 2529

Oniments, 21

**Ell Lilly and Company**  
Surgilube, 957, 1677

**Emory University**  
Zyprexa, 9-10, 259-260, 521-522, 845-846, 1023-1024, 1351-1352, 1585-1586, 1899-1900, 2023-2024

**Employer Support of the Guard and Reserve**  
Institutional, 26

**E.P.S., Inc.**  
Steri-Dropper, 1237

**Erlanger Medical Center**  
Position Available, 1662

**Ernst & Young LLP**  
Position Available, 458

**ESI Lederle**  
Institutional, Nov 1 OBC, Dec 1 OBC

**ESI Lederle, Inc.**  
Dipyridamole Injection, Jul 1 IFC, 1467, Jun 1 IBC, OBC, Aug 1 IBC, OBC

**European Association of Hospital Pharmacists**  
3rd Congress of The European Association of Hospital Pharmacists, 2804

## F

**Fairbanks Memorial Hospital**  
Position Available, 456, 591

**Fletcher Allen Health Care**  
Positions Available, 324

**Florida Medical Center**  
Positions Available, 1120

**Forest Pharmaceuticals, Inc.**  
Cervidil, 5-6, 231-232, 483-484, 735-736, 1009-1010, 1225-1226, 1471-1472, Aug 1 IFC, 1671, 1919-1920, 2145-2146, 2263-2264, 2423-2424, 2645-2646, 2781-2782

**Geneva Pharmaceuticals, Inc.**  
Institutional, 2319

**Fujisawa Pharmaceutical Company**  
AmBisome, 209, 1234-1235, 1576-1577, 1790-1791, 2441-2445, 2659-2663

## G

**Genetics Institute, Inc.**  
Position Available, 1212, 2523

**Gensia Laboratories, Ltd.**  
Etoposide, 129-130, 473-474, 609-610, 935-936, 1347-1348

**Gensia Sior Pharmaceuticals, Inc.**  
Institutional, Dec 15 OBC

**Glaxo Wellcome**  
Helix, 1393, 1495, 1587, 1685

Position Available, 2247, 2524

Seminar, 2265

Ultiva, 516-518, 838-840, 1038-1040

Zofran, 1249-1250, 2653-2654

**Glaxo Wellcome/Medivision**  
Institutional, 2309

**Good Samaritan Hospital**  
Position Available, 2135

**Grant/Riverside Methodist Hospitals**  
Positions Available, 594, 2011

## H

**Harry S. Truman Memorial Veterans Hospital**  
Positions Available, 2014

**HCA International**  
Positions Available, 1211, 2134

**Hoechst Marion Roussel**  
Institutional, 2025, Oct 1 IBC, 2321, 2535, 2647

**Hoechst-Roussel Pharmaceuticals Inc.**  
Position Available, 1557

**Howard University**  
Position Available, 1457

## I

**Idaho State University (Pocatello)**  
Position Available, 2754

**I Give for Kids/FFF Enterprises**  
Institutional, Jul 1 OBC, Sep 1 OBC

**Illinois Masonic Medical Center**  
Position Available, 2633

**Illinois Pharmacy Foundation**  
Position Available, 212

**International Hospital Recruitments**  
Positions Available, 2754

## J

**Jackson Memorial Hospital**  
Positions Available, 1343

**James A. Haley Veterans Hospital**  
Position Available, 324

**Janssen Pharmaceuticals**  
Fellowship Programs, 2407

Institutional, 139, 341, 607, 861

Position Available, 991, 2763

Risperdal, 93-94, 451-452, 487-488, May 1 IFC, 1005

**John F. Kennedy Memorial Hospital**  
Position Available, 1554

## K

**Kaiser Permanente**  
Position Available, 210, 991

**Kaiser Permanente (Atlanta)**  
Position Available, 1771

**Kama Enterprises, Inc.**  
Positions Available, 706, 2763

**Kent General Hospital**  
Position Available, 461

**Knoll Pharmaceuticals**  
Dilaudid, 133-134, 443-444, 875-876, 1341-1342, 1573-1574, 2275-2276, 2745-2746

## L

**Lake Hospital System, Inc.**  
Position Available, 591

**Lakeland Regional Medical Center**  
Positions Available, 1349

**Lederle Laboratories, A Division of American Cyanamid Company**  
Zosyn, Jan 1 IFC, 1, Feb 1 IFC, 227, Mar 1 IFC, 479, 1029

**Legacy Health System**  
Position Available, 1555, 2244

**Liberty Industries, Inc.**  
IV Prep Room, 1253, 2289

**Liposome Company**  
Abelcet, 27-28, 325-326, 751-752, 1251-1252, 1679-1680, 2175-2176

Symposium, 2298

**Long Beach Memorial Medical Center**  
Positions Available, 995

**Long Island University**  
Positions Available, 2413

**Loyola University Medical Center**  
Position Available, 1215

**Lyons Lavey Nickel Swift, Inc.**  
Position Available, 991, 2013

## M

- Maginnis & Associates, Inc.**  
Institutional, 7, 457, 737, 1257, 2049, 2353
- Maine Medical Center**  
Position Available, 1552, 2132
- Marshall Hospital**  
Position Available, 2135
- Marshfield Clinic**  
Position Available, 593
- Maui Memorial Hospital**  
Position Available, 1905
- Mayo Medical Center**  
Position Available, 992, 1662, 2630, 2748
- McFaul and Lyons, Inc.**  
Position Available, 2765
- Medical Communications Media**  
Institutional, 2791
- Medical Education Systems, Inc.**  
Positions Available, 1353
- Symposia, 868, 878, 2270, 2278, 2298, 2398
- Medical University of South Carolina**  
Position Available, 99, 1767, 2408
- MedImmune, Inc.**  
RespiGam, 2041-2042, 2303-2304
- MedManagement**  
Institutional, 2677
- Position Available, 1903
- Med Options USA**  
Positions Available, 2014, 2135, 2249, 2413, 2526, 2633, 2771, 2829
- Memorial University of Newfoundland**  
Position Available, 1354
- Merck-Medco Managed Care L.L.C.**  
Positions Available, 2410
- Merck Sharp & Dohme, Division of Merck & Co., Inc.**  
Fosamax, 201-204, 343-346, 631-634, 859, 965
- Pepcid, 113-114, 235-236
- Mercy Healthcare Sacramento**  
Position Available, 208
- Mercy Hospital (Detroit)**  
Position Available, 2768
- Methodist Hospital**  
Position Available, 1215
- Methodist Hospitals of Memphis**  
Position Available, 1554, 1664, 2248
- Methodist Medical Center (Dallas)**  
Position Available, 450, 1556
- Millipore Corporation**  
Symposium, 2337
- Moses H. Cone Memorial Hospital**  
Position Available, 844, 1555, 1905
- MultiCare Health System**  
Position Available, 212

## N

- National Cancer Institute**  
Institutional, 2129
- National Institutes of Health**  
Position Available, 2767
- National University of Singapore**  
Positions Available, 2409
- North Broward Hospital District**  
Positions Available, 1126
- North Carolina Baptist Hospitals**  
Position Available, 322, 2134
- Novartis Pharmaceuticals Corporation**  
Exelon, 1261, 2667
- Neoral, 2325-2326, 2531-2532
- Nova Southeastern University**  
Training Programs, 995

## O

- Ohio State University**  
Position Available, 460
- Ohmeda, Inc., The BOC Group**  
Atracurium, 140, 374, 624
- OmniCell Technologies, Inc.**  
Institutional, 135, 1151
- Oncology New Concepts, A Division of Cortex Communications**  
Symposium, 2155
- Organon Inc.**  
Symposium, 2367
- Zemuron, 2051-2052, 2545-2546

## Orlando Regional Healthcare System

- Positions Available, 2630
- Ortho Biotech Inc.**  
Procrit, 150-152, 640-642, 1158-1160, 1588-1590, 2056-2058, 2566-2568
- Ortho/McNeil Pharmaceuticals**  
Floxin, 611-612, 925-926, 1043-1044
- Levaquin, 377-378, 707-710, 833-836, 863-866, 1101-1104, 1141-1144
- Our Lady of Fatima Hospital, An Affiliate of St. Joseph's Health Services**  
Position Available, 2408
- Owen Healthcare, Inc.**  
Institutional, 2377, 2657
- Position Available, 1555

## P

- Paddock Laboratories, Inc.**  
Nystatin Topical Powder, 127-128
- Nystop, 351-352, 727-728, 873-874
- Parke-Davis and Company, Division of Warner-Lambert Company**  
Symposia, 868, 878
- Parke-Davis**  
Symposium, 2270
- Parke-Davis/Pfizer, Inc.**  
Lipitor, 739-742, 1113-1116, 1229-1232, 1475-1476, 1689-1690, 2149-2150, 2671-2672
- Symposium, 2278
- Pfizer Inc., Roerig Division**  
Norvasc, Nov 15 OBC
- Pfizer Pharmaceuticals**  
Certificate Program, 149
- Norvasc, Jan 15 OBC, Mar 15 OBC, May 15 OBC, Jul 15 OBC, Sep 15 OBC
- Pharmaceutical Placement Service**  
Position Available, 2412
- Pharmacy Technician Certification Board**  
1997 Examinations, 705, 1443
- Phoenix Memorial Hospital**  
Position Available, 1215
- Pinecrest/Delray Medical Center**  
Position Available, 1905
- Pitt County Memorial Hospital**  
Positions Available, 1359
- Premier Inc.**  
Position Available, 1343
- Presbyterian Healthcare System**  
Position Available, 1211
- Prescriptive Analysis**  
Position Available, 206
- Providence Health System**  
Position Available, 99, 323, 591, 991, 1213, 1340, 1769, 2012, 2245, 2522, 2764
- Providence Portland Medical Center**  
Position Available, 996
- Purdue Frederick**  
Symposium, 2359

## Q

- QS/1 Data Systems**  
Institutional, 489, 1107, 1569, 1703, 1939, 2153, 2361, 2435, 2783

## R

- Regional Medical Center (Madisonville)**  
Position Available, 2132
- Rhône-Poulenc Rorer Pharmaceuticals Inc.**  
Institutional, 131, 207, 373, 617
- Lovemox, 362-364, 1579-1582, 1799-1802, 2045-2048
- Position Available, 2827
- Symposium, 2371, 2543
- Tacotene, 143-144, 353, 453-454, 621-622, 725, 885, 979-980, 1033-1034, 1111
- Roche Laboratories, A Division of Hoffmann-La Roche Inc.**  
Fellowship Program, 2629
- Klonopin, 371-372
- Posicor, Aug 15 IBC, OBC, Oct 15 IBC, OBC
- Position Available, 2247
- Roxcephin, Feb 15 IBC, OBC, Apr 15 IBC, OBC, Jun 15 IBC, OBC
- Symposium, 2349
- Versed, 1795-1797, 1923-1925, 2171-2173

## Roxane Laboratories, Inc.

- Roxicodone, 35-36, 261-262, 525-526, 755-756, 1047-1048, 1271-1272, 1499-1500, 1705-1706, 1947-1948, 2179-2180, 2323-2324, 2455-2456, 2683-2684
- Rutgers-The State University of New Jersey**  
Fellowship Programs, 2632

## S

- Sacred Heart General Hospital (Eugene)**  
Positions Available, 1120, 1771
- St. Agnes Healthcare**  
Position Available, 456, 837, 1354
- St. Dominic-Jackson Memorial Hospital**  
Position Available, 2131
- Saint Francis Hospital (Tulsa)**  
Position Available, 703, 1556, 1906
- St. John's Regional Health Center**  
Position Available, 456
- Saint Joseph Medical Center**  
Position Available, 2765
- St. Jude Children's Research Hospital**  
Position Available, 1554, 2412
- St. Luke's Regional Medical Center (Boise)**  
Position Available, 1122
- Saint Margaret Mercy Healthcare Centers**  
Position Available, 991
- St. Nicholas Hospital**  
Position Available, 704, 1769
- Saint Thomas Health Services**  
Position Available, 1659
- St. Vincent's Medical Center of Richmond**  
Position Available, 2249
- Sandoz Pharmaceuticals**  
Neoral, 17-18, 331-332, 499-500, 841-842, 1255-1256, 1491-1492, 1699-1700
- Sanofi Winthrop Pharmaceuticals**  
Position Available, 2767
- Primacor, 501-502, 975-976, 1019-1020, 1337-1338, 1682-1684, 2177-2178, 2563-2564, 2681-2682
- Santa Rosa Health Care**  
Position Available, 2827
- Sarasota Memorial Hospital**  
Positions Available, 2826
- Saratoga Hospital and Nursing Home**  
Position Available, 2011
- Schein Pharmaceutical, Inc.**  
Infed, 248-250, 944-946, 1382-1384, 1910-1912, 2272-2274, 2788-2790
- Scientific Therapeutics Information**  
Position Available, 2525, 2631, 2767
- Scottsdale Memorial Hospital**  
Position Available, 593
- Sequus Pharmaceuticals, Inc.**  
Amphotec, 240-242, 598-600, 890-892, 1345-1346
- Serono Laboratories**  
Positions Available, 2828
- Shands Hospital**  
Position Available, 1211
- Sheboygan Memorial Medical Center**  
Position Available, 2525
- Shore Health System**  
Position Available, 1126, 1214, 1343
- Sibley Memorial Hospital**  
Position Available, 99
- Sierra Providence Health Network**  
Positions Available, 2525
- Sierra Staffing**  
Positions Available, 1658, 2014, 2249, 2526, 2771
- SIMS Deltec**  
Institutional, 145, 369, 485, 939, 1121
- SmithKline Beecham**  
Fellowship Programs, 2523, 2629, 2828
- Hycamtin, Apr 15 IFC, 855, Jun 1 IFC, 1221, Oct 15 IFC, 2259, Dec 15 IFC, 2777
- Kytril, 147-148, Feb 15 IFC, 335, 960-962, 1016-1018, 1268-1270, 1660-1662, 1786-1788, 1928-1930, 2334-2336
- Position Available, 590, 1214, 1353, 2827
- Solvay Pharmaceuticals**  
Position Available, 704
- Spectrum Chemical Mfg. Corp.**  
Institutional, 15, 321, 503, 747, 1021, 1335, 1485, 1697, 1945, 2173, 2437, 2673
- Stadlinnders Managed Pharmacy Services**  
Positions Available, 2527
- Strong Memorial Hospital/University of Rochester**  
Position Available, 2632
- Sunrise Hospital and Medical Center**  
Position Available, 2248, 2526

## Annual Index

### Sunscript Pharmacy Corporation

Position Available, 1769, 2134

### Swedish Medical Center (Seattle)

Positions Available, 1359

### Syracuse Veterans Affairs Medical Center

Positions Available, 1458

## T

### Tallahassee Memorial Regional Medical Center

Position Available, 592

### Tampa General Healthcare

Positions Available, 992

### Temple University School of Pharmacy

Position Available, 990, 2766

### Texas Tech Health Sciences Center

Positions Available, 2012

### Texas Tech Health Sciences Center (Lubbock)

Position Available, 1903

### Texas Tech University Health Sciences Center

Position Available, 2133

### Texas Tech University Health Sciences Center at Amarillo

Position Available, 1355

### The Bowdoin Group, Inc.

Positions Available, 2770

### The Cancer Institute of New Jersey

Position Available, 208

### Theradex

Position Available, 706, 1555

### Tuomey Regional Medical Center

Positions Available, 1906

### Two Rivers Community Hospital

Position Available, 2754

## U

### United Health Services Hospitals

Position Available, 461

### University Hospital (Stony Brook)

Positions Available, 2011

### University Hospital, Inc. (Cincinnati)

Positions Available, 994

### University Hospital, SUNY Health Science Center

Position Available, 706

### University Medical Center (Jacksonville)

Positions Available, 1905

### University Medical Center (Las Vegas)

Positions Available, 2133

### University of Arizona

Position Available, 2244, 2412

### University of Connecticut Health Center

Position Available, 458, 2631

### University of Illinois at Chicago

Training Programs, 212, 323, 459, 593, 837, 996, 2246

### University of Iowa Hospitals and Clinics

Positions Available, 323, 1767, 2133, 2518

### University of Kentucky (Lexington)

Position Available, 2134

### University of Kentucky Hospital

Position Available, 1211

### University of Maryland Medical System

Positions Available, 2131

### University of Michigan

Position Available, 1456

### University of North Carolina

Fellowship Programs, 2632

### University of North Carolina School of Pharmacy

Position Available, 460

### University of Pittsburgh Medical Center

Position Available, 1359, 2769

### University of Rhode Island

Position Available, 2132

### University of Southern California School of Pharmacy

Position Available, 1122, 2010

### University of Texas at Austin

Position Available, 1124, 1665

### University of Texas at El Paso

Position Available, 210, 2767

### University of Texas M. D. Anderson Cancer Center

Positions Available, 2131

### University of Toronto

Position Available, 2826

### University of Virginia Medical Center

Positions Available, 324, 1457, 2826

### University of Wisconsin Hospital and Clinics

Position Available, 1904, 2244

### U.S. Clinical Products, Inc.

Institutional, Jan 1 IBC, Mar 1 IBC, May 1 IBC, Jul 1

IBC, Sep 1 IBC, Nov 1 IBC

### U.S. Department of Health and Human Services

Organ and Tissue Donation, 1219

## V

### VA Connecticut Healthcare System

Positions Available, 2010

### VA Medical Center (Amarillo)

Position Available, 1349

### ValueRx

Positions Available, 1663, 2411

### Vencare Pharmacy Services

Position Available, 2765

### VHA Inc.

Residency Program, 2013

### ViaHealth

Positions Available, 2526, 2633, 2754

### Virginia Commonwealth University

Position Available, 1122

### Visiting Nurse Association of Greater Philadelphia

Positions Available, 328

### Vivus, Inc.

Position Available, 590

## W

### Walter Reed Army Medical Center

Positions Available, 2762

### Wilcox Memorial Hospital

Position Available, 1212

### William Beaumont Hospital

Positions Available, 1349

### Winter Haven Hospital, Inc.

Position Available, 1120

### Wyeth-Ayerst Laboratories, Inc.

Duract, 2027-2032

Normiflo, 1675-1676, Aug 15 IFC, 1779, Sep 1 IFC,

1915, Oct 1 IFC, 2141, 2267-2268, Nov 1 IFC, 2419,

Dec 1 IFC, 2641

Tubex, Jan 1 OBC, Feb 1 OBC, Mar 1 OBC, Apr 1

OBC, May 1 OBC

Symposium, 2315

## X

### Xavier University of Louisiana

Position Available, 1120, 2771

## Y

### Yale-New Haven Hospital

Positions Available, 2768

### Yuma Regional Medical Center

Position Available, 2013

## Z

### Zeneca Pharmaceuticals

Merrem, 213-218, 355-360, 719-722

Seroquel, 2182, 2251, 2255, 2281, 2297, 2363, 2427-

2432, 2555-2560, 2755-2760, 2793-2798

